data_1whm_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1whm _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.786 0.244 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.401 HG23 HD12 ' A' ' 24' ' ' ILE . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.423 HG11 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.417 HD13 ' CD1' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.423 ' CE1' HG11 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CD1' HD13 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CZ2' ' HA2' ' A' ' 58' ' ' GLY . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.413 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo . . . . . 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo . . . . . 0 C--O 1.23 0.121 0 CA-C-O 120.82 0.258 . . . . 0.0 112.336 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.42 HD13 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.42 ' CG ' HD13 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 C--O 1.23 0.1 0 CA-C-O 120.777 0.241 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.473 HD13 HG21 ' A' ' 30' ' ' ILE . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 43' ' ' TYR . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.413 HD23 ' CD1' ' A' ' 60' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CD2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.411 ' CE1' HD13 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.405 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' HD23 ' A' ' 35' ' ' LEU . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.418 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo . . . . . 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.753 0.23 . . . . 0.0 112.318 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.416 HD11 ' CD1' ' A' ' 44' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 35' ' ' LEU . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.426 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.426 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.422 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 N--CA 1.466 -0.128 0 CA-C-O 120.859 0.275 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.414 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.714 0.214 . . . . 0.0 112.351 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.4 HD13 ' CG ' ' A' ' 44' ' ' PHE . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.4 ' CG ' HD13 ' A' ' 35' ' ' LEU . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' MET . . . . . 0.4 ' CG ' ' CD1' ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.421 ' CZ2' ' HA2' ' A' ' 58' ' ' GLY . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.4 ' CD1' ' CG ' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.417 HD23 ' CZ2' ' A' ' 56' ' ' TRP . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . 0.42 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo . . . . . 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo . . . . . 0 C--O 1.231 0.135 0 CA-C-O 120.822 0.259 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.427 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.427 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo . . . . . 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo . . . . . 0 C--O 1.231 0.172 0 CA-C-O 120.815 0.256 . . . . 0.0 112.378 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.433 HD11 ' CG ' ' A' ' 44' ' ' PHE . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.433 ' CG ' HD11 ' A' ' 35' ' ' LEU . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.42 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.412 HD12 ' CZ3' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . 0.42 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo . . . . . 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 120.815 0.256 . . . . 0.0 112.398 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.417 HD13 ' CG ' ' A' ' 44' ' ' PHE . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' HD13 ' A' ' 35' ' ' LEU . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.419 ' CH2' HD12 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.419 HD12 ' CH2' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo . . . . . 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.87 0.279 . . . . 0.0 112.188 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.405 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.405 ' CG ' HD11 ' A' ' 35' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.418 HD23 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo . . . . . 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.814 0.256 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.416 HD12 ' CD2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.417 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.417 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.437 HG23 HD12 ' A' ' 83' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo . . . . . 0 C--O 1.232 0.186 0 CA-C-O 120.898 0.291 . . . . 0.0 112.147 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.424 HG22 HD12 ' A' ' 83' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo . . . . . 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.86 0.275 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.422 HG13 ' CD2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' A' ' 44' ' ' PHE . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.407 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.422 ' CD2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.402 ' CD2' HD13 ' A' ' 35' ' ' LEU . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.411 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.407 ' CE2' ' HD2' ' A' ' 36' ' ' PRO . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.411 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo . . . . . 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.231 0.137 0 CA-C-O 120.798 0.249 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.417 HG22 HD11 ' A' ' 24' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.402 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.419 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' HG2' ' A' ' 36' ' ' PRO . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.417 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.889 0.287 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.416 HG13 ' CD2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.444 ' CD1' ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.408 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.416 ' CD2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.444 ' CD2' ' CD1' ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.422 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.404 ' CD1' HD22 ' A' ' 35' ' ' LEU . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.422 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . 0.408 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo . . . . . 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.854 0.273 . . . . 0.0 112.063 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.418 HG11 ' CD1' ' A' ' 43' ' ' TYR . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.42 HD11 ' CG ' ' A' ' 44' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.418 ' CD1' HG11 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.42 ' CG ' HD11 ' A' ' 35' ' ' LEU . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.417 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.416 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.412 ' CD2' HD21 ' A' ' 35' ' ' LEU . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.417 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo . . . . . 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.914 0.298 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . 0.422 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.42 HG12 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.419 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.422 ' CE2' ' HA ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.421 ' CZ3' HD11 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CD1' ' HG2' ' A' ' 36' ' ' PRO . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.421 HD11 ' CZ3' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 120.875 0.281 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.406 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.425 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.425 ' CG ' HD11 ' A' ' 35' ' ' LEU . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.413 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.415 ' CD1' HD21 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.413 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.406 ' CG2' ' HB ' ' A' ' 16' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 120.857 0.274 . . . . 0.0 112.205 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . 0.404 HG23 HD12 ' A' ' 24' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.414 HG13 ' CD2' ' A' ' 43' ' ' TYR . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.446 ' CD1' ' CD1' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 0.446 ' CD1' ' CD1' ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.406 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.23 0.118 0 CA-C-O 120.808 0.253 . . . . 0.0 112.309 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' CD1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' LEU . . . . . 0.424 HD22 ' CD1' ' A' ' 60' ' ' PHE . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.412 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TYR . . . . . 0.417 ' CD1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' MET . . . . . 0.4 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' TRP . . . . . 0.42 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PHE . . . . . 0.424 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.415 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' HIS . . . . . 0.431 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo . . . . . 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -143.52 -176.09 4.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.928 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.7 m -140.61 155.16 46.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 115.14 -65.08 0.3 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.444 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 p -97.71 154.83 17.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 111.016 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -135.21 110.32 8.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.33 -178.73 16.64 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.472 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.67 139.89 38.06 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.521 2.147 . . . . 0.0 112.23 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.86 -46.17 0.83 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.386 2.057 . . . . 0.0 112.3 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.401 HG23 HD12 ' A' ' 24' ' ' ILE . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.423 HG11 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.417 HD13 ' CD1' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.423 ' CE1' HG11 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CD1' HD13 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CZ2' ' HA2' ' A' ' 58' ' ' GLY . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.413 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.61 -178.08 2.84 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -146.21 60.7 1.24 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -133.95 157.38 46.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 6.4 m -110.69 -33.11 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 82.5 -172.64 52.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.507 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.86 168.32 22.03 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.172 . . . . 0.0 112.299 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -131.41 -177.66 4.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 9.5 p -176.06 -40.46 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.496 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -125.98 177.37 6.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.979 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.9 t -154.89 165.97 35.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -107.78 28.7 11.66 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.9 p -157.13 35.03 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -150.57 137.06 18.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.96 104.97 0.4 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -66.98 158.71 55.43 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.422 2.081 . . . . 0.0 112.29 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -68.88 -46.83 1.44 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.566 2.178 . . . . 0.0 112.336 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.42 HD13 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.42 ' CG ' HD13 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.99 -168.59 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -110.38 -171.23 1.79 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.3 t -168.67 171.96 8.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 m 60.66 157.18 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -131.89 -82.03 0.22 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.464 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.73 -172.12 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.663 2.242 . . . . 0.0 112.277 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.5 p 61.29 153.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 42.7 m 63.11 123.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.463 -179.982 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -123.15 143.58 49.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.954 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.98 -42.23 8.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.902 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.99 -168.46 13.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.4 m -151.0 137.54 18.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.826 0.346 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -112.87 -67.25 1.01 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.5 72.7 0.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.534 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.13 163.53 1.51 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.603 2.202 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.12 -55.11 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.371 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.473 HD13 HG21 ' A' ' 30' ' ' ILE . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.408 HG13 ' CD2' ' A' ' 43' ' ' TYR . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.413 HD23 ' CD1' ' A' ' 60' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.408 ' CD2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.411 ' CE1' HD13 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.405 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.413 ' CD1' HD23 ' A' ' 35' ' ' LEU . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.418 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.51 -167.86 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -156.98 93.05 1.31 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.872 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -158.82 177.65 10.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.1 m -108.71 -179.73 3.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 180.0 -61.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.459 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.68 99.62 0.65 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.587 2.192 . . . . 0.0 112.278 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 11.9 t -152.59 76.11 1.13 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 50.0 m -124.31 168.7 12.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.488 179.937 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.109 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 p -68.72 -36.01 77.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.852 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -171.24 35.12 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.28 -62.11 5.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.487 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.34 -32.46 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.76 0.314 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -115.74 111.86 21.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.17 72.65 0.26 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.437 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.4 139.04 37.11 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.604 2.203 . . . . 0.0 112.229 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.78 -49.0 1.71 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.393 2.062 . . . . 0.0 112.318 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.416 HD11 ' CD1' ' A' ' 44' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD1' HD11 ' A' ' 35' ' ' LEU . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.426 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.426 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.416 ' CZ ' HD13 ' A' ' 35' ' ' LEU . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.422 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -71.82 -170.92 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -156.09 31.54 0.34 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.2 p -135.71 179.7 6.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 t -106.53 160.2 15.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.894 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 167.64 70.88 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.503 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.82 134.76 28.64 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.594 2.196 . . . . 0.0 112.282 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.7 t -129.89 107.75 9.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.916 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 m -99.09 172.41 7.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.872 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.453 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.564 -0.214 . . . . 0.0 112.564 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -65.12 131.31 46.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 t -130.3 158.31 40.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.958 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.09 -96.8 0.11 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.508 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m 60.94 40.4 15.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.937 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -124.64 85.2 2.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.93 -148.67 12.54 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_exo -51.56 149.72 17.72 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.615 2.21 . . . . 0.0 112.257 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.62 -45.55 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.545 2.164 . . . . 0.0 112.381 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.414 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -71.56 -169.5 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -134.75 114.06 12.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.89 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -137.66 107.81 6.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.941 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 42.6 p -113.17 82.56 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -89.78 -54.72 2.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.471 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.08 -58.8 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.629 2.219 . . . . 0.0 112.348 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.12 153.73 43.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.953 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.7 m 60.6 95.74 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.414 -1.214 . . . . 0.0 112.535 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 112.621 -0.192 . . . . 0.0 112.621 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -159.48 119.22 2.99 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -138.2 -172.73 3.34 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.72 172.49 34.05 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.469 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.9 t -106.15 136.16 46.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.888 0.375 . . . . 0.0 110.87 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 t -176.52 146.89 0.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.926 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.24 82.45 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.538 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.43 160.96 3.09 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.619 2.212 . . . . 0.0 112.213 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.67 -51.06 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.586 2.191 . . . . 0.0 112.351 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.4 HD13 ' CG ' ' A' ' 44' ' ' PHE . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.4 ' CG ' HD13 ' A' ' 35' ' ' LEU . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' MET . . . . . 0.4 ' CG ' ' CD1' ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.421 ' CZ2' ' HA2' ' A' ' 58' ' ' GLY . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.4 ' CD1' ' CG ' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.417 HD23 ' CZ2' ' A' ' 56' ' ' TRP . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . 0.42 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -73.82 -168.25 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -132.47 125.11 29.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.862 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 61.55 31.55 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.875 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.3 m -152.97 101.01 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.929 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -78.33 -164.83 26.06 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.524 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 -45.95 1.31 Allowed 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.611 2.207 . . . . 0.0 112.271 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.4 t -175.95 156.35 1.75 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.14 31.24 5.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.465 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.1 p -102.78 116.37 32.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.812 0.339 . . . . 0.0 110.97 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 t -144.69 83.68 1.71 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.17 144.08 13.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.491 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 69.4 m -79.9 62.76 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 m 60.73 94.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.945 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.61 -100.99 0.25 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.54 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.13 113.04 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.415 2.076 . . . . 0.0 112.239 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.45 -37.61 16.9 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.486 2.124 . . . . 0.0 112.292 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.427 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.427 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.42 -174.28 2.14 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 57.9 165.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 t -71.68 159.03 35.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.17 107.37 19.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.868 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 125.77 148.66 7.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.444 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.45 -45.11 0.88 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.621 2.214 . . . . 0.0 112.348 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 24.8 p -128.58 -174.17 3.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.1 t -70.36 -33.82 71.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.874 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.514 -179.953 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -105.37 -34.58 7.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.94 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 p -120.56 -177.81 3.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.97 121.13 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.544 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -143.61 114.41 7.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.877 0.37 . . . . 0.0 110.92 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.0 80.75 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.26 -76.23 0.98 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.545 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.04 150.62 82.59 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.623 2.215 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -68.7 -49.17 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.509 2.139 . . . . 0.0 112.378 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.433 HD11 ' CG ' ' A' ' 44' ' ' PHE . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.42 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.433 ' CG ' HD11 ' A' ' 35' ' ' LEU . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.42 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.412 HD12 ' CZ3' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . 0.42 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -69.32 -167.84 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.29 85.64 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -89.77 89.08 7.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.934 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 132.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.88 56.61 0.73 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.59 62.86 2.26 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.604 2.203 . . . . 0.0 112.317 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 33.8 m -93.7 119.06 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.932 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 60.41 178.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.376 -1.236 . . . . 0.0 112.507 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 112.534 -0.227 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -73.52 127.4 32.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 p -121.42 -44.17 2.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.06 -96.17 0.22 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.538 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.24 -171.71 1.92 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 110.804 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.9 t 62.72 147.63 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.97 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.32 -119.36 4.35 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.03 149.83 33.57 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.413 2.076 . . . . 0.0 112.305 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -74.1 -44.79 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.398 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.417 HD13 ' CG ' ' A' ' 44' ' ' PHE . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' CG ' HD13 ' A' ' 35' ' ' LEU . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.419 ' CH2' HD12 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.419 HD12 ' CH2' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.43 -168.42 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -98.62 156.59 16.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 37.2 m -124.98 168.89 12.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.0 m 60.99 156.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.848 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.43 -61.07 0.62 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.504 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.17 151.91 72.38 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.61 2.207 . . . . 0.0 112.338 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.6 p -118.56 -39.47 3.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 62.85 90.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.516 -179.958 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -72.25 128.86 36.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.813 0.339 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.71 95.24 6.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.24 -154.77 26.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.16 131.74 51.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.5 p -104.96 152.76 22.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.44 -92.66 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -70.86 139.13 35.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.464 2.109 . . . . 0.0 112.259 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.73 -61.58 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.393 2.062 . . . . 0.0 112.188 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.405 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.405 ' CG ' HD11 ' A' ' 35' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.418 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.418 HD23 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -66.49 171.74 10.18 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -106.04 87.49 2.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.947 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 m -138.02 174.24 10.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.58 35.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.51 92.29 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.476 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.54 142.69 54.56 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.461 2.107 . . . . 0.0 112.337 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 t -127.83 -49.59 1.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.856 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.3 m -84.6 106.74 16.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.354 -1.248 . . . . 0.0 112.457 179.985 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.135 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.5 t -131.39 37.05 3.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -123.57 114.4 19.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.24 115.23 5.23 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.497 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.6 p -123.84 102.23 7.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.4 p -129.33 170.82 13.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.848 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.22 -106.02 0.16 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.435 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.69 155.57 49.33 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.467 2.111 . . . . 0.0 112.333 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.06 -47.13 2.56 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.559 2.173 . . . . 0.0 112.203 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.416 HD12 ' CD2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.416 ' CD2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.417 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.417 ' HB2' ' CE3' ' A' ' 56' ' ' TRP . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.437 HG23 HD12 ' A' ' 83' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_exo -70.68 -179.73 3.55 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -119.25 63.57 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -109.79 44.64 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.873 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 64.1 m -121.37 90.12 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -159.74 -164.13 14.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.454 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -69.44 -46.8 1.21 Allowed 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.539 2.159 . . . . 0.0 112.336 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.55 -41.92 2.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.892 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 62.87 149.03 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.395 -1.225 . . . . 0.0 112.508 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.186 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.92 172.43 11.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.1 p -93.24 122.08 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.938 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.7 63.59 0.58 Allowed Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -146.72 -52.04 0.22 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -138.16 142.44 40.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.81 150.14 7.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.459 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.36 140.04 63.56 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.559 2.173 . . . . 0.0 112.223 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -60.21 -63.4 0.12 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.311 2.007 . . . . 0.0 112.147 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.424 HG22 HD12 ' A' ' 83' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.86 -170.47 0.4 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -123.26 -177.9 3.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.905 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.63 147.96 31.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.6 t -66.09 118.74 10.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -160.08 102.95 0.22 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.524 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.67 -26.83 13.73 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.499 2.133 . . . . 0.0 112.371 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.3 m -90.51 88.55 7.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.84 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.5 p -146.93 97.92 2.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.463 -179.964 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.7 m 60.38 31.92 20.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.43 93.78 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.884 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.25 78.0 0.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.436 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -69.19 144.09 53.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.828 0.347 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -135.66 111.46 9.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.83 163.07 9.5 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.555 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.25 133.8 48.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.568 2.179 . . . . 0.0 112.224 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.53 -44.99 0.62 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.408 2.072 . . . . 0.0 112.288 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.422 HG13 ' CD2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' A' ' 44' ' ' PHE . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.407 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.422 ' CD2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.402 ' CD2' HD13 ' A' ' 35' ' ' LEU . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.411 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.407 ' CE2' ' HD2' ' A' ' 36' ' ' PRO . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.411 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.46 -176.5 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -84.85 -176.68 6.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.935 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 24.3 m -125.66 105.4 8.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 54.6 p -114.65 121.05 42.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.98 61.53 0.62 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.513 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.37 93.64 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.547 2.165 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.71 -60.73 2.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.27 93.04 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.326 -1.263 . . . . 0.0 112.545 -179.974 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.154 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.56 -31.74 13.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 0.0 110.92 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -134.29 -53.53 0.84 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.2 82.57 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.7 m -111.15 110.5 21.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.818 0.342 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.4 m -92.03 98.83 11.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.98 168.15 32.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.47 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_exo -52.11 145.47 33.93 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.582 2.188 . . . . 0.0 112.194 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.1 -45.99 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.452 2.102 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.417 HG22 HD11 ' A' ' 24' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.402 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.419 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.402 ' CD1' ' HG2' ' A' ' 36' ' ' PRO . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.417 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.62 -178.05 1.76 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.22 124.16 36.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -158.58 28.82 0.23 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 t 57.68 96.18 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.947 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.75 -166.44 12.15 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.474 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.18 87.49 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.558 2.172 . . . . 0.0 112.268 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 97.3 p -85.96 116.96 24.51 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 96.1 p -174.79 147.26 1.0 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.557 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -121.64 141.12 51.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.77 103.25 4.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.58 141.38 3.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.498 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -159.43 83.02 0.76 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.865 0.364 . . . . 0.0 110.85 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 60.86 75.33 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.45 105.4 3.28 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.352 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.13 144.18 62.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.409 2.072 . . . . 0.0 112.266 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -73.63 -29.72 10.48 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.481 2.12 . . . . 0.0 112.37 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.416 HG13 ' CD2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.444 ' CD1' ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.408 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.416 ' CD2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.444 ' CD2' ' CD1' ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.422 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.404 ' CD1' HD22 ' A' ' 35' ' ' LEU . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.422 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . 0.408 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -78.11 -168.02 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.96 102.91 11.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 p -147.49 117.16 7.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.924 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.3 t -117.99 30.45 7.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.14 144.29 8.31 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.522 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_exo -56.54 -163.67 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.569 2.179 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.9 t -175.44 106.25 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -50.34 74.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.409 -1.217 . . . . 0.0 112.488 -179.948 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.92 111.61 9.25 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.869 0.366 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -70.6 87.87 0.68 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.879 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.85 -45.13 2.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -90.8 -57.44 2.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.329 . . . . 0.0 110.922 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.0 m -88.89 108.65 19.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.61 143.13 4.27 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -55.01 143.51 72.91 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.407 2.071 . . . . 0.0 112.269 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -57.82 -59.66 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.374 2.049 . . . . 0.0 112.063 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.418 HG11 ' CD1' ' A' ' 43' ' ' TYR . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.42 HD11 ' CG ' ' A' ' 44' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.418 ' CD1' HG11 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.42 ' CG ' HD11 ' A' ' 35' ' ' LEU . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.417 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.416 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.412 ' CD2' HD21 ' A' ' 35' ' ' LEU . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.417 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -69.08 -175.74 1.09 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -78.78 152.75 31.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.889 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.1 p -161.31 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.15 107.45 10.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -90.22 143.0 16.7 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -74.42 -34.75 4.3 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.572 2.181 . . . . 0.0 112.351 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.88 104.55 12.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.2 m -138.81 167.71 21.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.416 -1.213 . . . . 0.0 112.525 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.4 m 60.44 94.8 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.87 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.46 -46.61 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -86.24 -156.35 27.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.568 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -179.42 4.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.876 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -158.84 151.88 22.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.26 62.27 0.51 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.516 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -54.8 164.87 2.93 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.648 2.232 . . . . 0.0 112.342 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -59.45 -62.85 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.579 2.186 . . . . 0.0 112.164 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . 0.422 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.42 HG12 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.419 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.422 ' CE2' ' HA ' ' A' ' 33' ' ' ASP . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.421 ' CZ3' HD11 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.419 ' CD1' ' HG2' ' A' ' 36' ' ' PRO . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.421 HD11 ' CZ3' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -72.96 -168.17 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.15 87.89 2.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.57 -59.17 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.11 159.81 3.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.08 119.77 1.96 Allowed Glycine 0 CA--C 1.519 0.341 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.409 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.91 124.13 10.72 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.436 2.091 . . . . 0.0 112.329 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.89 31.95 3.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.2 m -123.5 177.08 5.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.48 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -152.16 170.15 20.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.865 0.364 . . . . 0.0 110.858 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.5 96.41 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.22 -92.55 1.89 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.503 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.5 m -100.73 93.86 5.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.896 0.379 . . . . 0.0 110.849 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 m -157.33 -179.3 8.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.872 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.72 79.94 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.59 125.59 11.87 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.564 2.176 . . . . 0.0 112.275 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -57.49 -59.84 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.428 2.086 . . . . 0.0 112.277 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.406 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.425 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.425 ' CG ' HD11 ' A' ' 35' ' ' LEU . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.413 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.415 ' CD1' HD21 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.413 ' HB2' ' CD2' ' A' ' 56' ' ' TRP . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.406 ' CG2' ' HB ' ' A' ' 16' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.56 -161.23 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -99.96 31.31 3.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 t -98.54 -169.92 1.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 31.4 t -174.34 -41.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -100.91 -88.34 2.01 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.463 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.32 -173.17 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.546 2.164 . . . . 0.0 112.226 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m 61.4 154.39 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.85 -179.97 5.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.412 -1.215 . . . . 0.0 112.466 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 66.43 -74.93 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.704 0.288 . . . . 0.0 110.915 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.7 t 63.2 -79.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.006 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.24 -97.87 1.15 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -167.1 97.44 0.52 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.9 m -118.58 131.26 56.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.918 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.36 -179.71 30.86 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.519 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.32 111.66 2.98 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.555 2.17 . . . . 0.0 112.279 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.71 -55.53 2.33 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.433 2.089 . . . . 0.0 112.205 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . 0.404 HG23 HD12 ' A' ' 24' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.414 HG13 ' CD2' ' A' ' 43' ' ' TYR . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.446 ' CD1' ' CD1' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.414 ' CD2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 0.446 ' CD1' ' CD1' ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.406 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -64.41 175.36 3.46 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.28 39.32 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.3 m -160.75 30.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.14 -170.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.867 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 173.93 93.36 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.564 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_exo -50.97 110.67 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.653 2.235 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 t -111.41 113.72 26.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.885 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -159.91 106.13 1.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.541 179.936 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.59 165.76 11.06 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.765 0.317 . . . . 0.0 110.862 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -156.03 123.61 5.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.9 92.64 2.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.512 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -157.28 -67.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 0.0 110.922 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 m -80.31 178.79 8.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.79 109.51 2.18 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.44 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.37 153.62 76.35 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.389 2.059 . . . . 0.0 112.289 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.544 2.163 . . . . 0.0 112.309 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.4 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.417 HG13 ' CD1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . 0.424 HD22 ' CD1' ' A' ' 60' ' ' PHE . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.412 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . 0.431 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TYR . . . . . 0.417 ' CD1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' MET . . . . . 0.4 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' TRP . . . . . 0.42 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.42 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PHE . . . . . 0.424 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.415 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' HIS . . . . . 0.431 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.73 169.56 14.32 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.61 97.93 3.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -146.59 153.17 40.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.8 t -150.71 122.11 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.32 -88.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.29 -30.37 42.24 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.604 2.202 . . . . 0.0 112.246 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -89.4 137.93 31.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.8 -175.99 2.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.511 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.786 0.244 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.614 HD22 HG11 ' A' ' 45' ' ' VAL . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.419 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.458 ' HA ' HD13 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 19' ' ' LYS . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.675 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.59 HD11 ' CD2' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.455 ' HG2' HD12 ' A' ' 41' ' ' LEU . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.455 HD12 ' HG2' ' A' ' 38' ' ' LYS . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.466 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.599 ' CE1' HG13 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.59 ' CD2' HD11 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.845 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.454 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.445 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.796 ' O ' HG12 ' A' ' 63' ' ' VAL . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.456 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.456 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.419 HG22 ' HG ' ' A' ' 77' ' ' LEU . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.454 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 80' ' ' ASN . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.459 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.845 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.452 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.586 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.7 Cg_endo . . . . . 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HG2' HD12 ' A' ' 79' ' ' ILE . 48.6 Cg_endo . . . . . 0 C--O 1.23 0.121 0 CA-C-O 120.82 0.258 . . . . 0.0 112.336 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.436 HD21 HG22 ' A' ' 29' ' ' VAL . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.433 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.445 HG12 ' HA ' ' A' ' 84' ' ' PRO . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.449 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.766 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' VAL . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.444 HG22 ' HB3' ' A' ' 17' ' ' SER . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 29' ' ' VAL . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.612 ' O ' HG13 ' A' ' 45' ' ' VAL . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.433 ' SG ' HG22 ' A' ' 45' ' ' VAL . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 42' ' ' GLY . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.557 ' HG2' HD12 ' A' ' 41' ' ' LEU . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.557 HD12 ' HG2' ' A' ' 38' ' ' LYS . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.468 ' CG ' HD11 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.653 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.427 ' HB ' HD12 ' A' ' 18' ' ' LEU . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.766 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.453 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.444 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.42 ' N ' HG23 ' A' ' 79' ' ' ILE . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.653 HD11 ' HB ' ' A' ' 45' ' ' VAL . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 82' ' ' ILE . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HA ' HG12 ' A' ' 16' ' ' VAL . 73.4 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 C--O 1.23 0.1 0 CA-C-O 120.777 0.241 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.654 HD23 HG11 ' A' ' 45' ' ' VAL . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.493 HD21 HG12 ' A' ' 82' ' ' ILE . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 23' ' ' THR . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.411 HG23 HG23 ' A' ' 20' ' ' VAL . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.639 HD11 ' CG2' ' A' ' 74' ' ' THR . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.71 ' O ' HG13 ' A' ' 45' ' ' VAL . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 42' ' ' GLY . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.754 HD12 ' CD1' ' A' ' 44' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.531 ' CD ' HD11 ' A' ' 65' ' ' LEU . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.445 ' CE2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.742 ' HB ' HD11 ' A' ' 82' ' ' ILE . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.445 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.657 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.734 ' O ' HG12 ' A' ' 63' ' ' VAL . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.531 HD11 ' CD ' ' A' ' 36' ' ' PRO . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 71' ' ' VAL . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.639 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.657 HD13 ' CH2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.552 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.742 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.525 ' CD1' HD12 ' A' ' 24' ' ' ILE . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.572 ' HB3' HG12 ' A' ' 16' ' ' VAL . 56.4 Cg_endo . . . . . 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.753 0.23 . . . . 0.0 112.318 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.684 HD23 HG11 ' A' ' 45' ' ' VAL . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 12' ' ' ILE . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HB3' ' A' ' 84' ' ' PRO . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 HG23 ' A' ' 23' ' ' THR . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.526 HG23 HG23 ' A' ' 20' ' ' VAL . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.585 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.489 HD11 HG23 ' A' ' 74' ' ' THR . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.605 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.652 ' SG ' HG22 ' A' ' 45' ' ' VAL . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.442 HG21 ' OE2' ' A' ' 39' ' ' GLU . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.503 HD13 ' CZ ' ' A' ' 60' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.442 ' OE2' HG21 ' A' ' 34' ' ' VAL . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.701 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.419 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.642 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.432 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.573 ' O ' HG12 ' A' ' 63' ' ' VAL . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.4 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.489 HG23 HD11 ' A' ' 30' ' ' ILE . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.434 HD11 ' HA2' ' A' ' 54' ' ' GLY . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.642 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.701 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.585 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.677 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.9 Cg_endo . . . . . 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 N--CA 1.466 -0.128 0 CA-C-O 120.859 0.275 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.529 ' CD2' HG11 ' A' ' 45' ' ' VAL . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.413 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.551 HD22 HD12 ' A' ' 77' ' ' LEU . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.567 HG23 HD13 ' A' ' 83' ' ' ILE . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.599 ' HG3' HG21 ' A' ' 20' ' ' VAL . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.522 HD11 HG23 ' A' ' 74' ' ' THR . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.628 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.648 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 42' ' ' GLY . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.65 HD13 ' CE2' ' A' ' 60' ' ' PHE . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.73 ' HB ' HD11 ' A' ' 82' ' ' ILE . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.429 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.453 ' O ' HD11 ' A' ' 75' ' ' ILE . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.404 ' HA2' HG12 ' A' ' 75' ' ' ILE . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.685 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.547 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.84 ' O ' HG12 ' A' ' 63' ' ' VAL . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.84 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.408 HD13 HD23 ' A' ' 35' ' ' LEU . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.708 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.708 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.556 HG21 ' CB ' ' A' ' 69' ' ' ALA . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 53' ' ' ILE . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.685 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.551 HD12 HD22 ' A' ' 18' ' ' LEU . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.453 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.453 ' N ' HG23 ' A' ' 79' ' ' ILE . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.73 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.567 HD13 HG23 ' A' ' 24' ' ' ILE . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.508 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.5 Cg_endo . . . . . 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.714 0.214 . . . . 0.0 112.351 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.5 HD13 HD11 ' A' ' 79' ' ' ILE . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.465 HG22 ' OD1' ' A' ' 13' ' ' ASN . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.465 ' OD1' HG22 ' A' ' 12' ' ' ILE . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.656 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.778 HD12 ' CD1' ' A' ' 83' ' ' ILE . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.637 HD11 HG23 ' A' ' 74' ' ' THR . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.67 ' O ' HG13 ' A' ' 45' ' ' VAL . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 42' ' ' GLY . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.786 HD11 HD21 ' A' ' 76' ' ' LEU . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.5 ' HG2' HD12 ' A' ' 41' ' ' LEU . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.5 HD12 ' HG2' ' A' ' 38' ' ' LYS . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.71 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.758 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.567 ' HG2' HD12 ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.45 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.488 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.818 ' O ' HG12 ' A' ' 63' ' ' VAL . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.478 ' CD1' HD22 ' A' ' 35' ' ' LEU . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.682 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.682 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.637 HG23 HD11 ' A' ' 30' ' ' ILE . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.567 HD12 ' HG2' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.786 HD21 HD11 ' A' ' 35' ' ' LEU . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.422 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' HIS . . . . . 0.433 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.5 HD11 HD13 ' A' ' 10' ' ' LEU . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.413 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.758 HD11 ' HB ' ' A' ' 45' ' ' VAL . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.778 ' CD1' HD12 ' A' ' 24' ' ' ILE . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.656 ' HB3' HG12 ' A' ' 16' ' ' VAL . 65.2 Cg_endo . . . . . 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo . . . . . 0 C--O 1.231 0.135 0 CA-C-O 120.822 0.259 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.556 HD21 HG21 ' A' ' 16' ' ' VAL . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.556 HG21 HD21 ' A' ' 10' ' ' LEU . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.486 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.814 HD13 HD12 ' A' ' 77' ' ' LEU . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' OE1' ' A' ' 25' ' ' GLU . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.58 ' CG2' HD12 ' A' ' 83' ' ' ILE . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.819 ' OE1' HG21 ' A' ' 20' ' ' VAL . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 47' ' ' VAL . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.502 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.651 HD11 HG23 ' A' ' 74' ' ' THR . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.574 ' O ' HG13 ' A' ' 45' ' ' VAL . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.521 HG13 ' CZ ' ' A' ' 43' ' ' TYR . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.824 HD11 HD21 ' A' ' 76' ' ' LEU . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.521 ' CZ ' HG13 ' A' ' 34' ' ' VAL . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD12 ' A' ' 35' ' ' LEU . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.747 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 28' ' ' THR . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.559 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.52 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.704 ' O ' HG12 ' A' ' 63' ' ' VAL . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.703 HD11 ' HB2' ' A' ' 60' ' ' PHE . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 57' ' ' ASP . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.651 HG23 HD11 ' A' ' 30' ' ' ILE . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.418 HG22 ' HG ' ' A' ' 77' ' ' LEU . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.824 HD21 HD11 ' A' ' 35' ' ' LEU . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.814 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.409 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.409 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.747 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.58 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.554 ' HB3' HG12 ' A' ' 16' ' ' VAL . 72.3 Cg_endo . . . . . 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HG2' HD12 ' A' ' 79' ' ' ILE . 43.6 Cg_endo . . . . . 0 C--O 1.231 0.172 0 CA-C-O 120.815 0.256 . . . . 0.0 112.378 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD23 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.466 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 29' ' ' VAL . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.683 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.62 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.513 HD13 HD12 ' A' ' 77' ' ' LEU . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.62 HG23 HG23 ' A' ' 23' ' ' THR . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.62 HG23 HG23 ' A' ' 20' ' ' VAL . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.62 HG22 ' HB3' ' A' ' 17' ' ' SER . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.808 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.406 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.582 ' SG ' HG22 ' A' ' 45' ' ' VAL . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.647 ' O ' HD23 ' A' ' 35' ' ' LEU . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.647 HD23 ' O ' ' A' ' 34' ' ' VAL . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.713 HG11 HD23 ' A' ' 10' ' ' LEU . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.455 HG12 ' HA3' ' A' ' 27' ' ' GLY . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.454 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.697 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.582 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.668 ' O ' HG12 ' A' ' 63' ' ' VAL . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.691 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.808 HG23 HD11 ' A' ' 30' ' ' ILE . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.697 HD13 ' CH2' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.513 HD12 HD13 ' A' ' 18' ' ' LEU . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' HIS . . . . . 0.425 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' A' ' 45' ' ' VAL . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.683 ' HB3' HG12 ' A' ' 16' ' ' VAL . 52.0 Cg_endo . . . . . 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 120.815 0.256 . . . . 0.0 112.398 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.581 HD23 HG13 ' A' ' 29' ' ' VAL . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.499 HD11 ' SG ' ' A' ' 32' ' ' CYS . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.595 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.673 HD13 HD12 ' A' ' 77' ' ' LEU . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.585 ' HB2' HD11 ' A' ' 83' ' ' ILE . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.672 HG23 HD13 ' A' ' 83' ' ' ILE . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 24' ' ' ILE . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG13 HD23 ' A' ' 10' ' ' LEU . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.781 HD11 HG23 ' A' ' 74' ' ' THR . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.7 ' O ' HG13 ' A' ' 45' ' ' VAL . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.499 ' SG ' HD11 ' A' ' 12' ' ' ILE . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.473 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 HD13 ' A' ' 65' ' ' LEU . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' A' ' 41' ' ' LEU . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.753 ' HB ' HD11 ' A' ' 82' ' ' ILE . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.532 ' CE ' HD12 ' A' ' 18' ' ' LEU . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.519 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.481 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.541 ' HB2' HD11 ' A' ' 65' ' ' LEU . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.541 HD11 ' HB2' ' A' ' 60' ' ' PHE . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.56 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.56 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.781 HG23 HD11 ' A' ' 30' ' ' ILE . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.519 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.673 HD12 HD13 ' A' ' 18' ' ' LEU . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.404 HG23 ' N ' ' A' ' 80' ' ' ASN . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.404 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.753 HD11 ' HB ' ' A' ' 45' ' ' VAL . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.672 HD13 HG23 ' A' ' 24' ' ' ILE . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.595 ' HB3' HG12 ' A' ' 16' ' ' VAL . 62.6 Cg_endo . . . . . 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.87 0.279 . . . . 0.0 112.188 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.71 HD11 HG11 ' A' ' 16' ' ' VAL . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.717 ' O ' HG11 ' A' ' 29' ' ' VAL . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.552 HG22 ' OD1' ' A' ' 13' ' ' ASN . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.552 ' OD1' HG22 ' A' ' 12' ' ' ILE . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.71 HG11 HD11 ' A' ' 10' ' ' LEU . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.466 HD13 HD12 ' A' ' 77' ' ' LEU . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.449 ' HB2' HD11 ' A' ' 83' ' ' ILE . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 83' ' ' ILE . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 24' ' ' ILE . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.717 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.682 HD11 HG23 ' A' ' 74' ' ' THR . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.624 ' O ' HG13 ' A' ' 45' ' ' VAL . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.439 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 41' ' ' LEU . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.627 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.473 ' HB3' HD11 ' A' ' 76' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.647 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.401 HG12 ' HA3' ' A' ' 27' ' ' GLY . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.414 ' HG2' HD12 ' A' ' 75' ' ' ILE . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.771 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.578 ' O ' HG12 ' A' ' 63' ' ' VAL . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.497 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.679 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.682 HG23 HD11 ' A' ' 30' ' ' ILE . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.442 HG22 ' HG ' ' A' ' 77' ' ' LEU . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.771 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.466 HD12 HD13 ' A' ' 18' ' ' LEU . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.647 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 24' ' ' ILE . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.426 ' HB3' HG12 ' A' ' 16' ' ' VAL . 17.1 Cg_exo . . . . . 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.814 0.256 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.625 HD22 HG11 ' A' ' 45' ' ' VAL . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.608 HD13 HD12 ' A' ' 77' ' ' LEU . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.429 HG21 HD12 ' A' ' 83' ' ' ILE . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.402 ' N ' HG22 ' A' ' 24' ' ' ILE . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG1' HD23 ' A' ' 10' ' ' LEU . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.75 HD11 HG23 ' A' ' 74' ' ' THR . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.727 ' SG ' HG22 ' A' ' 45' ' ' VAL . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.706 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.749 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.413 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.402 ' HB2' HD13 ' A' ' 30' ' ' ILE . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.431 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.748 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.748 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.781 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.575 ' O ' HD12 ' A' ' 30' ' ' ILE . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.781 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.75 HG23 HD11 ' A' ' 30' ' ' ILE . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.459 HD21 HD11 ' A' ' 35' ' ' LEU . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 18' ' ' LEU . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 80' ' ' ASN . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.427 ' N ' HG23 ' A' ' 79' ' ' ILE . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.749 HD11 ' HB ' ' A' ' 45' ' ' VAL . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.429 HD12 HG21 ' A' ' 24' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.695 ' HB3' HG12 ' A' ' 16' ' ' VAL . 11.4 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo . . . . . 0 C--O 1.232 0.186 0 CA-C-O 120.898 0.291 . . . . 0.0 112.147 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.754 HD23 HG11 ' A' ' 45' ' ' VAL . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.461 ' O ' HG23 ' A' ' 29' ' ' VAL . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.611 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.488 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 77' ' ' LEU . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.477 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 17' ' ' SER . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.504 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 14' ' ' SER . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 74' ' ' THR . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.62 ' O ' HG13 ' A' ' 45' ' ' VAL . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 42' ' ' GLY . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.829 HD11 HD21 ' A' ' 76' ' ' LEU . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HE2' ' CE2' ' A' ' 44' ' ' PHE . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.469 ' HB3' HD11 ' A' ' 76' ' ' LEU . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.754 HG11 HD23 ' A' ' 10' ' ' LEU . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.504 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.529 ' HA ' HG23 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.69 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 65' ' ' LEU . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 69' ' ' ALA . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.443 ' HB2' ' HB3' ' A' ' 66' ' ' CYS . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.593 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.431 HG23 HD11 ' A' ' 30' ' ' ILE . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.829 HD21 HD11 ' A' ' 35' ' ' LEU . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.514 HD12 HD13 ' A' ' 18' ' ' LEU . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.619 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.619 HD12 ' HA ' ' A' ' 79' ' ' ILE . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.406 ' CD1' HD12 ' A' ' 24' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.611 ' HB3' HG12 ' A' ' 16' ' ' VAL . 54.6 Cg_endo . . . . . 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.86 0.275 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.508 HD22 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.481 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.42 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.59 HD21 HG12 ' A' ' 82' ' ' ILE . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.659 ' CG2' HD13 ' A' ' 83' ' ' ILE . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.439 ' N ' HG22 ' A' ' 24' ' ' ILE . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.732 ' O ' HG13 ' A' ' 45' ' ' VAL . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.538 HG13 ' CE2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.578 HD11 HD21 ' A' ' 76' ' ' LEU . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.409 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.528 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.538 ' CE2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 31' ' ' PHE . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.501 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.425 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.696 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.544 ' O ' HG12 ' A' ' 63' ' ' VAL . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.415 ' N ' HG22 ' A' ' 63' ' ' VAL . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PHE . . . . . 0.491 ' O ' HD12 ' A' ' 30' ' ' ILE . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.696 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.529 HG23 HD11 ' A' ' 30' ' ' ILE . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.498 HG22 ' HG ' ' A' ' 77' ' ' LEU . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.578 HD21 HD11 ' A' ' 35' ' ' LEU . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.498 ' HG ' HG22 ' A' ' 75' ' ' ILE . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.41 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.41 ' N ' HG23 ' A' ' 79' ' ' ILE . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.688 HD11 ' HB ' ' A' ' 45' ' ' VAL . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.659 HD13 ' CG2' ' A' ' 24' ' ' ILE . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.42 ' HB3' HG12 ' A' ' 16' ' ' VAL . 53.0 Cg_endo . . . . . 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.231 0.137 0 CA-C-O 120.798 0.249 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.446 ' CD2' HG11 ' A' ' 45' ' ' VAL . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.494 HD21 HG12 ' A' ' 82' ' ' ILE . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.504 ' CG2' HD12 ' A' ' 83' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 30' ' ' ILE . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.813 HD11 HG23 ' A' ' 74' ' ' THR . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.676 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.569 ' SG ' HG22 ' A' ' 45' ' ' VAL . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.613 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.704 HD11 ' CD2' ' A' ' 76' ' ' LEU . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.69 ' HB3' HD12 ' A' ' 41' ' ' LEU . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.69 HD12 ' HB3' ' A' ' 38' ' ' LYS . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.613 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.557 ' CE1' HD12 ' A' ' 35' ' ' LEU . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.775 ' HB ' HD11 ' A' ' 82' ' ' ILE . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.406 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.497 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.852 ' O ' HG12 ' A' ' 63' ' ' VAL . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.852 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.44 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.813 HG23 HD11 ' A' ' 30' ' ' ILE . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.403 HD12 ' HG2' ' A' ' 49' ' ' MET . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.704 ' CD2' HD11 ' A' ' 35' ' ' LEU . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 80' ' ' ASN . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.407 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.775 HD11 ' HB ' ' A' ' 45' ' ' VAL . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.889 0.287 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 1.008 HD11 HG11 ' A' ' 16' ' ' VAL . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.426 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 1.008 HG11 HD11 ' A' ' 10' ' ' LEU . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.408 ' HB2' ' CG2' ' A' ' 24' ' ' ILE . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' HE2' ' A' ' 49' ' ' MET . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.618 HG23 HG23 ' A' ' 23' ' ' THR . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 20' ' ' VAL . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.456 HG22 ' N ' ' A' ' 25' ' ' GLU . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.456 ' N ' HG22 ' A' ' 24' ' ' ILE . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.44 ' O ' HG23 ' A' ' 30' ' ' ILE . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 74' ' ' THR . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.625 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.889 HD12 ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.426 ' CD ' HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 41' ' ' LEU . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.889 ' CD2' HD12 ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.736 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE2' HD12 ' A' ' 18' ' ' LEU . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.712 ' CH2' HD13 ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.76 ' O ' HG12 ' A' ' 63' ' ' VAL . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.76 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.436 HD12 ' HB2' ' A' ' 60' ' ' PHE . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.472 HG23 HD11 ' A' ' 30' ' ' ILE . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.712 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' HIS . . . . . 0.419 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.66 HD12 HD12 ' A' ' 82' ' ' ILE . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.736 HD11 ' HB ' ' A' ' 45' ' ' VAL . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.433 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo . . . . . 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.854 0.273 . . . . 0.0 112.063 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 HG11 ' A' ' 45' ' ' VAL . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.4 HG12 ' HB3' ' A' ' 84' ' ' PRO . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.519 HD12 ' HB ' ' A' ' 47' ' ' VAL . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 25' ' ' GLU . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 20' ' ' VAL . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' VAL . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.726 HD11 HG23 ' A' ' 74' ' ' THR . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.714 ' O ' HG13 ' A' ' 45' ' ' VAL . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' HG22 ' A' ' 45' ' ' VAL . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.667 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.444 HD22 ' CD2' ' A' ' 60' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.402 ' HB3' HD12 ' A' ' 41' ' ' LEU . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.402 HD12 ' HB3' ' A' ' 38' ' ' LYS . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.542 ' CE1' HG13 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.761 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.519 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.524 ' CG ' HD11 ' A' ' 53' ' ' ILE . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.524 HD11 ' CG ' ' A' ' 49' ' ' MET . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.595 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.424 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.819 ' O ' HG12 ' A' ' 63' ' ' VAL . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.819 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.408 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.726 HG23 HD11 ' A' ' 30' ' ' ILE . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.595 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 18' ' ' LEU . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.761 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB3' HG12 ' A' ' 16' ' ' VAL . 49.8 Cg_endo . . . . . 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.914 0.298 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 45' ' ' VAL . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.458 HD11 ' SG ' ' A' ' 32' ' ' CYS . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.674 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.472 HD21 HG12 ' A' ' 82' ' ' ILE . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 25' ' ' GLU . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.532 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 20' ' ' VAL . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.544 HG13 HD23 ' A' ' 10' ' ' LEU . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.634 HD11 HG23 ' A' ' 74' ' ' THR . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.623 ' O ' HG13 ' A' ' 45' ' ' VAL . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.458 ' SG ' HD11 ' A' ' 12' ' ' ILE . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASP . . . . . 0.433 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.662 HG13 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.589 HD21 HD21 ' A' ' 76' ' ' LEU . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.447 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.456 ' HG2' HG21 ' A' ' 34' ' ' VAL . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.649 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.662 ' CE1' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.777 ' HB ' HD11 ' A' ' 82' ' ' ILE . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.439 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.406 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.419 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.645 ' CH2' HD13 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.618 ' O ' HG12 ' A' ' 63' ' ' VAL . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.56 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.634 HG23 HD11 ' A' ' 30' ' ' ILE . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.645 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.777 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.532 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.674 ' HB3' HG12 ' A' ' 16' ' ' VAL . 61.1 Cg_endo . . . . . 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 120.875 0.281 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 10' ' ' LEU . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.516 ' O ' HG11 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 29' ' ' VAL . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.416 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.574 ' OG ' HG22 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 47' ' ' VAL . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 20' ' ' VAL . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 HG23 ' A' ' 20' ' ' VAL . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.574 HG22 ' OG ' ' A' ' 17' ' ' SER . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.516 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.86 HD11 HG23 ' A' ' 74' ' ' THR . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.694 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.576 HD11 ' CD2' ' A' ' 76' ' ' LEU . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.694 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.67 ' HB ' HD11 ' A' ' 82' ' ' ILE . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.562 ' HB ' HD11 ' A' ' 18' ' ' LEU . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.518 ' HE2' HD12 ' A' ' 75' ' ' ILE . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.405 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.482 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.562 ' CE1' HD13 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.631 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.86 HG23 HD11 ' A' ' 30' ' ' ILE . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.518 HD12 ' HE2' ' A' ' 49' ' ' MET . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 35' ' ' LEU . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.539 ' HA ' HD12 ' A' ' 82' ' ' ILE . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 45' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.568 HD12 HD12 ' A' ' 24' ' ' ILE . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 120.857 0.274 . . . . 0.0 112.205 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.427 HD21 HG21 ' A' ' 16' ' ' VAL . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.442 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 10' ' ' LEU . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.461 HD13 HD12 ' A' ' 77' ' ' LEU . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 24' ' ' ILE . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.42 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 14' ' ' SER . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.685 HD11 ' CG2' ' A' ' 74' ' ' THR . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.66 ' O ' HG13 ' A' ' 45' ' ' VAL . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.574 HG12 ' O ' ' A' ' 42' ' ' GLY . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.588 HD11 ' CG ' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.597 ' CB ' HD12 ' A' ' 41' ' ' LEU . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.597 HD12 ' CB ' ' A' ' 38' ' ' LYS . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.574 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.544 ' CE2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.588 ' CG ' HD11 ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.763 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.466 ' HE2' HD12 ' A' ' 75' ' ' ILE . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.415 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.808 ' O ' HG12 ' A' ' 63' ' ' VAL . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.808 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' CYS . . . . . 0.616 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.616 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.685 ' CG2' HD11 ' A' ' 30' ' ' ILE . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.466 HD12 ' HE2' ' A' ' 49' ' ' MET . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.587 HD21 HD11 ' A' ' 35' ' ' LEU . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.461 HD12 HD13 ' A' ' 18' ' ' LEU . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 80' ' ' ASN . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 79' ' ' ILE . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.763 HD11 ' HB ' ' A' ' 45' ' ' VAL . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.619 ' CD1' HD12 ' A' ' 24' ' ' ILE . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.23 0.118 0 CA-C-O 120.808 0.253 . . . . 0.0 112.309 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.854 HD11 HG11 ' A' ' 16' ' ' VAL . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.453 HG22 ' OD1' ' A' ' 13' ' ' ASN . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.453 ' OD1' HG22 ' A' ' 12' ' ' ILE . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.417 ' O ' HG23 ' A' ' 29' ' ' VAL . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.854 HG11 HD11 ' A' ' 10' ' ' LEU . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 23' ' ' THR . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.455 HG23 HG23 ' A' ' 20' ' ' VAL . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.441 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 30' ' ' ILE . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.62 HD11 HG23 ' A' ' 74' ' ' THR . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . 0.412 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.493 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.713 HG13 ' CE1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' LEU . . . . . 0.795 HD11 HD21 ' A' ' 76' ' ' LEU . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.41 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LYS . . . . . 0.53 ' CG ' HD12 ' A' ' 41' ' ' LEU . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.53 HD12 ' CG ' ' A' ' 38' ' ' LYS . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TYR . . . . . 0.713 ' CE1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CD1' HD12 ' A' ' 35' ' ' LEU . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.74 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' MET . . . . . 0.411 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.441 HD13 ' OE2' ' A' ' 25' ' ' GLU . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' TRP . . . . . 0.634 ' CH2' HD13 ' A' ' 76' ' ' LEU . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.49 ' OD1' HG12 ' A' ' 71' ' ' VAL . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.428 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PHE . . . . . 0.633 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 64' ' ' GLN . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLN . . . . . 0.441 ' N ' HG22 ' A' ' 63' ' ' VAL . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.451 HD11 ' HB2' ' A' ' 60' ' ' PHE . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.62 HG23 HD11 ' A' ' 30' ' ' ILE . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.48 HG22 ' CD1' ' A' ' 77' ' ' LEU . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.795 HD21 HD11 ' A' ' 35' ' ' LEU . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LEU . . . . . 0.48 ' CD1' HG22 ' A' ' 75' ' ' ILE . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' HIS . . . . . 0.437 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.74 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo . . . . . 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -143.52 -176.09 4.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.928 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.7 m -140.61 155.16 46.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 115.14 -65.08 0.3 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.444 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 p -97.71 154.83 17.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 111.016 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -135.21 110.32 8.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.33 -178.73 16.64 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.472 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.67 139.89 38.06 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.521 2.147 . . . . 0.0 112.23 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.86 -46.17 0.83 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.386 2.057 . . . . 0.0 112.3 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.614 HD22 HG11 ' A' ' 45' ' ' VAL . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.419 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.458 ' HA ' HD13 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 19' ' ' LYS . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.675 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.59 HD11 ' CD2' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.455 ' HG2' HD12 ' A' ' 41' ' ' LEU . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.455 HD12 ' HG2' ' A' ' 38' ' ' LYS . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.466 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.599 ' CE1' HG13 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.59 ' CD2' HD11 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.845 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.454 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.445 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.796 ' O ' HG12 ' A' ' 63' ' ' VAL . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.456 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.456 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.419 HG22 ' HG ' ' A' ' 77' ' ' LEU . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.454 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 80' ' ' ASN . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.459 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.845 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.452 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.586 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.7 Cg_endo -71.61 -178.08 2.84 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -146.21 60.7 1.24 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -133.95 157.38 46.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 6.4 m -110.69 -33.11 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 82.5 -172.64 52.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.507 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.86 168.32 22.03 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.172 . . . . 0.0 112.299 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -131.41 -177.66 4.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 9.5 p -176.06 -40.46 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.496 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -125.98 177.37 6.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.979 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.9 t -154.89 165.97 35.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -107.78 28.7 11.66 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.9 p -157.13 35.03 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -150.57 137.06 18.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.96 104.97 0.4 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -66.98 158.71 55.43 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.422 2.081 . . . . 0.0 112.29 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HG2' HD12 ' A' ' 79' ' ' ILE . 48.6 Cg_endo -68.88 -46.83 1.44 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.566 2.178 . . . . 0.0 112.336 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.436 HD21 HG22 ' A' ' 29' ' ' VAL . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.433 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.445 HG12 ' HA ' ' A' ' 84' ' ' PRO . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.449 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.766 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' VAL . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.444 HG22 ' HB3' ' A' ' 17' ' ' SER . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 29' ' ' VAL . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.612 ' O ' HG13 ' A' ' 45' ' ' VAL . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.433 ' SG ' HG22 ' A' ' 45' ' ' VAL . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 42' ' ' GLY . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.557 ' HG2' HD12 ' A' ' 41' ' ' LEU . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.557 HD12 ' HG2' ' A' ' 38' ' ' LYS . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.468 ' CG ' HD11 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.653 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.427 ' HB ' HD12 ' A' ' 18' ' ' LEU . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.766 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.453 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.444 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.42 ' N ' HG23 ' A' ' 79' ' ' ILE . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.653 HD11 ' HB ' ' A' ' 45' ' ' VAL . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 82' ' ' ILE . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HA ' HG12 ' A' ' 16' ' ' VAL . 73.4 Cg_endo -75.99 -168.59 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -110.38 -171.23 1.79 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.3 t -168.67 171.96 8.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 m 60.66 157.18 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -131.89 -82.03 0.22 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.464 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.73 -172.12 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.663 2.242 . . . . 0.0 112.277 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.5 p 61.29 153.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 42.7 m 63.11 123.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.463 -179.982 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -123.15 143.58 49.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.954 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.98 -42.23 8.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.902 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.99 -168.46 13.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.4 m -151.0 137.54 18.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.826 0.346 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -112.87 -67.25 1.01 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.5 72.7 0.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.534 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.13 163.53 1.51 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.603 2.202 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.12 -55.11 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.371 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.654 HD23 HG11 ' A' ' 45' ' ' VAL . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.493 HD21 HG12 ' A' ' 82' ' ' ILE . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 23' ' ' THR . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.411 HG23 HG23 ' A' ' 20' ' ' VAL . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.639 HD11 ' CG2' ' A' ' 74' ' ' THR . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.71 ' O ' HG13 ' A' ' 45' ' ' VAL . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 42' ' ' GLY . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.754 HD12 ' CD1' ' A' ' 44' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.531 ' CD ' HD11 ' A' ' 65' ' ' LEU . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.445 ' CE2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.742 ' HB ' HD11 ' A' ' 82' ' ' ILE . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.445 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.657 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.734 ' O ' HG12 ' A' ' 63' ' ' VAL . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.531 HD11 ' CD ' ' A' ' 36' ' ' PRO . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 71' ' ' VAL . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.639 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.657 HD13 ' CH2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.552 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.742 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.525 ' CD1' HD12 ' A' ' 24' ' ' ILE . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.572 ' HB3' HG12 ' A' ' 16' ' ' VAL . 56.4 Cg_endo -70.51 -167.86 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -156.98 93.05 1.31 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.872 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -158.82 177.65 10.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.1 m -108.71 -179.73 3.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 180.0 -61.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.459 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.68 99.62 0.65 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.587 2.192 . . . . 0.0 112.278 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 11.9 t -152.59 76.11 1.13 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 50.0 m -124.31 168.7 12.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.488 179.937 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.109 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 p -68.72 -36.01 77.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.852 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -171.24 35.12 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.28 -62.11 5.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.487 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.34 -32.46 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.76 0.314 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -115.74 111.86 21.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.17 72.65 0.26 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.437 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.4 139.04 37.11 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.604 2.203 . . . . 0.0 112.229 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.78 -49.0 1.71 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.393 2.062 . . . . 0.0 112.318 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.684 HD23 HG11 ' A' ' 45' ' ' VAL . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 12' ' ' ILE . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HB3' ' A' ' 84' ' ' PRO . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 HG23 ' A' ' 23' ' ' THR . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.526 HG23 HG23 ' A' ' 20' ' ' VAL . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.585 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.489 HD11 HG23 ' A' ' 74' ' ' THR . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.605 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.652 ' SG ' HG22 ' A' ' 45' ' ' VAL . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.442 HG21 ' OE2' ' A' ' 39' ' ' GLU . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.503 HD13 ' CZ ' ' A' ' 60' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.442 ' OE2' HG21 ' A' ' 34' ' ' VAL . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.701 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.419 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.642 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.432 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.573 ' O ' HG12 ' A' ' 63' ' ' VAL . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.4 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.489 HG23 HD11 ' A' ' 30' ' ' ILE . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.434 HD11 ' HA2' ' A' ' 54' ' ' GLY . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.642 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.701 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.585 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.677 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.9 Cg_endo -71.82 -170.92 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -156.09 31.54 0.34 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.2 p -135.71 179.7 6.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 t -106.53 160.2 15.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.894 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 167.64 70.88 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.503 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.82 134.76 28.64 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.594 2.196 . . . . 0.0 112.282 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.7 t -129.89 107.75 9.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.916 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 m -99.09 172.41 7.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.872 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.453 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.564 -0.214 . . . . 0.0 112.564 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -65.12 131.31 46.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 t -130.3 158.31 40.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.958 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.09 -96.8 0.11 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.508 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m 60.94 40.4 15.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.937 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -124.64 85.2 2.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.93 -148.67 12.54 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_exo -51.56 149.72 17.72 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.615 2.21 . . . . 0.0 112.257 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.62 -45.55 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.545 2.164 . . . . 0.0 112.381 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.529 ' CD2' HG11 ' A' ' 45' ' ' VAL . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.413 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.551 HD22 HD12 ' A' ' 77' ' ' LEU . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.567 HG23 HD13 ' A' ' 83' ' ' ILE . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.599 ' HG3' HG21 ' A' ' 20' ' ' VAL . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.522 HD11 HG23 ' A' ' 74' ' ' THR . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.628 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.648 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 42' ' ' GLY . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.65 HD13 ' CE2' ' A' ' 60' ' ' PHE . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.73 ' HB ' HD11 ' A' ' 82' ' ' ILE . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.429 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.453 ' O ' HD11 ' A' ' 75' ' ' ILE . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.404 ' HA2' HG12 ' A' ' 75' ' ' ILE . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.685 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.547 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.84 ' O ' HG12 ' A' ' 63' ' ' VAL . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.84 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.408 HD13 HD23 ' A' ' 35' ' ' LEU . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.708 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.708 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.556 HG21 ' CB ' ' A' ' 69' ' ' ALA . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 53' ' ' ILE . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.685 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.551 HD12 HD22 ' A' ' 18' ' ' LEU . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.453 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.453 ' N ' HG23 ' A' ' 79' ' ' ILE . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.73 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.567 HD13 HG23 ' A' ' 24' ' ' ILE . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.508 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.5 Cg_endo -71.56 -169.5 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -134.75 114.06 12.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.89 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -137.66 107.81 6.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.941 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 42.6 p -113.17 82.56 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -89.78 -54.72 2.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.471 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.08 -58.8 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.629 2.219 . . . . 0.0 112.348 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.12 153.73 43.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.953 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.7 m 60.6 95.74 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.414 -1.214 . . . . 0.0 112.535 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 112.621 -0.192 . . . . 0.0 112.621 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -159.48 119.22 2.99 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -138.2 -172.73 3.34 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.72 172.49 34.05 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.469 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.9 t -106.15 136.16 46.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.888 0.375 . . . . 0.0 110.87 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 t -176.52 146.89 0.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.926 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.24 82.45 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.538 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.43 160.96 3.09 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.619 2.212 . . . . 0.0 112.213 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.67 -51.06 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.586 2.191 . . . . 0.0 112.351 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.5 HD13 HD11 ' A' ' 79' ' ' ILE . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.465 HG22 ' OD1' ' A' ' 13' ' ' ASN . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.465 ' OD1' HG22 ' A' ' 12' ' ' ILE . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.656 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.778 HD12 ' CD1' ' A' ' 83' ' ' ILE . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.637 HD11 HG23 ' A' ' 74' ' ' THR . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.67 ' O ' HG13 ' A' ' 45' ' ' VAL . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 42' ' ' GLY . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.786 HD11 HD21 ' A' ' 76' ' ' LEU . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.5 ' HG2' HD12 ' A' ' 41' ' ' LEU . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.5 HD12 ' HG2' ' A' ' 38' ' ' LYS . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.71 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.758 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.567 ' HG2' HD12 ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.45 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.488 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.818 ' O ' HG12 ' A' ' 63' ' ' VAL . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.478 ' CD1' HD22 ' A' ' 35' ' ' LEU . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.682 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.682 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.637 HG23 HD11 ' A' ' 30' ' ' ILE . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.567 HD12 ' HG2' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.786 HD21 HD11 ' A' ' 35' ' ' LEU . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.422 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' HIS . . . . . 0.433 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.5 HD11 HD13 ' A' ' 10' ' ' LEU . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.413 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.758 HD11 ' HB ' ' A' ' 45' ' ' VAL . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.778 ' CD1' HD12 ' A' ' 24' ' ' ILE . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.656 ' HB3' HG12 ' A' ' 16' ' ' VAL . 65.2 Cg_endo -73.82 -168.25 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -132.47 125.11 29.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.862 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 61.55 31.55 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.875 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.3 m -152.97 101.01 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.929 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -78.33 -164.83 26.06 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.524 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 -45.95 1.31 Allowed 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.611 2.207 . . . . 0.0 112.271 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.4 t -175.95 156.35 1.75 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.14 31.24 5.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.465 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.1 p -102.78 116.37 32.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.812 0.339 . . . . 0.0 110.97 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 t -144.69 83.68 1.71 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.17 144.08 13.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.491 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 69.4 m -79.9 62.76 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 m 60.73 94.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.945 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.61 -100.99 0.25 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.54 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.13 113.04 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.415 2.076 . . . . 0.0 112.239 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.45 -37.61 16.9 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.486 2.124 . . . . 0.0 112.292 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.556 HD21 HG21 ' A' ' 16' ' ' VAL . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.556 HG21 HD21 ' A' ' 10' ' ' LEU . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.486 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.814 HD13 HD12 ' A' ' 77' ' ' LEU . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' OE1' ' A' ' 25' ' ' GLU . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.58 ' CG2' HD12 ' A' ' 83' ' ' ILE . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.819 ' OE1' HG21 ' A' ' 20' ' ' VAL . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 47' ' ' VAL . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.502 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.651 HD11 HG23 ' A' ' 74' ' ' THR . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.574 ' O ' HG13 ' A' ' 45' ' ' VAL . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.521 HG13 ' CZ ' ' A' ' 43' ' ' TYR . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.824 HD11 HD21 ' A' ' 76' ' ' LEU . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.521 ' CZ ' HG13 ' A' ' 34' ' ' VAL . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD12 ' A' ' 35' ' ' LEU . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.747 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 28' ' ' THR . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.559 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.52 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.704 ' O ' HG12 ' A' ' 63' ' ' VAL . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.703 HD11 ' HB2' ' A' ' 60' ' ' PHE . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 57' ' ' ASP . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.651 HG23 HD11 ' A' ' 30' ' ' ILE . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.418 HG22 ' HG ' ' A' ' 77' ' ' LEU . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.824 HD21 HD11 ' A' ' 35' ' ' LEU . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.814 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.409 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.409 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.747 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.58 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.554 ' HB3' HG12 ' A' ' 16' ' ' VAL . 72.3 Cg_endo -77.42 -174.28 2.14 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 57.9 165.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 t -71.68 159.03 35.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.17 107.37 19.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.868 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 125.77 148.66 7.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.444 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.45 -45.11 0.88 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.621 2.214 . . . . 0.0 112.348 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 24.8 p -128.58 -174.17 3.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.1 t -70.36 -33.82 71.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.874 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.514 -179.953 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -105.37 -34.58 7.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.94 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 p -120.56 -177.81 3.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.97 121.13 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.544 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -143.61 114.41 7.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.877 0.37 . . . . 0.0 110.92 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.0 80.75 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.26 -76.23 0.98 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.545 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.04 150.62 82.59 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.623 2.215 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HG2' HD12 ' A' ' 79' ' ' ILE . 43.6 Cg_endo -68.7 -49.17 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.509 2.139 . . . . 0.0 112.378 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD23 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.466 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 29' ' ' VAL . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.683 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.62 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.513 HD13 HD12 ' A' ' 77' ' ' LEU . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.62 HG23 HG23 ' A' ' 23' ' ' THR . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.62 HG23 HG23 ' A' ' 20' ' ' VAL . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.62 HG22 ' HB3' ' A' ' 17' ' ' SER . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.808 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.406 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.582 ' SG ' HG22 ' A' ' 45' ' ' VAL . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.647 ' O ' HD23 ' A' ' 35' ' ' LEU . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.647 HD23 ' O ' ' A' ' 34' ' ' VAL . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.713 HG11 HD23 ' A' ' 10' ' ' LEU . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.455 HG12 ' HA3' ' A' ' 27' ' ' GLY . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.454 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.697 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.582 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.668 ' O ' HG12 ' A' ' 63' ' ' VAL . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.691 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.808 HG23 HD11 ' A' ' 30' ' ' ILE . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.697 HD13 ' CH2' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.513 HD12 HD13 ' A' ' 18' ' ' LEU . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' HIS . . . . . 0.425 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' A' ' 45' ' ' VAL . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.683 ' HB3' HG12 ' A' ' 16' ' ' VAL . 52.0 Cg_endo -69.32 -167.84 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.29 85.64 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -89.77 89.08 7.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.934 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 132.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.88 56.61 0.73 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.59 62.86 2.26 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.604 2.203 . . . . 0.0 112.317 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 33.8 m -93.7 119.06 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.932 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 60.41 178.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.376 -1.236 . . . . 0.0 112.507 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 112.534 -0.227 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -73.52 127.4 32.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 p -121.42 -44.17 2.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.06 -96.17 0.22 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.538 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.24 -171.71 1.92 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 110.804 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.9 t 62.72 147.63 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.97 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.32 -119.36 4.35 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.03 149.83 33.57 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.413 2.076 . . . . 0.0 112.305 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -74.1 -44.79 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.398 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.581 HD23 HG13 ' A' ' 29' ' ' VAL . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.499 HD11 ' SG ' ' A' ' 32' ' ' CYS . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.595 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.673 HD13 HD12 ' A' ' 77' ' ' LEU . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.585 ' HB2' HD11 ' A' ' 83' ' ' ILE . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.672 HG23 HD13 ' A' ' 83' ' ' ILE . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 24' ' ' ILE . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG13 HD23 ' A' ' 10' ' ' LEU . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.781 HD11 HG23 ' A' ' 74' ' ' THR . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.7 ' O ' HG13 ' A' ' 45' ' ' VAL . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.499 ' SG ' HD11 ' A' ' 12' ' ' ILE . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.473 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 HD13 ' A' ' 65' ' ' LEU . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' A' ' 41' ' ' LEU . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.753 ' HB ' HD11 ' A' ' 82' ' ' ILE . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.532 ' CE ' HD12 ' A' ' 18' ' ' LEU . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.519 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.481 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.541 ' HB2' HD11 ' A' ' 65' ' ' LEU . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.541 HD11 ' HB2' ' A' ' 60' ' ' PHE . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.56 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.56 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.781 HG23 HD11 ' A' ' 30' ' ' ILE . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.519 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.673 HD12 HD13 ' A' ' 18' ' ' LEU . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.404 HG23 ' N ' ' A' ' 80' ' ' ASN . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.404 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.753 HD11 ' HB ' ' A' ' 45' ' ' VAL . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.672 HD13 HG23 ' A' ' 24' ' ' ILE . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.595 ' HB3' HG12 ' A' ' 16' ' ' VAL . 62.6 Cg_endo -73.43 -168.42 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -98.62 156.59 16.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 37.2 m -124.98 168.89 12.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.0 m 60.99 156.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.848 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.43 -61.07 0.62 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.504 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.17 151.91 72.38 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.61 2.207 . . . . 0.0 112.338 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.6 p -118.56 -39.47 3.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 62.85 90.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.516 -179.958 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -72.25 128.86 36.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.813 0.339 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.71 95.24 6.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.24 -154.77 26.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.16 131.74 51.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.5 p -104.96 152.76 22.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.44 -92.66 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 56.6 Cg_endo -70.86 139.13 35.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.464 2.109 . . . . 0.0 112.259 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.6 Cg_exo -57.73 -61.58 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.393 2.062 . . . . 0.0 112.188 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.71 HD11 HG11 ' A' ' 16' ' ' VAL . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.717 ' O ' HG11 ' A' ' 29' ' ' VAL . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.552 HG22 ' OD1' ' A' ' 13' ' ' ASN . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.552 ' OD1' HG22 ' A' ' 12' ' ' ILE . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.71 HG11 HD11 ' A' ' 10' ' ' LEU . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.466 HD13 HD12 ' A' ' 77' ' ' LEU . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.449 ' HB2' HD11 ' A' ' 83' ' ' ILE . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 83' ' ' ILE . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 24' ' ' ILE . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.717 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.682 HD11 HG23 ' A' ' 74' ' ' THR . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.624 ' O ' HG13 ' A' ' 45' ' ' VAL . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.439 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 41' ' ' LEU . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.627 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.473 ' HB3' HD11 ' A' ' 76' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.647 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.401 HG12 ' HA3' ' A' ' 27' ' ' GLY . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.414 ' HG2' HD12 ' A' ' 75' ' ' ILE . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.771 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.578 ' O ' HG12 ' A' ' 63' ' ' VAL . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.497 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.679 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.682 HG23 HD11 ' A' ' 30' ' ' ILE . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.442 HG22 ' HG ' ' A' ' 77' ' ' LEU . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.771 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.466 HD12 HD13 ' A' ' 18' ' ' LEU . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.647 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 24' ' ' ILE . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.426 ' HB3' HG12 ' A' ' 16' ' ' VAL . 17.1 Cg_exo -66.49 171.74 10.18 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -106.04 87.49 2.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.947 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 m -138.02 174.24 10.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.58 35.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.51 92.29 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.476 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.54 142.69 54.56 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.461 2.107 . . . . 0.0 112.337 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 t -127.83 -49.59 1.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.856 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.3 m -84.6 106.74 16.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.354 -1.248 . . . . 0.0 112.457 179.985 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.135 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.5 t -131.39 37.05 3.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -123.57 114.4 19.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.24 115.23 5.23 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.497 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.6 p -123.84 102.23 7.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.4 p -129.33 170.82 13.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.848 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.22 -106.02 0.16 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.435 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.69 155.57 49.33 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.467 2.111 . . . . 0.0 112.333 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.06 -47.13 2.56 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.559 2.173 . . . . 0.0 112.203 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.625 HD22 HG11 ' A' ' 45' ' ' VAL . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.608 HD13 HD12 ' A' ' 77' ' ' LEU . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.429 HG21 HD12 ' A' ' 83' ' ' ILE . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.402 ' N ' HG22 ' A' ' 24' ' ' ILE . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG1' HD23 ' A' ' 10' ' ' LEU . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.75 HD11 HG23 ' A' ' 74' ' ' THR . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.727 ' SG ' HG22 ' A' ' 45' ' ' VAL . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.706 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.749 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.413 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.402 ' HB2' HD13 ' A' ' 30' ' ' ILE . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.431 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.748 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.748 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.781 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.575 ' O ' HD12 ' A' ' 30' ' ' ILE . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.781 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.75 HG23 HD11 ' A' ' 30' ' ' ILE . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.459 HD21 HD11 ' A' ' 35' ' ' LEU . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 18' ' ' LEU . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 80' ' ' ASN . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.427 ' N ' HG23 ' A' ' 79' ' ' ILE . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.749 HD11 ' HB ' ' A' ' 45' ' ' VAL . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.429 HD12 HG21 ' A' ' 24' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.695 ' HB3' HG12 ' A' ' 16' ' ' VAL . 11.4 Cg_exo -70.68 -179.73 3.55 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -119.25 63.57 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -109.79 44.64 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.873 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 64.1 m -121.37 90.12 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -159.74 -164.13 14.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.454 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -69.44 -46.8 1.21 Allowed 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.539 2.159 . . . . 0.0 112.336 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.55 -41.92 2.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.892 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 62.87 149.03 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.395 -1.225 . . . . 0.0 112.508 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.186 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.92 172.43 11.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.1 p -93.24 122.08 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.938 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.7 63.59 0.58 Allowed Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -146.72 -52.04 0.22 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -138.16 142.44 40.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.81 150.14 7.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.459 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.414 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 51.2 Cg_exo -53.36 140.04 63.56 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.559 2.173 . . . . 0.0 112.223 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.3 Cg_exo -60.21 -63.4 0.12 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.311 2.007 . . . . 0.0 112.147 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.754 HD23 HG11 ' A' ' 45' ' ' VAL . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.461 ' O ' HG23 ' A' ' 29' ' ' VAL . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.611 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.488 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 77' ' ' LEU . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.477 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 17' ' ' SER . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.504 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 14' ' ' SER . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 74' ' ' THR . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.62 ' O ' HG13 ' A' ' 45' ' ' VAL . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 42' ' ' GLY . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.829 HD11 HD21 ' A' ' 76' ' ' LEU . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HE2' ' CE2' ' A' ' 44' ' ' PHE . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.469 ' HB3' HD11 ' A' ' 76' ' ' LEU . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.754 HG11 HD23 ' A' ' 10' ' ' LEU . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.504 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.529 ' HA ' HG23 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.69 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 65' ' ' LEU . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 69' ' ' ALA . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.443 ' HB2' ' HB3' ' A' ' 66' ' ' CYS . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.593 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.431 HG23 HD11 ' A' ' 30' ' ' ILE . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.829 HD21 HD11 ' A' ' 35' ' ' LEU . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.514 HD12 HD13 ' A' ' 18' ' ' LEU . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.619 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.619 HD12 ' HA ' ' A' ' 79' ' ' ILE . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.406 ' CD1' HD12 ' A' ' 24' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.611 ' HB3' HG12 ' A' ' 16' ' ' VAL . 54.6 Cg_endo -69.86 -170.47 0.4 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -123.26 -177.9 3.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.905 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.63 147.96 31.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.6 t -66.09 118.74 10.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -160.08 102.95 0.22 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.524 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.67 -26.83 13.73 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.499 2.133 . . . . 0.0 112.371 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.3 m -90.51 88.55 7.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.84 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.5 p -146.93 97.92 2.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.463 -179.964 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.7 m 60.38 31.92 20.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.43 93.78 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.884 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.25 78.0 0.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.436 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -69.19 144.09 53.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.828 0.347 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -135.66 111.46 9.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.83 163.07 9.5 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.555 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.25 133.8 48.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.568 2.179 . . . . 0.0 112.224 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.53 -44.99 0.62 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.408 2.072 . . . . 0.0 112.288 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.508 HD22 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.481 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.42 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.59 HD21 HG12 ' A' ' 82' ' ' ILE . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.659 ' CG2' HD13 ' A' ' 83' ' ' ILE . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.439 ' N ' HG22 ' A' ' 24' ' ' ILE . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.732 ' O ' HG13 ' A' ' 45' ' ' VAL . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.538 HG13 ' CE2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.578 HD11 HD21 ' A' ' 76' ' ' LEU . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.409 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.528 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.538 ' CE2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 31' ' ' PHE . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.501 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.425 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.696 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.544 ' O ' HG12 ' A' ' 63' ' ' VAL . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.415 ' N ' HG22 ' A' ' 63' ' ' VAL . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PHE . . . . . 0.491 ' O ' HD12 ' A' ' 30' ' ' ILE . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.696 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.529 HG23 HD11 ' A' ' 30' ' ' ILE . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.498 HG22 ' HG ' ' A' ' 77' ' ' LEU . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.578 HD21 HD11 ' A' ' 35' ' ' LEU . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.498 ' HG ' HG22 ' A' ' 75' ' ' ILE . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.41 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.41 ' N ' HG23 ' A' ' 79' ' ' ILE . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.688 HD11 ' HB ' ' A' ' 45' ' ' VAL . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.659 HD13 ' CG2' ' A' ' 24' ' ' ILE . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.42 ' HB3' HG12 ' A' ' 16' ' ' VAL . 53.0 Cg_endo -69.46 -176.5 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -84.85 -176.68 6.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.935 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 24.3 m -125.66 105.4 8.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 54.6 p -114.65 121.05 42.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.98 61.53 0.62 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.513 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.37 93.64 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.547 2.165 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.71 -60.73 2.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.27 93.04 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.326 -1.263 . . . . 0.0 112.545 -179.974 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.154 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.56 -31.74 13.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 0.0 110.92 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -134.29 -53.53 0.84 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.2 82.57 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.7 m -111.15 110.5 21.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.818 0.342 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.4 m -92.03 98.83 11.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.98 168.15 32.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.47 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_exo -52.11 145.47 33.93 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.582 2.188 . . . . 0.0 112.194 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.1 -45.99 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.452 2.102 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.446 ' CD2' HG11 ' A' ' 45' ' ' VAL . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.494 HD21 HG12 ' A' ' 82' ' ' ILE . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.504 ' CG2' HD12 ' A' ' 83' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 30' ' ' ILE . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.813 HD11 HG23 ' A' ' 74' ' ' THR . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.676 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.569 ' SG ' HG22 ' A' ' 45' ' ' VAL . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.613 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.704 HD11 ' CD2' ' A' ' 76' ' ' LEU . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.69 ' HB3' HD12 ' A' ' 41' ' ' LEU . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.69 HD12 ' HB3' ' A' ' 38' ' ' LYS . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.613 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.557 ' CE1' HD12 ' A' ' 35' ' ' LEU . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.775 ' HB ' HD11 ' A' ' 82' ' ' ILE . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.406 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.497 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.852 ' O ' HG12 ' A' ' 63' ' ' VAL . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.852 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.44 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.813 HG23 HD11 ' A' ' 30' ' ' ILE . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.403 HD12 ' HG2' ' A' ' 49' ' ' MET . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.704 ' CD2' HD11 ' A' ' 35' ' ' LEU . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 80' ' ' ASN . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.407 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.775 HD11 ' HB ' ' A' ' 45' ' ' VAL . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.62 -178.05 1.76 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.22 124.16 36.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -158.58 28.82 0.23 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 t 57.68 96.18 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.947 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.75 -166.44 12.15 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.474 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.18 87.49 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.558 2.172 . . . . 0.0 112.268 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 97.3 p -85.96 116.96 24.51 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 96.1 p -174.79 147.26 1.0 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.557 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -121.64 141.12 51.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.77 103.25 4.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.58 141.38 3.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.498 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -159.43 83.02 0.76 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.865 0.364 . . . . 0.0 110.85 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 60.86 75.33 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.45 105.4 3.28 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.352 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.13 144.18 62.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.409 2.072 . . . . 0.0 112.266 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -73.63 -29.72 10.48 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.481 2.12 . . . . 0.0 112.37 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 1.008 HD11 HG11 ' A' ' 16' ' ' VAL . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.426 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 1.008 HG11 HD11 ' A' ' 10' ' ' LEU . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.408 ' HB2' ' CG2' ' A' ' 24' ' ' ILE . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' HE2' ' A' ' 49' ' ' MET . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.618 HG23 HG23 ' A' ' 23' ' ' THR . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 20' ' ' VAL . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.456 HG22 ' N ' ' A' ' 25' ' ' GLU . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.456 ' N ' HG22 ' A' ' 24' ' ' ILE . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.44 ' O ' HG23 ' A' ' 30' ' ' ILE . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 74' ' ' THR . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.625 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.889 HD12 ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.426 ' CD ' HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 41' ' ' LEU . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.889 ' CD2' HD12 ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.736 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE2' HD12 ' A' ' 18' ' ' LEU . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.712 ' CH2' HD13 ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.76 ' O ' HG12 ' A' ' 63' ' ' VAL . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.76 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.436 HD12 ' HB2' ' A' ' 60' ' ' PHE . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.472 HG23 HD11 ' A' ' 30' ' ' ILE . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.712 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' HIS . . . . . 0.419 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.66 HD12 HD12 ' A' ' 82' ' ' ILE . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.736 HD11 ' HB ' ' A' ' 45' ' ' VAL . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.433 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -78.11 -168.02 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.96 102.91 11.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 p -147.49 117.16 7.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.924 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.3 t -117.99 30.45 7.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.14 144.29 8.31 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.522 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_exo -56.54 -163.67 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.569 2.179 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.9 t -175.44 106.25 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -50.34 74.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.409 -1.217 . . . . 0.0 112.488 -179.948 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.92 111.61 9.25 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.869 0.366 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -70.6 87.87 0.68 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.879 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.85 -45.13 2.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -90.8 -57.44 2.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.329 . . . . 0.0 110.922 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.0 m -88.89 108.65 19.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.61 143.13 4.27 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 53.2 Cg_exo -55.01 143.51 72.91 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.407 2.071 . . . . 0.0 112.269 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.9 Cg_exo -57.82 -59.66 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.374 2.049 . . . . 0.0 112.063 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 HG11 ' A' ' 45' ' ' VAL . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.4 HG12 ' HB3' ' A' ' 84' ' ' PRO . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.519 HD12 ' HB ' ' A' ' 47' ' ' VAL . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 25' ' ' GLU . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 20' ' ' VAL . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' VAL . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.726 HD11 HG23 ' A' ' 74' ' ' THR . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.714 ' O ' HG13 ' A' ' 45' ' ' VAL . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' HG22 ' A' ' 45' ' ' VAL . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.667 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.444 HD22 ' CD2' ' A' ' 60' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.402 ' HB3' HD12 ' A' ' 41' ' ' LEU . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.402 HD12 ' HB3' ' A' ' 38' ' ' LYS . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.542 ' CE1' HG13 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.761 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.519 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.524 ' CG ' HD11 ' A' ' 53' ' ' ILE . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.524 HD11 ' CG ' ' A' ' 49' ' ' MET . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.595 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.424 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.819 ' O ' HG12 ' A' ' 63' ' ' VAL . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.819 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.408 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.726 HG23 HD11 ' A' ' 30' ' ' ILE . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.595 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 18' ' ' LEU . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.761 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB3' HG12 ' A' ' 16' ' ' VAL . 49.8 Cg_endo -69.08 -175.74 1.09 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -78.78 152.75 31.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.889 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.1 p -161.31 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.15 107.45 10.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -90.22 143.0 16.7 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -74.42 -34.75 4.3 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.572 2.181 . . . . 0.0 112.351 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.88 104.55 12.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.2 m -138.81 167.71 21.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.416 -1.213 . . . . 0.0 112.525 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.4 m 60.44 94.8 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.87 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.46 -46.61 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -86.24 -156.35 27.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.568 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -179.42 4.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.876 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -158.84 151.88 22.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.26 62.27 0.51 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.516 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -54.8 164.87 2.93 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.648 2.232 . . . . 0.0 112.342 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -59.45 -62.85 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.579 2.186 . . . . 0.0 112.164 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 45' ' ' VAL . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.458 HD11 ' SG ' ' A' ' 32' ' ' CYS . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.674 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.472 HD21 HG12 ' A' ' 82' ' ' ILE . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 25' ' ' GLU . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.532 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 20' ' ' VAL . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.544 HG13 HD23 ' A' ' 10' ' ' LEU . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.634 HD11 HG23 ' A' ' 74' ' ' THR . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.623 ' O ' HG13 ' A' ' 45' ' ' VAL . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.458 ' SG ' HD11 ' A' ' 12' ' ' ILE . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASP . . . . . 0.433 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.662 HG13 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.589 HD21 HD21 ' A' ' 76' ' ' LEU . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.447 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.456 ' HG2' HG21 ' A' ' 34' ' ' VAL . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.649 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.662 ' CE1' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.777 ' HB ' HD11 ' A' ' 82' ' ' ILE . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.439 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.406 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.419 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.645 ' CH2' HD13 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.618 ' O ' HG12 ' A' ' 63' ' ' VAL . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.56 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.634 HG23 HD11 ' A' ' 30' ' ' ILE . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.645 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.777 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.532 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.674 ' HB3' HG12 ' A' ' 16' ' ' VAL . 61.1 Cg_endo -72.96 -168.17 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.15 87.89 2.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.57 -59.17 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.11 159.81 3.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.08 119.77 1.96 Allowed Glycine 0 CA--C 1.519 0.341 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.409 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.91 124.13 10.72 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.436 2.091 . . . . 0.0 112.329 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.89 31.95 3.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.2 m -123.5 177.08 5.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.48 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -152.16 170.15 20.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.865 0.364 . . . . 0.0 110.858 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.5 96.41 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.22 -92.55 1.89 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.503 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.5 m -100.73 93.86 5.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.896 0.379 . . . . 0.0 110.849 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 m -157.33 -179.3 8.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.872 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.72 79.94 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.59 125.59 11.87 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.564 2.176 . . . . 0.0 112.275 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -57.49 -59.84 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.428 2.086 . . . . 0.0 112.277 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 10' ' ' LEU . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.516 ' O ' HG11 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 29' ' ' VAL . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.416 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.574 ' OG ' HG22 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 47' ' ' VAL . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 20' ' ' VAL . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 HG23 ' A' ' 20' ' ' VAL . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.574 HG22 ' OG ' ' A' ' 17' ' ' SER . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.516 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.86 HD11 HG23 ' A' ' 74' ' ' THR . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.694 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.576 HD11 ' CD2' ' A' ' 76' ' ' LEU . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.694 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.67 ' HB ' HD11 ' A' ' 82' ' ' ILE . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.562 ' HB ' HD11 ' A' ' 18' ' ' LEU . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.518 ' HE2' HD12 ' A' ' 75' ' ' ILE . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.405 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.482 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.562 ' CE1' HD13 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.631 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.86 HG23 HD11 ' A' ' 30' ' ' ILE . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.518 HD12 ' HE2' ' A' ' 49' ' ' MET . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 35' ' ' LEU . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.539 ' HA ' HD12 ' A' ' 82' ' ' ILE . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 45' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.568 HD12 HD12 ' A' ' 24' ' ' ILE . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.56 -161.23 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -99.96 31.31 3.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 t -98.54 -169.92 1.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 31.4 t -174.34 -41.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -100.91 -88.34 2.01 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.463 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.32 -173.17 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.546 2.164 . . . . 0.0 112.226 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m 61.4 154.39 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.85 -179.97 5.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.412 -1.215 . . . . 0.0 112.466 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 66.43 -74.93 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.704 0.288 . . . . 0.0 110.915 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.7 t 63.2 -79.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.006 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.24 -97.87 1.15 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -167.1 97.44 0.52 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.9 m -118.58 131.26 56.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.918 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.36 -179.71 30.86 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.519 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.32 111.66 2.98 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.555 2.17 . . . . 0.0 112.279 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.71 -55.53 2.33 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.433 2.089 . . . . 0.0 112.205 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.427 HD21 HG21 ' A' ' 16' ' ' VAL . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.442 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 10' ' ' LEU . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.461 HD13 HD12 ' A' ' 77' ' ' LEU . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 24' ' ' ILE . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.42 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 14' ' ' SER . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.685 HD11 ' CG2' ' A' ' 74' ' ' THR . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.66 ' O ' HG13 ' A' ' 45' ' ' VAL . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.574 HG12 ' O ' ' A' ' 42' ' ' GLY . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.588 HD11 ' CG ' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.597 ' CB ' HD12 ' A' ' 41' ' ' LEU . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.597 HD12 ' CB ' ' A' ' 38' ' ' LYS . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.574 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.544 ' CE2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.588 ' CG ' HD11 ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.763 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.466 ' HE2' HD12 ' A' ' 75' ' ' ILE . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.415 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.808 ' O ' HG12 ' A' ' 63' ' ' VAL . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.808 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' CYS . . . . . 0.616 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.616 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.685 ' CG2' HD11 ' A' ' 30' ' ' ILE . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.466 HD12 ' HE2' ' A' ' 49' ' ' MET . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.587 HD21 HD11 ' A' ' 35' ' ' LEU . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.461 HD12 HD13 ' A' ' 18' ' ' LEU . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 80' ' ' ASN . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 79' ' ' ILE . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.763 HD11 ' HB ' ' A' ' 45' ' ' VAL . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.619 ' CD1' HD12 ' A' ' 24' ' ' ILE . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -64.41 175.36 3.46 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.28 39.32 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.3 m -160.75 30.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.14 -170.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.867 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 173.93 93.36 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.564 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_exo -50.97 110.67 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.653 2.235 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 t -111.41 113.72 26.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.885 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -159.91 106.13 1.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.541 179.936 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.59 165.76 11.06 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.765 0.317 . . . . 0.0 110.862 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -156.03 123.61 5.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.9 92.64 2.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.512 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -157.28 -67.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 0.0 110.922 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 m -80.31 178.79 8.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.79 109.51 2.18 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.44 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.37 153.62 76.35 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.389 2.059 . . . . 0.0 112.289 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.544 2.163 . . . . 0.0 112.309 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.854 HD11 HG11 ' A' ' 16' ' ' VAL . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.453 HG22 ' OD1' ' A' ' 13' ' ' ASN . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.453 ' OD1' HG22 ' A' ' 12' ' ' ILE . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.417 ' O ' HG23 ' A' ' 29' ' ' VAL . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.854 HG11 HD11 ' A' ' 10' ' ' LEU . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 23' ' ' THR . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.455 HG23 HG23 ' A' ' 20' ' ' VAL . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.441 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 30' ' ' ILE . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.62 HD11 HG23 ' A' ' 74' ' ' THR . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . 0.412 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.493 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.713 HG13 ' CE1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . 0.795 HD11 HD21 ' A' ' 76' ' ' LEU . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.41 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LYS . . . . . 0.53 ' CG ' HD12 ' A' ' 41' ' ' LEU . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.53 HD12 ' CG ' ' A' ' 38' ' ' LYS . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TYR . . . . . 0.713 ' CE1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CD1' HD12 ' A' ' 35' ' ' LEU . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.74 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' MET . . . . . 0.411 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.441 HD13 ' OE2' ' A' ' 25' ' ' GLU . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' TRP . . . . . 0.634 ' CH2' HD13 ' A' ' 76' ' ' LEU . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.49 ' OD1' HG12 ' A' ' 71' ' ' VAL . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.428 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PHE . . . . . 0.633 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 64' ' ' GLN . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLN . . . . . 0.441 ' N ' HG22 ' A' ' 63' ' ' VAL . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.451 HD11 ' HB2' ' A' ' 60' ' ' PHE . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.62 HG23 HD11 ' A' ' 30' ' ' ILE . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.48 HG22 ' CD1' ' A' ' 77' ' ' LEU . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.795 HD21 HD11 ' A' ' 35' ' ' LEU . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LEU . . . . . 0.48 ' CD1' HG22 ' A' ' 75' ' ' ILE . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' HIS . . . . . 0.437 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.74 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.73 169.56 14.32 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.61 97.93 3.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -146.59 153.17 40.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.8 t -150.71 122.11 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.32 -88.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.29 -30.37 42.24 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.604 2.202 . . . . 0.0 112.246 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -89.4 137.93 31.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.8 -175.99 2.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.511 179.985 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.786 0.244 . . . . 0.0 112.3 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.614 HD22 HG11 ' A' ' 45' ' ' VAL . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.419 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.458 ' HA ' HD13 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 19' ' ' LYS . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.675 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.59 HD11 ' CD2' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.455 ' HG2' HD12 ' A' ' 41' ' ' LEU . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.455 HD12 ' HG2' ' A' ' 38' ' ' LYS . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.466 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.599 ' CE1' HG13 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.59 ' CD2' HD11 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.845 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.454 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.445 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.796 ' O ' HG12 ' A' ' 63' ' ' VAL . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.456 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.456 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.419 HG22 ' HG ' ' A' ' 77' ' ' LEU . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.454 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 80' ' ' ASN . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.459 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.845 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.452 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.586 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.7 Cg_endo . . . . . 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HG2' HD12 ' A' ' 79' ' ' ILE . 48.6 Cg_endo . . . . . 0 C--O 1.23 0.121 0 CA-C-O 120.82 0.258 . . . . 0.0 112.336 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.436 HD21 HG22 ' A' ' 29' ' ' VAL . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.433 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.445 HG12 ' HA ' ' A' ' 84' ' ' PRO . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.449 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.766 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' VAL . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.444 HG22 ' HB3' ' A' ' 17' ' ' SER . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 29' ' ' VAL . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.612 ' O ' HG13 ' A' ' 45' ' ' VAL . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.433 ' SG ' HG22 ' A' ' 45' ' ' VAL . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 42' ' ' GLY . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.557 ' HG2' HD12 ' A' ' 41' ' ' LEU . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.557 HD12 ' HG2' ' A' ' 38' ' ' LYS . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.468 ' CG ' HD11 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.653 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.427 ' HB ' HD12 ' A' ' 18' ' ' LEU . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.766 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.453 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.444 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.42 ' N ' HG23 ' A' ' 79' ' ' ILE . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.653 HD11 ' HB ' ' A' ' 45' ' ' VAL . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 82' ' ' ILE . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HA ' HG12 ' A' ' 16' ' ' VAL . 73.4 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 C--O 1.23 0.1 0 CA-C-O 120.777 0.241 . . . . 0.0 112.371 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.654 HD23 HG11 ' A' ' 45' ' ' VAL . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.493 HD21 HG12 ' A' ' 82' ' ' ILE . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 23' ' ' THR . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.411 HG23 HG23 ' A' ' 20' ' ' VAL . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.639 HD11 ' CG2' ' A' ' 74' ' ' THR . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.71 ' O ' HG13 ' A' ' 45' ' ' VAL . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 42' ' ' GLY . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.754 HD12 ' CD1' ' A' ' 44' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.531 ' CD ' HD11 ' A' ' 65' ' ' LEU . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.445 ' CE2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.742 ' HB ' HD11 ' A' ' 82' ' ' ILE . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.445 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.657 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.734 ' O ' HG12 ' A' ' 63' ' ' VAL . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.531 HD11 ' CD ' ' A' ' 36' ' ' PRO . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 71' ' ' VAL . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.639 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.657 HD13 ' CH2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.552 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.742 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.525 ' CD1' HD12 ' A' ' 24' ' ' ILE . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.572 ' HB3' HG12 ' A' ' 16' ' ' VAL . 56.4 Cg_endo . . . . . 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo . . . . . 0 C--O 1.232 0.175 0 CA-C-O 120.753 0.23 . . . . 0.0 112.318 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.684 HD23 HG11 ' A' ' 45' ' ' VAL . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 12' ' ' ILE . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HB3' ' A' ' 84' ' ' PRO . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 HG23 ' A' ' 23' ' ' THR . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.526 HG23 HG23 ' A' ' 20' ' ' VAL . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.585 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.489 HD11 HG23 ' A' ' 74' ' ' THR . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.605 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.652 ' SG ' HG22 ' A' ' 45' ' ' VAL . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.442 HG21 ' OE2' ' A' ' 39' ' ' GLU . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.503 HD13 ' CZ ' ' A' ' 60' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.442 ' OE2' HG21 ' A' ' 34' ' ' VAL . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.701 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.419 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.642 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.432 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.573 ' O ' HG12 ' A' ' 63' ' ' VAL . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.4 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.489 HG23 HD11 ' A' ' 30' ' ' ILE . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.434 HD11 ' HA2' ' A' ' 54' ' ' GLY . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.642 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.701 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.585 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.677 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.9 Cg_endo . . . . . 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 N--CA 1.466 -0.128 0 CA-C-O 120.859 0.275 . . . . 0.0 112.381 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.529 ' CD2' HG11 ' A' ' 45' ' ' VAL . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.413 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.551 HD22 HD12 ' A' ' 77' ' ' LEU . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.567 HG23 HD13 ' A' ' 83' ' ' ILE . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.599 ' HG3' HG21 ' A' ' 20' ' ' VAL . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.522 HD11 HG23 ' A' ' 74' ' ' THR . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.628 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.648 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 42' ' ' GLY . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.65 HD13 ' CE2' ' A' ' 60' ' ' PHE . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.73 ' HB ' HD11 ' A' ' 82' ' ' ILE . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.429 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.453 ' O ' HD11 ' A' ' 75' ' ' ILE . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.404 ' HA2' HG12 ' A' ' 75' ' ' ILE . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.685 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.547 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.84 ' O ' HG12 ' A' ' 63' ' ' VAL . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.84 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.408 HD13 HD23 ' A' ' 35' ' ' LEU . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.708 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.708 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.556 HG21 ' CB ' ' A' ' 69' ' ' ALA . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 53' ' ' ILE . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.685 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.551 HD12 HD22 ' A' ' 18' ' ' LEU . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.453 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.453 ' N ' HG23 ' A' ' 79' ' ' ILE . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.73 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.567 HD13 HG23 ' A' ' 24' ' ' ILE . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.508 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.5 Cg_endo . . . . . 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo . . . . . 0 C--O 1.231 0.161 0 CA-C-O 120.714 0.214 . . . . 0.0 112.351 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.5 HD13 HD11 ' A' ' 79' ' ' ILE . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.465 HG22 ' OD1' ' A' ' 13' ' ' ASN . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.465 ' OD1' HG22 ' A' ' 12' ' ' ILE . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.656 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.778 HD12 ' CD1' ' A' ' 83' ' ' ILE . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.637 HD11 HG23 ' A' ' 74' ' ' THR . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.67 ' O ' HG13 ' A' ' 45' ' ' VAL . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 42' ' ' GLY . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.786 HD11 HD21 ' A' ' 76' ' ' LEU . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.5 ' HG2' HD12 ' A' ' 41' ' ' LEU . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.5 HD12 ' HG2' ' A' ' 38' ' ' LYS . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.71 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.758 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.567 ' HG2' HD12 ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.45 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.488 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.818 ' O ' HG12 ' A' ' 63' ' ' VAL . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.478 ' CD1' HD22 ' A' ' 35' ' ' LEU . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.682 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.682 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.637 HG23 HD11 ' A' ' 30' ' ' ILE . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.567 HD12 ' HG2' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.786 HD21 HD11 ' A' ' 35' ' ' LEU . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.422 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . 0.433 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.5 HD11 HD13 ' A' ' 10' ' ' LEU . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.413 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.758 HD11 ' HB ' ' A' ' 45' ' ' VAL . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.778 ' CD1' HD12 ' A' ' 24' ' ' ILE . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.656 ' HB3' HG12 ' A' ' 16' ' ' VAL . 65.2 Cg_endo . . . . . 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo . . . . . 0 C--O 1.231 0.135 0 CA-C-O 120.822 0.259 . . . . 0.0 112.292 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.556 HD21 HG21 ' A' ' 16' ' ' VAL . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.556 HG21 HD21 ' A' ' 10' ' ' LEU . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.486 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.814 HD13 HD12 ' A' ' 77' ' ' LEU . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' OE1' ' A' ' 25' ' ' GLU . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.58 ' CG2' HD12 ' A' ' 83' ' ' ILE . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.819 ' OE1' HG21 ' A' ' 20' ' ' VAL . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 47' ' ' VAL . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.502 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.651 HD11 HG23 ' A' ' 74' ' ' THR . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.574 ' O ' HG13 ' A' ' 45' ' ' VAL . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.521 HG13 ' CZ ' ' A' ' 43' ' ' TYR . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.824 HD11 HD21 ' A' ' 76' ' ' LEU . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.521 ' CZ ' HG13 ' A' ' 34' ' ' VAL . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD12 ' A' ' 35' ' ' LEU . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.747 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 28' ' ' THR . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.559 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.52 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.704 ' O ' HG12 ' A' ' 63' ' ' VAL . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.703 HD11 ' HB2' ' A' ' 60' ' ' PHE . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 57' ' ' ASP . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.651 HG23 HD11 ' A' ' 30' ' ' ILE . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.418 HG22 ' HG ' ' A' ' 77' ' ' LEU . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.824 HD21 HD11 ' A' ' 35' ' ' LEU . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.814 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.409 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.409 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.747 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.58 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.554 ' HB3' HG12 ' A' ' 16' ' ' VAL . 72.3 Cg_endo . . . . . 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HG2' HD12 ' A' ' 79' ' ' ILE . 43.6 Cg_endo . . . . . 0 C--O 1.231 0.172 0 CA-C-O 120.815 0.256 . . . . 0.0 112.378 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.713 HD23 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.466 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 29' ' ' VAL . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.683 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.62 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.513 HD13 HD12 ' A' ' 77' ' ' LEU . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.62 HG23 HG23 ' A' ' 23' ' ' THR . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.62 HG23 HG23 ' A' ' 20' ' ' VAL . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.62 HG22 ' HB3' ' A' ' 17' ' ' SER . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.808 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.406 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.582 ' SG ' HG22 ' A' ' 45' ' ' VAL . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.647 ' O ' HD23 ' A' ' 35' ' ' LEU . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.647 HD23 ' O ' ' A' ' 34' ' ' VAL . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.713 HG11 HD23 ' A' ' 10' ' ' LEU . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.455 HG12 ' HA3' ' A' ' 27' ' ' GLY . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.454 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.697 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.582 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.668 ' O ' HG12 ' A' ' 63' ' ' VAL . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.691 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.808 HG23 HD11 ' A' ' 30' ' ' ILE . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.697 HD13 ' CH2' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.513 HD12 HD13 ' A' ' 18' ' ' LEU . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . 0.425 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' A' ' 45' ' ' VAL . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.683 ' HB3' HG12 ' A' ' 16' ' ' VAL . 52.0 Cg_endo . . . . . 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo . . . . . 0 N--CA 1.465 -0.168 0 CA-C-O 120.815 0.256 . . . . 0.0 112.398 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.581 HD23 HG13 ' A' ' 29' ' ' VAL . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.499 HD11 ' SG ' ' A' ' 32' ' ' CYS . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.595 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.673 HD13 HD12 ' A' ' 77' ' ' LEU . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.585 ' HB2' HD11 ' A' ' 83' ' ' ILE . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.672 HG23 HD13 ' A' ' 83' ' ' ILE . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 24' ' ' ILE . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG13 HD23 ' A' ' 10' ' ' LEU . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.781 HD11 HG23 ' A' ' 74' ' ' THR . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.7 ' O ' HG13 ' A' ' 45' ' ' VAL . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.499 ' SG ' HD11 ' A' ' 12' ' ' ILE . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.473 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 HD13 ' A' ' 65' ' ' LEU . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' A' ' 41' ' ' LEU . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.753 ' HB ' HD11 ' A' ' 82' ' ' ILE . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.532 ' CE ' HD12 ' A' ' 18' ' ' LEU . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.519 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.481 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.541 ' HB2' HD11 ' A' ' 65' ' ' LEU . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.541 HD11 ' HB2' ' A' ' 60' ' ' PHE . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.56 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.56 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.781 HG23 HD11 ' A' ' 30' ' ' ILE . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.519 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.673 HD12 HD13 ' A' ' 18' ' ' LEU . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.404 HG23 ' N ' ' A' ' 80' ' ' ASN . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.404 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.753 HD11 ' HB ' ' A' ' 45' ' ' VAL . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.672 HD13 HG23 ' A' ' 24' ' ' ILE . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.595 ' HB3' HG12 ' A' ' 16' ' ' VAL . 62.6 Cg_endo . . . . . 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.87 0.279 . . . . 0.0 112.188 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.71 HD11 HG11 ' A' ' 16' ' ' VAL . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.717 ' O ' HG11 ' A' ' 29' ' ' VAL . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.552 HG22 ' OD1' ' A' ' 13' ' ' ASN . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.552 ' OD1' HG22 ' A' ' 12' ' ' ILE . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.71 HG11 HD11 ' A' ' 10' ' ' LEU . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.466 HD13 HD12 ' A' ' 77' ' ' LEU . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.449 ' HB2' HD11 ' A' ' 83' ' ' ILE . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 83' ' ' ILE . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 24' ' ' ILE . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.717 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.682 HD11 HG23 ' A' ' 74' ' ' THR . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.624 ' O ' HG13 ' A' ' 45' ' ' VAL . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.439 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 41' ' ' LEU . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.627 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.473 ' HB3' HD11 ' A' ' 76' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.647 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.401 HG12 ' HA3' ' A' ' 27' ' ' GLY . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.414 ' HG2' HD12 ' A' ' 75' ' ' ILE . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.771 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.578 ' O ' HG12 ' A' ' 63' ' ' VAL . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.497 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.679 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.682 HG23 HD11 ' A' ' 30' ' ' ILE . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.442 HG22 ' HG ' ' A' ' 77' ' ' LEU . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.771 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.466 HD12 HD13 ' A' ' 18' ' ' LEU . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.647 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 24' ' ' ILE . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.426 ' HB3' HG12 ' A' ' 16' ' ' VAL . 17.1 Cg_exo . . . . . 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.814 0.256 . . . . 0.0 112.203 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.625 HD22 HG11 ' A' ' 45' ' ' VAL . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.695 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.608 HD13 HD12 ' A' ' 77' ' ' LEU . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.429 HG21 HD12 ' A' ' 83' ' ' ILE . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.402 ' N ' HG22 ' A' ' 24' ' ' ILE . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG1' HD23 ' A' ' 10' ' ' LEU . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.75 HD11 HG23 ' A' ' 74' ' ' THR . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.727 ' SG ' HG22 ' A' ' 45' ' ' VAL . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.706 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.749 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.413 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.402 ' HB2' HD13 ' A' ' 30' ' ' ILE . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.431 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.748 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.748 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.781 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.575 ' O ' HD12 ' A' ' 30' ' ' ILE . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.781 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.75 HG23 HD11 ' A' ' 30' ' ' ILE . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.459 HD21 HD11 ' A' ' 35' ' ' LEU . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 18' ' ' LEU . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 80' ' ' ASN . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.427 ' N ' HG23 ' A' ' 79' ' ' ILE . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.749 HD11 ' HB ' ' A' ' 45' ' ' VAL . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.429 HD12 HG21 ' A' ' 24' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.695 ' HB3' HG12 ' A' ' 16' ' ' VAL . 11.4 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo . . . . . 0 C--O 1.232 0.186 0 CA-C-O 120.898 0.291 . . . . 0.0 112.147 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.754 HD23 HG11 ' A' ' 45' ' ' VAL . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.461 ' O ' HG23 ' A' ' 29' ' ' VAL . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.611 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.488 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 77' ' ' LEU . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.477 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 17' ' ' SER . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.504 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 14' ' ' SER . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 74' ' ' THR . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.62 ' O ' HG13 ' A' ' 45' ' ' VAL . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 42' ' ' GLY . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.829 HD11 HD21 ' A' ' 76' ' ' LEU . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HE2' ' CE2' ' A' ' 44' ' ' PHE . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.469 ' HB3' HD11 ' A' ' 76' ' ' LEU . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.754 HG11 HD23 ' A' ' 10' ' ' LEU . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.504 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.529 ' HA ' HG23 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.69 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 65' ' ' LEU . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 69' ' ' ALA . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.443 ' HB2' ' HB3' ' A' ' 66' ' ' CYS . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.593 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.431 HG23 HD11 ' A' ' 30' ' ' ILE . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.829 HD21 HD11 ' A' ' 35' ' ' LEU . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.514 HD12 HD13 ' A' ' 18' ' ' LEU . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.619 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.619 HD12 ' HA ' ' A' ' 79' ' ' ILE . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.406 ' CD1' HD12 ' A' ' 24' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.611 ' HB3' HG12 ' A' ' 16' ' ' VAL . 54.6 Cg_endo . . . . . 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.86 0.275 . . . . 0.0 112.288 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.508 HD22 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.481 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.42 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.59 HD21 HG12 ' A' ' 82' ' ' ILE . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.659 ' CG2' HD13 ' A' ' 83' ' ' ILE . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.439 ' N ' HG22 ' A' ' 24' ' ' ILE . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.732 ' O ' HG13 ' A' ' 45' ' ' VAL . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.538 HG13 ' CE2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.578 HD11 HD21 ' A' ' 76' ' ' LEU . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.409 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.528 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.538 ' CE2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 31' ' ' PHE . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.501 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.425 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.696 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.544 ' O ' HG12 ' A' ' 63' ' ' VAL . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.415 ' N ' HG22 ' A' ' 63' ' ' VAL . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . 0.491 ' O ' HD12 ' A' ' 30' ' ' ILE . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.696 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.529 HG23 HD11 ' A' ' 30' ' ' ILE . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.498 HG22 ' HG ' ' A' ' 77' ' ' LEU . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.578 HD21 HD11 ' A' ' 35' ' ' LEU . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.498 ' HG ' HG22 ' A' ' 75' ' ' ILE . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.41 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.41 ' N ' HG23 ' A' ' 79' ' ' ILE . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.688 HD11 ' HB ' ' A' ' 45' ' ' VAL . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.659 HD13 ' CG2' ' A' ' 24' ' ' ILE . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.42 ' HB3' HG12 ' A' ' 16' ' ' VAL . 53.0 Cg_endo . . . . . 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo . . . . . 0 C--O 1.231 0.137 0 CA-C-O 120.798 0.249 . . . . 0.0 112.349 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.446 ' CD2' HG11 ' A' ' 45' ' ' VAL . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.494 HD21 HG12 ' A' ' 82' ' ' ILE . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.504 ' CG2' HD12 ' A' ' 83' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 30' ' ' ILE . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.813 HD11 HG23 ' A' ' 74' ' ' THR . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.676 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.569 ' SG ' HG22 ' A' ' 45' ' ' VAL . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.613 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.704 HD11 ' CD2' ' A' ' 76' ' ' LEU . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.69 ' HB3' HD12 ' A' ' 41' ' ' LEU . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.69 HD12 ' HB3' ' A' ' 38' ' ' LYS . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.613 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.557 ' CE1' HD12 ' A' ' 35' ' ' LEU . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.775 ' HB ' HD11 ' A' ' 82' ' ' ILE . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.406 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.497 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.852 ' O ' HG12 ' A' ' 63' ' ' VAL . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.852 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.44 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.813 HG23 HD11 ' A' ' 30' ' ' ILE . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.403 HD12 ' HG2' ' A' ' 49' ' ' MET . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.704 ' CD2' HD11 ' A' ' 35' ' ' LEU . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 80' ' ' ASN . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.407 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.775 HD11 ' HB ' ' A' ' 45' ' ' VAL . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo . . . . . 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo . . . . . 0 C--O 1.232 0.192 0 CA-C-O 120.889 0.287 . . . . 0.0 112.37 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 1.008 HD11 HG11 ' A' ' 16' ' ' VAL . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.426 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 1.008 HG11 HD11 ' A' ' 10' ' ' LEU . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.408 ' HB2' ' CG2' ' A' ' 24' ' ' ILE . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' HE2' ' A' ' 49' ' ' MET . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.618 HG23 HG23 ' A' ' 23' ' ' THR . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 20' ' ' VAL . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.456 HG22 ' N ' ' A' ' 25' ' ' GLU . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.456 ' N ' HG22 ' A' ' 24' ' ' ILE . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.44 ' O ' HG23 ' A' ' 30' ' ' ILE . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 74' ' ' THR . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.625 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.889 HD12 ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.426 ' CD ' HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 41' ' ' LEU . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.889 ' CD2' HD12 ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.736 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE2' HD12 ' A' ' 18' ' ' LEU . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.712 ' CH2' HD13 ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.76 ' O ' HG12 ' A' ' 63' ' ' VAL . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.76 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.436 HD12 ' HB2' ' A' ' 60' ' ' PHE . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.472 HG23 HD11 ' A' ' 30' ' ' ILE . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.712 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . 0.419 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.66 HD12 HD12 ' A' ' 82' ' ' ILE . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.736 HD11 ' HB ' ' A' ' 45' ' ' VAL . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.433 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo . . . . . 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo . . . . . 0 C--O 1.231 0.158 0 CA-C-O 120.854 0.273 . . . . 0.0 112.063 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 HG11 ' A' ' 45' ' ' VAL . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.4 HG12 ' HB3' ' A' ' 84' ' ' PRO . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.519 HD12 ' HB ' ' A' ' 47' ' ' VAL . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 25' ' ' GLU . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 20' ' ' VAL . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' VAL . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.726 HD11 HG23 ' A' ' 74' ' ' THR . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.714 ' O ' HG13 ' A' ' 45' ' ' VAL . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' HG22 ' A' ' 45' ' ' VAL . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.667 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.444 HD22 ' CD2' ' A' ' 60' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.402 ' HB3' HD12 ' A' ' 41' ' ' LEU . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.402 HD12 ' HB3' ' A' ' 38' ' ' LYS . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.542 ' CE1' HG13 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.761 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.519 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.524 ' CG ' HD11 ' A' ' 53' ' ' ILE . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.524 HD11 ' CG ' ' A' ' 49' ' ' MET . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.595 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.424 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.819 ' O ' HG12 ' A' ' 63' ' ' VAL . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.819 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.408 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.726 HG23 HD11 ' A' ' 30' ' ' ILE . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.595 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 18' ' ' LEU . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.761 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB3' HG12 ' A' ' 16' ' ' VAL . 49.8 Cg_endo . . . . . 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo . . . . . 0 C--O 1.231 0.174 0 CA-C-O 120.914 0.298 . . . . 0.0 112.164 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 45' ' ' VAL . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.458 HD11 ' SG ' ' A' ' 32' ' ' CYS . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.674 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.472 HD21 HG12 ' A' ' 82' ' ' ILE . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 25' ' ' GLU . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.532 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 20' ' ' VAL . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.544 HG13 HD23 ' A' ' 10' ' ' LEU . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.634 HD11 HG23 ' A' ' 74' ' ' THR . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.623 ' O ' HG13 ' A' ' 45' ' ' VAL . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.458 ' SG ' HD11 ' A' ' 12' ' ' ILE . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . 0.433 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.662 HG13 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.589 HD21 HD21 ' A' ' 76' ' ' LEU . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.447 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.456 ' HG2' HG21 ' A' ' 34' ' ' VAL . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.649 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.662 ' CE1' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.777 ' HB ' HD11 ' A' ' 82' ' ' ILE . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.439 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.406 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.419 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.645 ' CH2' HD13 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.618 ' O ' HG12 ' A' ' 63' ' ' VAL . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.56 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.634 HG23 HD11 ' A' ' 30' ' ' ILE . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.645 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.777 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.532 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.674 ' HB3' HG12 ' A' ' 16' ' ' VAL . 61.1 Cg_endo . . . . . 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 C--O 1.231 0.148 0 CA-C-O 120.875 0.281 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 10' ' ' LEU . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.516 ' O ' HG11 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 29' ' ' VAL . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.416 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.574 ' OG ' HG22 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 47' ' ' VAL . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 20' ' ' VAL . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 HG23 ' A' ' 20' ' ' VAL . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.574 HG22 ' OG ' ' A' ' 17' ' ' SER . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.516 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.86 HD11 HG23 ' A' ' 74' ' ' THR . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.694 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.576 HD11 ' CD2' ' A' ' 76' ' ' LEU . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.694 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.67 ' HB ' HD11 ' A' ' 82' ' ' ILE . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.562 ' HB ' HD11 ' A' ' 18' ' ' LEU . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.518 ' HE2' HD12 ' A' ' 75' ' ' ILE . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.405 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.482 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.562 ' CE1' HD13 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.631 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.86 HG23 HD11 ' A' ' 30' ' ' ILE . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.518 HD12 ' HE2' ' A' ' 49' ' ' MET . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 35' ' ' LEU . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.539 ' HA ' HD12 ' A' ' 82' ' ' ILE . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 45' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.568 HD12 HD12 ' A' ' 24' ' ' ILE . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo . . . . . 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo . . . . . 0 C--O 1.232 0.196 0 CA-C-O 120.857 0.274 . . . . 0.0 112.205 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.427 HD21 HG21 ' A' ' 16' ' ' VAL . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.442 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 10' ' ' LEU . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.461 HD13 HD12 ' A' ' 77' ' ' LEU . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 24' ' ' ILE . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.42 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 14' ' ' SER . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.685 HD11 ' CG2' ' A' ' 74' ' ' THR . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.66 ' O ' HG13 ' A' ' 45' ' ' VAL . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.574 HG12 ' O ' ' A' ' 42' ' ' GLY . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.588 HD11 ' CG ' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.597 ' CB ' HD12 ' A' ' 41' ' ' LEU . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.597 HD12 ' CB ' ' A' ' 38' ' ' LYS . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.574 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.544 ' CE2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.588 ' CG ' HD11 ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.763 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.466 ' HE2' HD12 ' A' ' 75' ' ' ILE . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.415 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.808 ' O ' HG12 ' A' ' 63' ' ' VAL . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.808 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . 0.616 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.616 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.685 ' CG2' HD11 ' A' ' 30' ' ' ILE . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.466 HD12 ' HE2' ' A' ' 49' ' ' MET . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.587 HD21 HD11 ' A' ' 35' ' ' LEU . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.461 HD12 HD13 ' A' ' 18' ' ' LEU . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 80' ' ' ASN . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 79' ' ' ILE . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.763 HD11 ' HB ' ' A' ' 45' ' ' VAL . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.619 ' CD1' HD12 ' A' ' 24' ' ' ILE . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo . . . . . 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.23 0.118 0 CA-C-O 120.808 0.253 . . . . 0.0 112.309 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.854 HD11 HG11 ' A' ' 16' ' ' VAL . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.453 HG22 ' OD1' ' A' ' 13' ' ' ASN . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.453 ' OD1' HG22 ' A' ' 12' ' ' ILE . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.417 ' O ' HG23 ' A' ' 29' ' ' VAL . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.854 HG11 HD11 ' A' ' 10' ' ' LEU . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 23' ' ' THR . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.455 HG23 HG23 ' A' ' 20' ' ' VAL . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.441 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 30' ' ' ILE . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.62 HD11 HG23 ' A' ' 74' ' ' THR . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . 0.412 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.493 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.713 HG13 ' CE1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' LEU . . . . . 0.795 HD11 HD21 ' A' ' 76' ' ' LEU . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.41 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LYS . . . . . 0.53 ' CG ' HD12 ' A' ' 41' ' ' LEU . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.53 HD12 ' CG ' ' A' ' 38' ' ' LYS . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TYR . . . . . 0.713 ' CE1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CD1' HD12 ' A' ' 35' ' ' LEU . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.74 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' MET . . . . . 0.411 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.441 HD13 ' OE2' ' A' ' 25' ' ' GLU . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' TRP . . . . . 0.634 ' CH2' HD13 ' A' ' 76' ' ' LEU . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.49 ' OD1' HG12 ' A' ' 71' ' ' VAL . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.428 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PHE . . . . . 0.633 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 64' ' ' GLN . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLN . . . . . 0.441 ' N ' HG22 ' A' ' 63' ' ' VAL . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.451 HD11 ' HB2' ' A' ' 60' ' ' PHE . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.62 HG23 HD11 ' A' ' 30' ' ' ILE . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.48 HG22 ' CD1' ' A' ' 77' ' ' LEU . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.795 HD21 HD11 ' A' ' 35' ' ' LEU . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LEU . . . . . 0.48 ' CD1' HG22 ' A' ' 75' ' ' ILE . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' HIS . . . . . 0.437 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.74 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo . . . . . 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.211 0 N-CA-C 112.516 -0.233 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -143.52 -176.09 4.82 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.796 0.331 . . . . 0.0 110.928 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.7 m -140.61 155.16 46.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 115.14 -65.08 0.3 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.444 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 7.3 p -97.71 154.83 17.33 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 111.016 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.8 t -135.21 110.32 8.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.838 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 119.33 -178.73 16.64 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.472 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.67 139.89 38.06 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.521 2.147 . . . . 0.0 112.23 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -70.86 -46.17 0.83 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.386 2.057 . . . . 0.0 112.3 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.614 HD22 HG11 ' A' ' 45' ' ' VAL . 5.8 tp -73.4 133.04 43.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.906 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 -61.87 133.08 54.99 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.932 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.9 mm -79.48 146.51 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.152 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 60.76 31.16 20.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.841 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.3 m -108.78 -179.95 4.01 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.924 179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -110.63 119.69 39.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.586 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.7 m -145.67 146.79 19.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.419 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -92.34 174.71 7.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.013 -179.937 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 4.0 mt -139.54 133.86 31.41 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.91 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.458 ' HA ' HD13 ' A' ' 24' ' ' ILE . 0.0 OUTLIER -79.22 94.91 5.5 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.8 m -104.79 121.37 56.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.105 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.05 -108.85 1.92 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.457 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.26 27.54 8.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.96 179.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.5 t -156.05 168.72 26.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.903 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.458 HD13 ' HA ' ' A' ' 19' ' ' LYS . 10.0 mm -110.82 153.84 12.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.013 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 17.2 mm-40 -136.16 118.16 15.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.952 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 36.0 m -61.48 141.07 57.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.899 179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.4 -176.12 27.22 Favored Glycine 0 N--CA 1.452 -0.247 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.46 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 m -118.56 153.28 34.49 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.373 . . . . 0.0 110.877 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.5 t -89.58 147.0 5.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.018 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 14.8 pt -151.26 -43.43 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.185 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 55.4 t80 -129.26 138.19 51.5 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.845 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.675 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -152.31 97.93 2.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.961 179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -162.36 -172.82 3.32 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.853 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.599 HG13 ' CE1' ' A' ' 43' ' ' TYR . 31.3 m -94.21 -179.72 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.154 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.59 HD11 ' CD2' ' A' ' 44' ' ' PHE . 5.8 mt -133.63 154.34 80.63 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.12 128.78 28.39 Favored 'Trans proline' 0 C--N 1.344 0.339 0 C-N-CA 122.549 2.166 . . . . 0.0 112.309 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.34 28.12 66.59 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.465 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.455 ' HG2' HD12 ' A' ' 41' ' ' LEU . 40.4 mttt -148.14 31.18 0.85 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.75 0.309 . . . . 0.0 110.886 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 64.4 mt-10 -77.18 -32.05 55.85 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.843 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -70.66 -30.07 66.58 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.909 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.455 HD12 ' HG2' ' A' ' 38' ' ' LYS . 17.2 mt -58.73 -35.37 72.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.999 179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.466 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 141.87 -125.88 2.83 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.479 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.599 ' CE1' HG13 ' A' ' 34' ' ' VAL . 13.4 m-85 -141.92 101.12 3.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.784 0.326 . . . . 0.0 110.932 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.59 ' CD2' HD11 ' A' ' 35' ' ' LEU . 10.7 m-85 -63.82 153.76 35.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.854 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.845 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -143.38 131.1 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.199 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -96.62 114.42 4.95 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.38 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.3 t -104.39 129.21 57.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 111.173 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -94.58 97.18 9.94 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.844 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 6.6 mmt -67.73 161.69 25.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.907 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.58 -31.68 32.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.857 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -96.08 156.84 36.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.818 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.32 81.35 0.97 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.552 2.168 . . . . 0.0 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 11.3 pt -141.49 27.99 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.181 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -79.19 -176.51 48.68 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -177.24 38.34 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.795 0.331 . . . . 0.0 110.879 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.454 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.4 t90 -162.33 109.33 1.3 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.445 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 4.4 t0 -75.35 -30.34 60.19 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.914 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.12 47.33 0.43 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.44 179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 56.7 mtt180 -137.86 165.89 25.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.822 0.344 . . . . 0.0 110.991 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.796 ' O ' HG12 ' A' ' 63' ' ' VAL . 12.9 t80 -145.53 99.43 3.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.782 179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 61.22 29.65 18.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.947 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.99 -47.4 1.05 Allowed Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.623 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.796 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.5 p -66.63 149.04 11.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.824 0.345 . . . . 0.0 111.136 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.0 tp60 -102.93 124.62 48.78 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.794 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 95.9 mt -107.42 -41.79 4.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.957 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.456 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 17.8 t -117.84 115.43 24.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.894 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 11.3 m -82.1 -39.35 23.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.808 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -65.91 -24.63 66.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.115 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.456 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -61.09 164.04 5.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.109 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -162.81 131.42 3.99 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.564 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.7 p -70.3 66.77 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.974 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -156.2 -43.07 0.08 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.068 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -129.78 -42.02 1.29 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.191 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 58.2 m -56.3 150.72 14.05 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.919 0.39 . . . . 0.0 111.226 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.419 HG22 ' HG ' ' A' ' 77' ' ' LEU . 29.1 mt -149.74 113.43 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.14 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.454 HD13 ' CH2' ' A' ' 56' ' ' TRP . 7.2 tp -91.11 114.88 27.52 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.936 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 73.1 mt -146.93 -179.99 7.2 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.05 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -69.07 135.51 50.9 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.966 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.459 HG23 ' N ' ' A' ' 80' ' ' ASN . 12.8 tt -50.15 -42.95 20.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.995 -179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.459 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.5 m-20 -55.49 -26.9 45.27 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.543 179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.01 -25.77 59.02 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.744 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.845 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.47 147.44 9.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.054 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.452 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.8 mm -129.16 90.03 46.37 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.032 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.586 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.7 Cg_endo -71.61 -178.08 2.84 Favored 'Trans proline' 0 C--N 1.345 0.373 0 C-N-CA 122.544 2.163 . . . . 0.0 112.381 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -146.21 60.7 1.24 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -133.95 157.38 46.17 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.885 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 6.4 m -110.69 -33.11 6.65 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.962 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 82.5 -172.64 52.39 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.507 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -69.86 168.32 22.03 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.559 2.172 . . . . 0.0 112.299 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.1 m -131.41 -177.66 4.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 9.5 p -176.06 -40.46 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.864 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.011 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.496 -179.992 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -125.98 177.37 6.38 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.712 0.291 . . . . 0.0 110.979 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 37.9 t -154.89 165.97 35.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.921 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -107.78 28.7 11.66 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.9 p -157.13 35.03 0.29 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.85 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -150.57 137.06 18.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.829 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 81.96 104.97 0.4 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.463 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -66.98 158.71 55.43 Favored 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.422 2.081 . . . . 0.0 112.29 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.441 ' HG2' HD12 ' A' ' 79' ' ' ILE . 48.6 Cg_endo -68.88 -46.83 1.44 Allowed 'Trans proline' 0 C--N 1.344 0.314 0 C-N-CA 122.566 2.178 . . . . 0.0 112.336 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.436 HD21 HG22 ' A' ' 29' ' ' VAL . 11.1 tp -78.94 129.46 34.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.877 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -69.64 125.73 27.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.872 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.433 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.2 mm -73.01 155.41 7.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.11 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.433 ' N ' HG22 ' A' ' 12' ' ' ILE . 2.4 m120 60.3 30.88 20.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.958 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.0 m -117.7 158.16 25.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.85 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 5.9 mmt180 -85.37 116.33 23.64 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.849 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.445 HG12 ' HA ' ' A' ' 84' ' ' PRO . 34.1 m -142.28 143.66 25.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.044 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.449 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.9 OUTLIER -90.82 174.5 7.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.99 179.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.766 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 3.3 mt -141.91 145.44 34.57 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.87 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 10.5 tttm -81.89 94.36 7.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' VAL . 27.7 m -102.8 113.57 39.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.121 179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.72 -105.32 1.04 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.472 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mt-10 -123.96 28.85 6.67 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.039 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.8 t -156.5 169.5 24.5 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.883 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.444 HG22 ' HB3' ' A' ' 17' ' ' SER . 6.6 mm -106.41 151.42 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.02 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.22 119.86 16.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.97 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -59.41 150.46 26.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.862 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -164.64 -173.84 33.73 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.576 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -123.55 153.61 40.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.79 0.329 . . . . 0.0 110.853 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.6 t -92.25 154.52 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.453 HG23 ' O ' ' A' ' 29' ' ' VAL . 15.0 pt -156.54 -43.09 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.246 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.612 ' O ' HG13 ' A' ' 45' ' ' VAL . 26.3 t80 -128.85 122.0 29.45 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.889 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.433 ' SG ' HG22 ' A' ' 45' ' ' VAL . 37.9 t -139.78 106.48 5.37 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -176.52 -169.05 0.27 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.941 -179.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.404 HG12 ' O ' ' A' ' 42' ' ' GLY . 18.8 m -90.32 179.81 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.468 HD11 ' CG ' ' A' ' 44' ' ' PHE . 9.9 mt -122.7 151.54 60.58 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.94 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.25 125.59 17.94 Favored 'Trans proline' 0 C--N 1.344 0.309 0 C-N-CA 122.602 2.201 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.25 27.55 63.05 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.573 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.557 ' HG2' HD12 ' A' ' 41' ' ' LEU . 16.0 mttt -150.72 39.41 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.831 0.348 . . . . 0.0 110.887 179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -80.34 -31.34 38.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.842 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 38.8 m -66.83 -27.8 67.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.967 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.557 HD12 ' HG2' ' A' ' 38' ' ' LYS . 11.2 mt -57.04 -54.35 47.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.978 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 165.25 -126.57 1.5 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.606 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -144.9 92.45 2.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.843 0.354 . . . . 0.0 110.852 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.468 ' CG ' HD11 ' A' ' 35' ' ' LEU . 49.5 m-85 -69.97 155.58 40.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.856 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.653 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.2 t -148.65 141.44 18.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.164 -179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.04 114.13 4.92 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.358 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.427 ' HB ' HD12 ' A' ' 18' ' ' LEU . 26.0 t -101.34 114.41 40.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.826 0.346 . . . . 0.0 111.137 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.3 95.7 5.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.87 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.766 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 1.9 mmt -60.11 159.02 10.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.994 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -76.18 -31.75 58.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.805 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.6 m-20 -107.63 158.69 32.7 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.894 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.29 82.08 0.89 Allowed 'Trans proline' 0 C--N 1.344 0.303 0 C-N-CA 122.481 2.12 . . . . 0.0 112.376 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 26.5 pt -139.24 27.94 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.19 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -94.25 -167.62 37.15 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.542 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -175.31 38.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.916 0.389 . . . . 0.0 110.988 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 13.2 t90 -142.45 109.59 5.57 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -66.37 -22.92 66.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 100.43 48.47 1.54 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.329 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.6 mtt180 -146.23 170.85 15.9 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.783 0.325 . . . . 0.0 111.001 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . . . . . . . . . 53.8 t80 -135.88 90.03 2.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.821 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.2 t70 62.14 30.33 17.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.929 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 126.92 -63.01 0.61 Allowed Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 11.2 p -59.6 137.96 21.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.754 0.312 . . . . 0.0 111.13 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tp60 -93.18 110.72 22.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 96.0 mt -85.71 -35.66 20.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.915 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.453 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 15.4 t -132.45 95.61 3.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.993 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.2 m -64.94 -37.76 88.7 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.871 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -64.39 -31.62 72.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.827 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.453 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -68.89 129.8 40.98 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.022 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 19.2 m -109.4 159.47 16.98 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.827 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.549 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -88.87 52.24 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.076 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -171.48 34.25 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.886 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.73 -56.74 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.887 179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.444 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.1 m -70.1 142.68 52.59 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.988 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.7 mt -139.34 121.92 17.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.09 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 6.4 tp -84.77 111.01 19.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.916 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 8.0 mt -143.27 174.81 10.39 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.945 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.4 t-80 -71.96 137.73 47.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.949 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.55 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.2 tt -48.03 -41.02 9.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.043 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.42 ' N ' HG23 ' A' ' 79' ' ' ILE . 5.4 t30 -55.81 -28.65 57.3 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.489 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -74.63 -27.15 60.32 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.6 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.653 HD11 ' HB ' ' A' ' 45' ' ' VAL . 23.8 mt -77.98 146.99 7.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.043 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.489 HD13 ' O ' ' A' ' 82' ' ' ILE . 27.1 mm -124.35 89.93 51.43 Favored Pre-proline 0 C--N 1.331 -0.235 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.148 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.445 ' HA ' HG12 ' A' ' 16' ' ' VAL . 73.4 Cg_endo -75.99 -168.59 0.56 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.61 2.207 . . . . 0.0 112.361 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -110.38 -171.23 1.79 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 45.3 t -168.67 171.96 8.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.929 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 m 60.66 157.18 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.003 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -131.89 -82.03 0.22 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.464 179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.73 -172.12 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.663 2.242 . . . . 0.0 112.277 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.5 p 61.29 153.58 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.933 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 42.7 m 63.11 123.25 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.982 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.444 -1.198 . . . . 0.0 112.463 -179.982 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.231 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -123.15 143.58 49.9 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.789 0.328 . . . . 0.0 110.954 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.98 -42.23 8.38 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.902 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.99 -168.46 13.32 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.519 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.4 m -151.0 137.54 18.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.826 0.346 . . . . 0.0 110.878 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -112.87 -67.25 1.01 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 65.5 72.7 0.69 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.534 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.13 163.53 1.51 Allowed 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.603 2.202 . . . . 0.0 112.296 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -63.12 -55.11 0.84 Allowed 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.583 2.189 . . . . 0.0 112.371 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.654 HD23 HG11 ' A' ' 45' ' ' VAL . 13.4 tp -73.84 137.62 43.91 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.907 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.65 122.55 16.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.916 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.1 mm -76.68 146.78 8.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.063 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.4 m120 60.88 29.09 18.8 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.9 m -111.14 167.85 9.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.727 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 27.1 mmt-85 -95.55 120.91 36.62 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.945 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.572 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -145.31 146.08 20.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.131 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -93.87 173.02 7.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.136 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.493 HD21 HG12 ' A' ' 82' ' ' ILE . 13.1 mt -138.73 134.72 33.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.806 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 9.6 tttm -82.72 92.56 7.22 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.411 HG23 HG23 ' A' ' 23' ' ' THR . 5.9 m -99.83 116.15 42.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 62.45 -103.02 0.55 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -126.64 31.33 5.36 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.802 0.334 . . . . 0.0 110.848 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.411 HG23 HG23 ' A' ' 20' ' ' VAL . 3.9 t -153.75 176.02 12.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.866 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.525 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.1 mm -118.14 157.63 19.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.027 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -144.0 112.83 6.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 11.7 m -65.0 139.68 58.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.844 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.79 -172.99 22.42 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.558 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.8 m -118.78 149.04 42.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.82 0.343 . . . . 0.0 110.821 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 19.4 t -89.18 139.53 17.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.138 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.639 HD11 ' CG2' ' A' ' 74' ' ' THR . 14.0 pt -139.53 -43.13 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.263 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.71 ' O ' HG13 ' A' ' 45' ' ' VAL . 24.0 t80 -122.71 144.76 48.94 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.931 179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.7 t -157.2 98.46 1.72 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.935 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -169.71 158.33 7.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.883 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.523 HG12 ' O ' ' A' ' 42' ' ' GLY . 29.9 m -59.25 165.61 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.142 179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.754 HD12 ' CD1' ' A' ' 44' ' ' PHE . 6.4 mt -102.64 144.9 29.53 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.746 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.531 ' CD ' HD11 ' A' ' 65' ' ' LEU . 58.4 Cg_exo -51.59 120.82 7.53 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.257 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.96 26.75 69.35 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.423 -179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.3 mttt -140.78 29.96 1.88 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.79 0.328 . . . . 0.0 110.86 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 -64.62 -30.79 71.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -32.57 74.11 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 68.8 mt -63.5 -52.26 62.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.523 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.79 -138.37 6.22 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.563 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.445 ' CE2' HG13 ' A' ' 34' ' ' VAL . 25.8 m-85 -125.31 96.8 4.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.827 0.346 . . . . 0.0 110.949 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.754 ' CD1' HD12 ' A' ' 35' ' ' LEU . 23.7 m-85 -63.27 160.41 15.84 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.842 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.742 ' HB ' HD11 ' A' ' 82' ' ' ILE . 17.9 t -151.12 139.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.224 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.94 116.25 5.42 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.344 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 20.8 t -102.43 117.81 48.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.296 -179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -79.77 93.27 5.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.755 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.445 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 16.2 mmt -58.93 151.96 20.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.943 -179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -68.6 -31.93 71.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.837 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -106.01 153.56 40.09 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.91 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.34 83.61 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.586 2.19 . . . . 0.0 112.244 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 15.2 pt -140.5 28.64 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.213 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.7 -168.01 39.5 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.451 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -176.14 39.33 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.938 179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.657 ' CH2' HD13 ' A' ' 76' ' ' LEU . 15.6 t90 -146.65 114.9 6.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -73.2 -35.03 66.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.842 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 120.72 38.25 0.67 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.471 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 37.3 mtt180 -137.62 162.06 34.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.822 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.734 ' O ' HG12 ' A' ' 63' ' ' VAL . 62.4 t80 -137.89 102.07 4.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.972 179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 62.92 28.64 16.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.973 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.74 -49.79 0.82 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.724 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.734 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -62.5 137.23 24.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.907 0.384 . . . . 0.0 111.144 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -88.99 121.45 31.35 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.531 HD11 ' CD ' ' A' ' 36' ' ' PRO . 38.4 mt -100.86 -41.6 6.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.928 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.4 t -131.98 114.42 14.59 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.959 179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 40.2 m -82.08 -37.54 26.21 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -65.05 -25.51 67.85 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.007 179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -66.37 158.23 29.8 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.166 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 12.5 m -140.28 154.54 46.86 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.907 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.529 HG22 ' O ' ' A' ' 71' ' ' VAL . 12.6 p -88.77 52.53 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.925 0.393 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -168.64 32.22 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.021 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.1 m 177.37 -62.28 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.943 179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.639 ' CG2' HD11 ' A' ' 30' ' ' ILE . 51.2 m -61.87 139.68 58.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.93 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.25 113.05 13.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.061 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.657 HD13 ' CH2' ' A' ' 56' ' ' TRP . 13.2 tp -77.34 111.18 12.73 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.922 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.438 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -138.07 -180.0 6.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.3 t-80 -80.82 140.21 35.56 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.953 -179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.552 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.9 tt -48.83 -42.82 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.097 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.463 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.2 t-20 -57.18 -28.01 62.44 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.606 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -77.9 -21.52 51.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.958 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.742 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.6 mt -80.87 143.54 12.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.021 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.525 ' CD1' HD12 ' A' ' 24' ' ' ILE . 3.8 mt -126.87 89.92 50.87 Favored Pre-proline 0 C--N 1.329 -0.299 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.206 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.572 ' HB3' HG12 ' A' ' 16' ' ' VAL . 56.4 Cg_endo -70.51 -167.86 0.28 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.609 2.206 . . . . 0.0 112.241 179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -156.98 93.05 1.31 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.872 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -158.82 177.65 10.95 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 74.1 m -108.71 -179.73 3.95 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 180.0 -61.57 0.08 OUTLIER Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.459 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -68.68 99.62 0.65 Allowed 'Trans proline' 0 C--N 1.343 0.259 0 C-N-CA 122.587 2.192 . . . . 0.0 112.278 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 11.9 t -152.59 76.11 1.13 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.919 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 50.0 m -124.31 168.7 12.63 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.919 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.077 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.488 179.937 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.109 0 N-CA-C 112.552 -0.219 . . . . 0.0 112.552 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 46.9 p -68.72 -36.01 77.87 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.852 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 m -171.24 35.12 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.28 -62.11 5.43 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.487 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -79.34 -32.46 43.28 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.76 0.314 . . . . 0.0 110.904 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t -115.74 111.86 21.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.17 72.65 0.26 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.437 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.4 139.04 37.11 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 122.604 2.203 . . . . 0.0 112.229 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.78 -49.0 1.71 Allowed 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.393 2.062 . . . . 0.0 112.318 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.684 HD23 HG11 ' A' ' 45' ' ' VAL . 12.2 tp -76.25 125.2 28.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -63.3 141.64 58.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.863 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.6 mm -80.72 155.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.018 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 12' ' ' ILE . 20.4 t30 60.13 29.63 19.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.871 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.2 m -110.03 172.2 7.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.791 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 14.0 mmt-85 -106.96 121.41 44.39 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.944 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG12 ' HB3' ' A' ' 84' ' ' PRO . 26.9 m -144.74 144.6 21.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.176 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -92.84 175.4 6.82 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.023 -179.927 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.421 HD13 HD12 ' A' ' 77' ' ' LEU . 9.0 mt -138.46 135.62 35.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.97 101.92 11.39 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.526 HG23 HG23 ' A' ' 23' ' ' THR . 5.4 m -110.05 114.9 48.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.137 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 61.84 -98.55 0.19 Allowed Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.474 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 -130.6 31.0 4.61 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.526 HG23 HG23 ' A' ' 20' ' ' VAL . 3.6 t -153.01 173.47 15.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.911 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.585 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.9 mm -121.7 154.2 25.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.029 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -140.5 117.13 10.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.878 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.7 m -61.68 147.29 46.42 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.981 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -156.98 -171.85 23.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -120.37 154.91 34.42 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.784 0.326 . . . . 0.0 110.924 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.2 t -97.84 128.71 48.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.129 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.489 HD11 HG23 ' A' ' 74' ' ' THR . 14.4 pt -133.71 -43.35 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.37 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.605 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.1 t80 -119.44 148.81 42.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.807 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.652 ' SG ' HG22 ' A' ' 45' ' ' VAL . 7.4 t -166.64 107.45 0.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.933 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -177.55 167.16 2.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.94 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.442 HG21 ' OE2' ' A' ' 39' ' ' GLU . 23.4 m -66.34 160.5 3.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.143 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.503 HD13 ' CZ ' ' A' ' 60' ' ' PHE . 9.3 mt -99.61 154.41 37.28 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.854 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_exo -51.24 118.96 4.79 Favored 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.547 2.164 . . . . 0.0 112.364 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.28 27.28 52.49 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.589 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -136.23 33.22 2.83 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.883 0.373 . . . . 0.0 110.942 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.442 ' OE2' HG21 ' A' ' 34' ' ' VAL . 22.7 mt-10 -67.2 -29.56 69.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.921 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.59 -30.74 71.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.977 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 10.8 mt -58.94 -53.07 62.55 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.918 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 156.54 -115.78 0.68 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.599 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -147.8 90.72 1.87 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.885 0.374 . . . . 0.0 110.946 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -60.06 152.4 24.19 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.755 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.701 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.6 t -144.03 134.32 20.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.155 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.07 110.27 3.92 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.327 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.1 t -96.09 128.14 47.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.804 0.335 . . . . 0.0 111.254 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -97.3 102.65 14.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.812 179.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.419 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.0 mmt -72.68 161.95 30.11 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.953 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -81.23 -31.6 33.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.816 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -101.43 157.08 34.35 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.839 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -70.18 81.76 0.9 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.538 2.159 . . . . 0.0 112.328 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.5 pt -141.37 29.14 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.237 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.434 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.48 -170.61 43.61 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.476 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -175.91 38.17 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.798 0.333 . . . . 0.0 110.944 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.642 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 6.3 t90 -148.25 120.17 8.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -96.88 27.15 4.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.027 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.432 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 61.45 40.37 98.58 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.509 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 16.2 mtt180 -136.07 155.11 50.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.739 0.304 . . . . 0.0 111.0 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.573 ' O ' HG12 ' A' ' 63' ' ' VAL . 1.1 t80 -132.75 94.81 3.46 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.922 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 19.6 t70 63.53 30.6 15.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.012 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.32 -55.88 0.59 Allowed Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.596 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.573 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -60.38 140.02 18.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.114 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -97.99 125.94 43.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 40.3 mt -109.76 -31.35 7.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.94 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 4.8 t -130.39 90.72 2.98 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.861 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -59.35 -30.62 68.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.943 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -72.72 -35.09 67.5 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.837 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.4 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.37 134.82 57.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.21 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.7 m -123.35 157.73 32.64 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.829 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.515 ' O ' HG13 ' A' ' 71' ' ' VAL . 12.7 p -84.17 55.4 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.153 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -177.2 35.74 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.886 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 177.8 -60.22 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.893 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.489 HG23 HD11 ' A' ' 30' ' ' ILE . 37.3 m -69.47 147.93 50.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.944 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.434 HD11 ' HA2' ' A' ' 54' ' ' GLY . 30.9 mt -148.18 116.74 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.1 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.642 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 10.8 tp -89.65 115.05 26.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.919 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.421 HD12 HD13 ' A' ' 18' ' ' LEU . 33.9 mt -143.23 179.99 6.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.926 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -76.55 134.24 39.48 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 12.3 tt -48.54 -38.84 9.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.48 -27.82 62.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.563 179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -81.06 -24.89 37.51 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.862 179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.701 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.3 mt -73.4 149.75 8.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.01 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.585 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -131.83 89.9 37.7 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.195 179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.677 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.9 Cg_endo -71.82 -170.92 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.568 2.179 . . . . 0.0 112.322 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -156.09 31.54 0.34 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.9 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 39.2 p -135.71 179.7 6.18 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.866 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 4.0 t -106.53 160.2 15.6 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.894 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 167.64 70.88 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.503 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.82 134.76 28.64 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.594 2.196 . . . . 0.0 112.282 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 3.7 t -129.89 107.75 9.61 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.916 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 m -99.09 172.41 7.4 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.872 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.352 -1.249 . . . . 0.0 112.453 -179.999 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.183 0 N-CA-C 112.564 -0.214 . . . . 0.0 112.564 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -65.12 131.31 46.21 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 110.895 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 t -130.3 158.31 40.14 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.958 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.09 -96.8 0.11 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.508 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 67.3 m 60.94 40.4 15.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.807 0.337 . . . . 0.0 110.937 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 5.2 m -124.64 85.2 2.38 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.879 -179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.93 -148.67 12.54 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_exo -51.56 149.72 17.72 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.615 2.21 . . . . 0.0 112.257 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.62 -45.55 0.54 Allowed 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.545 2.164 . . . . 0.0 112.381 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.529 ' CD2' HG11 ' A' ' 45' ' ' VAL . 13.7 tp -75.15 133.29 41.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 69.7 mt-10 -70.18 127.86 34.28 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.882 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.8 mm -77.42 153.75 5.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.072 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 32.4 m120 60.45 30.96 20.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.4 m -117.11 179.97 3.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.818 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 8.8 mmt-85 -108.25 122.29 46.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.975 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.508 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.8 m -142.79 147.55 20.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.025 179.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.413 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.3 OUTLIER -91.54 168.7 11.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.947 -179.997 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.551 HD22 HD12 ' A' ' 77' ' ' LEU . 10.2 mt -138.33 126.85 23.34 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.9 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.7 tttt -73.01 91.12 1.54 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.914 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.599 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.6 m -105.43 118.35 52.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.098 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 65.97 -117.26 9.52 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.463 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -115.73 31.35 6.76 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.783 0.325 . . . . 0.0 110.891 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.5 t -158.61 174.59 14.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.942 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.567 HG23 HD13 ' A' ' 83' ' ' ILE . 13.4 mm -108.29 154.21 9.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.068 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.599 ' HG3' HG21 ' A' ' 20' ' ' VAL . 5.0 mm-40 -135.8 113.59 11.06 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.973 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.0 m -68.29 132.6 47.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.865 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -148.12 -176.96 22.07 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.549 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -113.01 151.72 30.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.7 t -90.69 144.33 9.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.165 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.522 HD11 HG23 ' A' ' 74' ' ' THR . 7.4 pt -146.34 -42.97 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.193 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.628 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.2 t80 -126.64 152.94 46.02 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.889 179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.648 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.2 t -166.87 101.3 0.55 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.937 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -172.77 -175.62 1.32 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.487 HG12 ' O ' ' A' ' 42' ' ' GLY . 15.5 m -86.35 164.98 2.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.243 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.65 HD13 ' CE2' ' A' ' 60' ' ' PHE . 17.8 mt -111.13 157.31 39.18 Favored Pre-proline 0 C--N 1.327 -0.392 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.895 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -52.19 123.19 12.06 Favored 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.531 2.154 . . . . 0.0 112.301 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.37 28.78 59.59 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.555 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 23.7 mtpt -141.24 36.43 1.71 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.801 0.334 . . . . 0.0 110.98 -179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 25.2 mt-10 -76.9 -30.91 56.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -64.05 -30.1 71.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.88 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.4 mt -58.61 -47.71 83.44 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.487 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 150.55 -117.98 0.89 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.561 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.68 93.25 2.44 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.822 0.344 . . . . 0.0 110.909 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -62.56 154.47 28.73 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.826 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.73 ' HB ' HD11 ' A' ' 82' ' ' ILE . 20.1 t -143.95 133.94 20.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.196 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.77 112.97 4.59 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.349 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.9 t -105.59 130.11 57.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.815 0.341 . . . . 0.0 111.178 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -92.56 99.21 11.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.744 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.429 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.1 mmt -68.25 154.83 40.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.941 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 7.9 t0 -75.63 -31.63 59.92 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 47.4 m-20 -96.81 158.79 32.93 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.882 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.16 80.52 0.99 Allowed 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.511 2.14 . . . . 0.0 112.348 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.453 ' O ' HD11 ' A' ' 75' ' ' ILE . 32.1 pt -138.06 28.0 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.149 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.404 ' HA2' HG12 ' A' ' 75' ' ' ILE . . . -78.71 175.24 55.02 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.605 -179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -170.94 35.09 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.833 0.349 . . . . 0.0 110.908 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.685 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 14.8 t90 -158.13 124.32 4.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.854 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.547 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 2.7 t70 -80.06 -30.73 39.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.05 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.404 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.21 32.87 1.73 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.479 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -139.49 166.99 23.1 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.808 0.337 . . . . 0.0 110.787 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.84 ' O ' HG12 ' A' ' 63' ' ' VAL . 4.5 t80 -144.99 104.21 3.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.975 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 61.11 28.84 18.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.031 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 112.66 -50.67 0.75 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.653 -0.784 . . . . 0.0 112.61 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.84 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.3 p -59.07 145.26 11.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.798 0.332 . . . . 0.0 111.132 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -104.66 122.74 46.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.935 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.408 HD13 HD23 ' A' ' 35' ' ' LEU . 13.9 mt -113.72 -38.0 4.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.869 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.708 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.6 t -111.07 93.95 4.74 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.935 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.8 p -71.51 -26.34 62.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 27.9 m-85 -97.37 32.96 2.09 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.986 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.708 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -108.52 175.78 5.35 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.999 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.64 133.96 0.22 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.995 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -68.83 71.87 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.94 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 17.7 tt0 -168.17 -40.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.3 m -126.82 -40.15 1.92 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.193 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.556 HG21 ' CB ' ' A' ' 69' ' ' ALA . 12.6 m -60.75 140.26 57.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.192 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.453 HD11 ' O ' ' A' ' 53' ' ' ILE . 53.2 mt -147.89 119.22 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.958 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.685 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 13.7 tp -92.55 116.74 29.26 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.93 179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.551 HD12 HD22 ' A' ' 18' ' ' LEU . 91.8 mt -142.33 174.67 10.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.885 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -72.97 138.58 46.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.002 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.453 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.1 tp -50.51 -42.43 21.58 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.995 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.453 ' N ' HG23 ' A' ' 79' ' ' ILE . 89.2 m-20 -57.67 -26.57 61.86 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.675 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -80.64 -13.59 58.9 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.112 179.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.73 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.6 mt -87.14 143.27 11.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.146 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.567 HD13 HG23 ' A' ' 24' ' ' ILE . 3.9 mp -125.82 90.01 51.26 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.059 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.508 ' HB3' HG12 ' A' ' 16' ' ' VAL . 58.5 Cg_endo -71.56 -169.5 0.43 Allowed 'Trans proline' 0 C--N 1.345 0.342 0 C-N-CA 122.48 2.12 . . . . 0.0 112.374 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -134.75 114.06 12.27 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.89 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.8 m -137.66 107.81 6.4 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.941 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 42.6 p -113.17 82.56 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.89 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -89.78 -54.72 2.14 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.471 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.08 -58.8 1.36 Allowed 'Trans proline' 0 C--N 1.344 0.325 0 C-N-CA 122.629 2.219 . . . . 0.0 112.348 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -68.12 153.73 43.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.953 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.7 m 60.6 95.74 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.909 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.414 -1.214 . . . . 0.0 112.535 -179.98 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 112.621 -0.192 . . . . 0.0 112.621 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 t -159.48 119.22 2.99 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.842 0.353 . . . . 0.0 110.884 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.3 m -138.2 -172.73 3.34 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.977 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 166.72 172.49 34.05 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.469 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.9 t -106.15 136.16 46.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.888 0.375 . . . . 0.0 110.87 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 t -176.52 146.89 0.63 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.926 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -179.24 82.45 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.753 -0.736 . . . . 0.0 112.538 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -52.43 160.96 3.09 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 122.619 2.212 . . . . 0.0 112.213 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.67 -51.06 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.586 2.191 . . . . 0.0 112.351 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.5 HD13 HD11 ' A' ' 79' ' ' ILE . 13.2 tp -83.47 128.91 34.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.872 -179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.0 mt-10 -57.58 143.34 41.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.034 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.465 HG22 ' OD1' ' A' ' 13' ' ' ASN . 27.0 mm -84.73 145.94 7.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.279 -0.418 . . . . 0.0 111.111 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.465 ' OD1' HG22 ' A' ' 12' ' ' ILE . 23.9 m-20 59.7 30.23 19.82 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.931 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.1 m -102.07 177.54 4.86 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.914 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.1 mmm-85 -112.31 114.27 26.93 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.862 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.656 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.6 m -137.52 148.74 25.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 26' ' ' SER . 0.5 OUTLIER -93.55 170.87 9.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.09 -179.882 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.49 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 8.8 mt -136.46 130.71 33.01 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.742 180.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 2.2 tttt -76.84 98.54 4.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.041 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.4 m -110.79 113.87 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.154 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 64.62 -112.74 5.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.449 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -118.45 31.99 6.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 110.987 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.4 m -159.79 159.58 32.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.778 HD12 ' CD1' ' A' ' 83' ' ' ILE . 7.8 mm -102.81 158.33 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.051 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -141.87 115.17 8.87 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.988 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 1.3 m -64.33 142.72 58.32 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.832 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.14 -177.03 28.01 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.579 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.6 m -113.91 149.92 34.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.808 0.337 . . . . 0.0 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -90.81 149.52 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.637 HD11 HG23 ' A' ' 74' ' ' THR . 9.3 pt -153.2 -43.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.342 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.67 ' O ' HG13 ' A' ' 45' ' ' VAL . 43.0 t80 -123.19 125.38 45.0 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.955 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.5 t -139.89 87.79 2.19 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.852 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -159.14 177.48 11.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.814 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.71 HG12 ' O ' ' A' ' 42' ' ' GLY . 22.6 m -88.02 172.47 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.133 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.786 HD11 HD21 ' A' ' 76' ' ' LEU . 11.9 mt -122.28 158.09 56.69 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.938 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.92 125.61 17.63 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.618 2.212 . . . . 0.0 112.261 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.7 27.48 73.28 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.556 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.5 ' HG2' HD12 ' A' ' 41' ' ' LEU . 17.9 mttt -152.89 30.52 0.5 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 110.935 179.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 -77.1 -31.31 55.79 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.855 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 71.0 m -80.18 -28.64 38.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.5 HD12 ' HG2' ' A' ' 38' ' ' LYS . 46.3 mt -57.83 -43.93 86.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.984 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.71 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 162.63 -137.86 5.05 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.592 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -140.86 92.74 2.53 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.809 0.338 . . . . 0.0 110.939 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -60.41 154.03 21.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.807 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.758 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.6 t -146.14 136.08 17.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.214 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.63 109.95 3.93 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.422 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 21.5 t -96.24 123.97 48.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.819 0.342 . . . . 0.0 111.153 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -89.19 93.29 9.51 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.88 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.567 ' HG2' HD12 ' A' ' 75' ' ' ILE . 6.9 mmt -62.63 159.55 15.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.978 -179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -70.04 -35.65 74.45 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.849 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -100.74 154.11 37.35 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.75 74.52 1.28 Allowed 'Trans proline' 0 C--N 1.344 0.293 0 C-N-CA 122.582 2.188 . . . . 0.0 112.226 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.45 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.8 pt -126.44 30.17 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.179 179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -96.39 -170.42 34.67 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.539 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -174.65 36.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.488 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 12.3 t90 -144.5 120.06 10.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -98.68 30.85 3.12 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.877 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 59.82 54.35 38.28 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.469 179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 7.2 mtp180 -142.26 154.67 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.878 0.371 . . . . 0.0 110.922 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.818 ' O ' HG12 ' A' ' 63' ' ' VAL . 27.9 t80 -137.4 90.41 2.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.794 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.2 t70 65.46 29.49 11.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.951 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 114.25 -39.57 2.76 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.818 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.5 p -73.63 137.79 22.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 111.137 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -91.05 125.56 35.88 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.867 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.478 ' CD1' HD22 ' A' ' 35' ' ' LEU . 73.4 mt -111.9 -37.66 5.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.865 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.682 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.5 t -120.23 110.72 16.92 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.63 -33.78 58.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.876 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 23.8 m-85 -77.02 -10.25 59.25 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.323 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.682 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -71.74 177.16 4.33 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.883 0.373 . . . . 0.0 111.117 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.92 130.11 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.884 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.3 p -67.24 75.18 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.003 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -167.44 -41.62 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.084 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.5 m -129.6 -44.57 1.22 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.111 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.637 HG23 HD11 ' A' ' 30' ' ' ILE . 7.1 m -57.48 128.03 35.01 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.017 -179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.567 HD12 ' HG2' ' A' ' 49' ' ' MET . 3.9 mt -129.24 113.18 27.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.002 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.786 HD21 HD11 ' A' ' 35' ' ' LEU . 21.4 tp -84.13 124.33 31.02 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.886 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.422 HD12 HD22 ' A' ' 18' ' ' LEU . 66.2 mt -153.26 174.63 14.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.992 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . 0.433 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.0 t-80 -74.15 135.69 42.87 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.971 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.5 HD11 HD13 ' A' ' 10' ' ' LEU . 0.9 OUTLIER -48.09 -40.43 9.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.034 179.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.413 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.0 OUTLIER -57.4 -28.93 63.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.627 179.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -78.08 -22.82 48.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.903 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.758 HD11 ' HB ' ' A' ' 45' ' ' VAL . 28.8 mt -74.7 147.64 8.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.374 -0.375 . . . . 0.0 111.116 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.778 ' CD1' HD12 ' A' ' 24' ' ' ILE . 17.5 mt -129.71 89.96 44.91 Favored Pre-proline 0 C--N 1.331 -0.201 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.004 179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.656 ' HB3' HG12 ' A' ' 16' ' ' VAL . 65.2 Cg_endo -73.82 -168.25 0.44 Allowed 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.641 2.228 . . . . 0.0 112.276 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 tp10 -132.47 125.11 29.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.862 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 61.55 31.55 18.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.875 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.3 m -152.97 101.01 2.55 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.929 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -78.33 -164.83 26.06 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.524 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 -45.95 1.31 Allowed 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.611 2.207 . . . . 0.0 112.271 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 29.4 t -175.95 156.35 1.75 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.14 31.24 5.51 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.883 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.384 -1.231 . . . . 0.0 112.465 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.524 -0.23 . . . . 0.0 112.524 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.1 p -102.78 116.37 32.44 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.812 0.339 . . . . 0.0 110.97 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 10.9 t -144.69 83.68 1.71 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 92.17 144.08 13.28 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.491 179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 69.4 m -79.9 62.76 4.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.854 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 39.5 m 60.73 94.59 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.945 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.61 -100.99 0.25 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.54 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.13 113.04 1.09 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 122.415 2.076 . . . . 0.0 112.239 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -67.45 -37.61 16.9 Favored 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.486 2.124 . . . . 0.0 112.292 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.556 HD21 HG21 ' A' ' 16' ' ' VAL . 11.9 tp -84.0 128.03 34.28 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.877 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 32.6 mt-10 -63.71 132.23 50.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.881 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.8 mm -75.01 149.8 7.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.134 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 22.6 m120 60.42 31.62 20.39 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 39.6 m -113.19 170.13 8.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -101.7 124.34 47.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.881 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.556 HG21 HD21 ' A' ' 10' ' ' LEU . 29.0 m -148.58 148.92 15.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.174 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.486 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -94.89 176.34 6.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.834 -179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.814 HD13 HD12 ' A' ' 77' ' ' LEU . 4.7 mt -143.22 136.94 28.6 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.8 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -83.12 90.4 7.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.026 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.819 HG21 ' OE1' ' A' ' 25' ' ' GLU . 5.9 m -103.7 122.28 56.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.096 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 63.1 -111.51 4.17 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.436 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -121.06 27.69 8.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.815 0.34 . . . . 0.0 111.0 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -156.1 169.03 25.43 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.856 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.58 ' CG2' HD12 ' A' ' 83' ' ' ILE . 10.0 mm -107.11 156.69 7.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.038 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.819 ' OE1' HG21 ' A' ' 20' ' ' VAL . 31.8 mt-10 -138.94 117.79 12.38 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.882 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 58.0 m -68.15 136.67 54.03 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.949 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.67 -171.7 20.4 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.484 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 47' ' ' VAL . 16.9 m -116.94 157.62 25.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.814 0.34 . . . . 0.0 110.917 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.502 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.4 t -91.63 152.67 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.238 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.651 HD11 HG23 ' A' ' 74' ' ' THR . 13.8 pt -157.94 -43.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.261 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.574 ' O ' HG13 ' A' ' 45' ' ' VAL . 9.4 t80 -130.83 134.54 46.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.895 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.513 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -150.44 100.27 2.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.933 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -170.0 178.66 3.86 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.943 -179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.521 HG13 ' CZ ' ' A' ' 43' ' ' TYR . 30.5 m -79.1 174.33 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.192 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.824 HD11 HD21 ' A' ' 76' ' ' LEU . 14.1 mt -123.36 153.03 65.32 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.902 -179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -52.57 125.44 17.86 Favored 'Trans proline' 0 C--N 1.344 0.296 0 C-N-CA 122.553 2.168 . . . . 0.0 112.231 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.76 28.27 65.38 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.526 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 43.4 mttp -143.49 31.12 1.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.768 0.318 . . . . 0.0 110.926 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -74.52 -31.26 62.09 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.907 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 2.4 t -69.6 -31.56 69.78 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.976 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.1 mt -60.23 -49.25 78.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.882 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.419 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.02 -130.53 2.68 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.772 -0.727 . . . . 0.0 112.522 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.521 ' CZ ' HG13 ' A' ' 34' ' ' VAL . 1.4 m-85 -136.17 98.78 3.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD12 ' A' ' 35' ' ' LEU . 36.2 m-85 -64.13 154.08 35.73 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.861 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.747 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.5 132.21 8.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.2 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.96 118.32 6.08 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.406 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 28' ' ' THR . 16.8 t -108.57 128.82 63.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.785 0.326 . . . . 0.0 111.228 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -88.53 97.78 11.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 14.9 mmt -70.0 171.83 8.85 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.905 -179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -84.79 -34.04 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.854 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -97.03 161.84 24.91 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.853 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.18 63.01 2.03 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 122.595 2.197 . . . . 0.0 112.291 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 19.2 pt -115.77 29.84 2.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.136 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.18 165.53 30.33 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.506 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -161.47 31.06 0.13 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.796 0.331 . . . . 0.0 110.861 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.559 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 17.9 t90 -154.25 108.75 3.04 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.93 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.52 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 18.9 t70 -73.46 -29.9 62.84 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.975 -179.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 118.1 45.51 0.49 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.418 -179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 65.2 mtt180 -143.51 171.23 14.44 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.838 0.351 . . . . 0.0 110.836 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.704 ' O ' HG12 ' A' ' 63' ' ' VAL . 2.3 t80 -135.2 90.96 2.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.856 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 6.2 t0 62.2 30.75 17.72 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.922 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.98 -51.62 0.77 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.498 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.704 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -61.13 131.69 26.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.877 0.37 . . . . 0.0 111.097 -179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 17.0 tp60 -82.52 132.79 35.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.928 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.703 HD11 ' HB2' ' A' ' 60' ' ' PHE . 46.6 mt -115.24 -44.56 2.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.904 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 24.2 t -130.43 125.47 34.57 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 69.2 m -82.86 -31.36 28.0 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.853 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.73 -32.28 71.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.913 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 57' ' ' ASP . . . -60.33 154.6 19.8 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.97 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 53.0 m -152.85 132.82 13.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.5 p -71.17 72.7 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.965 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -170.12 -40.01 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.973 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -125.47 -42.66 1.95 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.002 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.651 HG23 HD11 ' A' ' 30' ' ' ILE . 25.3 m -60.3 141.28 56.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.049 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.418 HG22 ' HG ' ' A' ' 77' ' ' LEU . 31.5 mt -138.29 114.51 10.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.163 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.824 HD21 HD11 ' A' ' 35' ' ' LEU . 14.8 tp -86.1 118.28 25.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.807 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.814 HD12 HD13 ' A' ' 18' ' ' LEU . 78.3 mt -150.75 172.5 15.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.935 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -67.94 136.95 54.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.852 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.409 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.0 OUTLIER -49.26 -40.27 13.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.2 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.995 179.972 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.409 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.3 m-80 -56.75 -28.14 60.67 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.424 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -74.56 -26.13 59.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.567 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.747 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.2 mt -75.8 146.01 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.998 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.58 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -128.43 89.84 48.47 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.216 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.554 ' HB3' HG12 ' A' ' 16' ' ' VAL . 72.3 Cg_endo -77.42 -174.28 2.14 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.578 2.185 . . . . 0.0 112.335 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 57.9 165.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.964 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 t -71.68 159.03 35.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.887 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -97.17 107.37 19.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.868 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 125.77 148.66 7.25 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.444 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -71.45 -45.11 0.88 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.621 2.214 . . . . 0.0 112.348 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 24.8 p -128.58 -174.17 3.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.888 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.1 t -70.36 -33.82 71.9 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.874 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.514 -179.953 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.55 -0.22 . . . . 0.0 112.55 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.3 m -105.37 -34.58 7.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.94 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.1 p -120.56 -177.81 3.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.866 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 96.97 121.13 4.06 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.544 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -143.61 114.41 7.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.877 0.37 . . . . 0.0 110.92 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -154.0 80.75 1.14 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.864 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -107.26 -76.23 0.98 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.545 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -67.04 150.62 82.59 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.623 2.215 . . . . 0.0 112.324 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HG2' HD12 ' A' ' 79' ' ' ILE . 43.6 Cg_endo -68.7 -49.17 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.509 2.139 . . . . 0.0 112.378 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.713 HD23 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -75.71 134.93 40.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' O ' HG11 ' A' ' 29' ' ' VAL . 4.2 mt-10 -78.44 149.09 33.33 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.833 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.466 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.9 mm -86.12 157.45 3.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.466 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.4 m-20 59.84 29.64 19.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.924 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 29' ' ' VAL . 37.4 m -115.26 160.01 20.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.86 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -99.52 112.3 24.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.914 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.683 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -131.66 147.63 32.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.139 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.62 ' HB3' HG22 ' A' ' 24' ' ' ILE . 0.7 OUTLIER -93.62 166.71 12.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.96 -179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.513 HD13 HD12 ' A' ' 77' ' ' LEU . 6.8 mt -129.76 140.63 51.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.9 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.57 101.93 11.8 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.92 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.62 HG23 HG23 ' A' ' 23' ' ' THR . 5.5 m -108.38 115.69 49.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.11 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.75 -97.44 0.1 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.5 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 89.5 mt-10 -130.23 28.3 5.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.812 0.339 . . . . 0.0 110.983 179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.62 HG23 HG23 ' A' ' 20' ' ' VAL . 1.7 t -151.48 167.21 28.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.926 -179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.62 HG22 ' HB3' ' A' ' 17' ' ' SER . 10.5 mm -110.48 145.6 16.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.056 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.1 mm-40 -129.15 119.16 23.63 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.805 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 73.3 m -63.38 142.56 58.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.887 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.455 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -156.95 175.56 34.43 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.402 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.1 m -111.08 149.79 30.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.888 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' ILE . 21.3 t -86.83 153.57 3.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.808 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -157.95 -43.07 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.29 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.406 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.6 t80 -130.23 125.46 34.94 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.951 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.582 ' SG ' HG22 ' A' ' 45' ' ' VAL . 42.7 t -140.77 110.78 6.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.98 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -177.31 -169.47 0.24 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.938 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.647 ' O ' HD23 ' A' ' 35' ' ' LEU . 31.6 m -96.12 176.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.095 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.647 HD23 ' O ' ' A' ' 34' ' ' VAL . 14.0 mt -129.93 159.37 70.33 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.965 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -54.17 127.56 26.3 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.586 2.19 . . . . 0.0 112.274 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.38 28.46 62.01 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.517 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 67.8 mttt -145.17 31.57 1.12 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.855 0.36 . . . . 0.0 110.93 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -79.02 -32.77 45.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.1 m -67.94 -31.29 70.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.872 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 14.3 mt -59.42 -44.25 92.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.836 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.517 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 151.03 -130.05 3.07 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -136.06 98.69 3.94 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.908 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -65.69 153.77 40.76 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.755 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.713 HG11 HD23 ' A' ' 10' ' ' LEU . 21.5 t -146.25 135.58 17.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.354 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -94.33 116.6 5.32 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.278 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.455 HG12 ' HA3' ' A' ' 27' ' ' GLY . 20.5 t -106.79 128.21 61.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.87 0.367 . . . . 0.0 111.336 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -95.23 102.92 14.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.703 179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.454 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 6.3 mmt -72.23 171.07 12.75 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.969 -179.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -90.12 -31.38 17.12 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.88 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -98.24 161.3 25.84 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -71.06 83.46 0.93 Allowed 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.59 2.193 . . . . 0.0 112.426 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 13.4 pt -142.5 25.73 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.282 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -84.7 -179.5 51.29 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.538 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -177.48 37.84 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.813 0.34 . . . . 0.0 110.961 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.697 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.9 t90 -146.92 121.09 9.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.881 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -98.56 27.33 4.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.017 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.582 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 57.13 51.47 57.25 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.608 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 76.3 mtt180 -145.72 158.33 43.86 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.886 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.668 ' O ' HG12 ' A' ' 63' ' ' VAL . 22.1 t80 -133.76 89.96 2.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.797 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 64.29 27.93 13.81 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.973 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 119.78 -44.08 1.45 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.679 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.668 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.5 p -72.54 127.79 34.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.786 0.327 . . . . 0.0 111.244 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -82.84 121.62 27.16 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.867 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 42.4 mt -105.87 -44.47 4.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.966 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.691 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 50.6 t -111.15 109.13 19.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.958 179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.4 p -71.67 -29.53 64.71 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.978 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -96.28 41.24 1.11 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.91 179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.691 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -126.1 108.29 11.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.004 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -105.64 131.54 52.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.966 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.4 p -66.4 77.1 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.987 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -165.06 -42.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -127.04 -41.06 1.82 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.153 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.808 HG23 HD11 ' A' ' 30' ' ' ILE . 19.9 m -61.57 141.44 57.75 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.133 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 44.2 mt -145.82 116.2 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.008 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.697 HD13 ' CH2' ' A' ' 56' ' ' TRP . 5.7 tp -88.13 118.31 27.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.813 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.513 HD12 HD13 ' A' ' 18' ' ' LEU . 82.4 mt -147.36 179.99 7.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.011 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . 0.425 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -75.68 134.91 40.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.999 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.451 ' HA ' HD12 ' A' ' 82' ' ' ILE . 12.2 tt -49.34 -35.89 9.01 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.92 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -59.3 -28.19 66.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.436 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.59 1.56 45.45 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.152 179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.546 HD11 ' HB ' ' A' ' 45' ' ' VAL . 22.6 mt -102.59 148.49 7.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-O 120.759 0.314 . . . . 0.0 111.045 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 31.6 mt -132.62 92.05 28.38 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.172 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.683 ' HB3' HG12 ' A' ' 16' ' ' VAL . 52.0 Cg_endo -69.32 -167.84 0.23 Allowed 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.537 2.158 . . . . 0.0 112.238 179.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -89.29 85.64 6.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.902 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.6 m -89.77 89.08 7.62 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.934 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.02 132.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.881 179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.88 56.61 0.73 Allowed Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.59 62.86 2.26 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.604 2.203 . . . . 0.0 112.317 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 33.8 m -93.7 119.06 32.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.932 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 60.41 178.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.883 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.376 -1.236 . . . . 0.0 112.507 179.977 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 112.534 -0.227 . . . . 0.0 112.534 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.4 m -73.52 127.4 32.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.903 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 16.3 p -121.42 -44.17 2.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.863 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 65.06 -96.17 0.22 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.538 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -108.24 -171.71 1.92 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 110.804 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.9 t 62.72 147.63 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.97 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 118.32 -119.36 4.35 Favored Glycine 0 CA--C 1.519 0.321 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.502 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -54.03 149.83 33.57 Favored 'Trans proline' 0 C--N 1.346 0.43 0 C-N-CA 122.413 2.076 . . . . 0.0 112.305 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -74.1 -44.79 0.41 Allowed 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 122.542 2.161 . . . . 0.0 112.398 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.581 HD23 HG13 ' A' ' 29' ' ' VAL . 14.3 tp -82.43 127.47 33.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.942 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -67.89 141.51 56.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.89 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.499 HD11 ' SG ' ' A' ' 32' ' ' CYS . 24.3 mm -81.63 154.97 4.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.12 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 0.5 OUTLIER 60.84 30.8 19.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.941 179.999 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m -115.0 164.71 13.78 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.91 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.48 125.54 49.24 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.897 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.595 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.6 m -145.45 148.85 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.165 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.41 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.4 OUTLIER -93.2 174.21 7.34 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.035 -179.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.673 HD13 HD12 ' A' ' 77' ' ' LEU . 12.8 mt -137.13 133.32 35.16 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.88 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.585 ' HB2' HD11 ' A' ' 83' ' ' ILE . 7.6 tmtt? -85.45 102.04 13.13 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.908 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.0 m -115.51 119.11 60.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.17 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 60.08 -108.28 1.69 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.553 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.3 mm-40 -122.78 31.74 5.96 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.761 0.315 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -156.0 167.71 29.54 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.797 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.672 HG23 HD13 ' A' ' 83' ' ' ILE . 10.3 mm -115.76 161.24 14.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.032 179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 24' ' ' ILE . 65.4 mt-10 -143.63 117.2 9.17 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.917 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 52.7 m -67.6 137.51 55.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.778 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -151.81 -177.82 25.93 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.573 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 6.7 m -111.4 157.85 19.76 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.783 0.325 . . . . 0.0 110.847 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG13 HD23 ' A' ' 10' ' ' LEU . 21.8 t -97.28 123.84 49.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.195 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.781 HD11 HG23 ' A' ' 74' ' ' THR . 14.5 pt -124.64 -39.61 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.29 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.7 ' O ' HG13 ' A' ' 45' ' ' VAL . 81.8 t80 -130.31 156.86 43.97 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.833 179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.499 ' SG ' HD11 ' A' ' 12' ' ' ILE . 5.3 p -169.32 104.05 0.37 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.962 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -176.06 -168.57 0.28 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.936 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.473 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.4 m -95.89 165.85 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.167 -179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.52 HD22 HD13 ' A' ' 65' ' ' LEU . 16.2 mt -115.07 160.82 32.38 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.863 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.18 124.47 14.94 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.512 2.141 . . . . 0.0 112.357 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.06 32.04 66.25 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.816 -0.707 . . . . 0.0 112.558 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.3 mttt -146.58 30.71 0.99 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 110.887 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -79.21 -31.11 43.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.838 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 10.0 t -70.87 -31.4 68.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.901 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.419 HD23 ' HA ' ' A' ' 41' ' ' LEU . 17.7 mt -59.74 -45.63 91.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.972 179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.473 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 159.04 -135.8 4.38 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.468 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 4.6 m-85 -137.29 96.51 3.28 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.845 0.355 . . . . 0.0 110.85 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -63.26 163.79 9.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.864 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.753 ' HB ' HD11 ' A' ' 82' ' ' ILE . 22.2 t -152.22 135.41 7.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.199 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.5 109.95 3.93 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.378 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.428 ' CG2' HD11 ' A' ' 18' ' ' LEU . 25.7 t -97.5 126.56 50.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.86 0.362 . . . . 0.0 111.139 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -92.65 95.73 9.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.532 ' CE ' HD12 ' A' ' 18' ' ' LEU . 2.5 mmt -58.77 164.48 2.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.949 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -80.35 -31.41 37.97 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.867 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -106.78 159.56 29.45 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.919 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.07 81.66 0.64 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.526 2.151 . . . . 0.0 112.28 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 17.2 pt -140.33 30.41 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.126 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.44 -168.14 43.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 180.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -177.2 37.68 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.519 ' CZ3' HD13 ' A' ' 76' ' ' LEU . 11.5 t90 -154.79 124.64 6.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.954 179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -78.73 -28.34 44.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.976 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.481 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 115.62 28.88 2.61 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.56 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 22.6 mtt180 -132.82 176.7 8.24 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.771 0.319 . . . . 0.0 110.818 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.541 ' HB2' HD11 ' A' ' 65' ' ' LEU . 27.5 t80 -136.1 90.02 2.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.908 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 57.18 29.39 16.58 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.118 179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.12 -61.14 0.67 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.579 -179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.47 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.4 p -58.36 131.63 22.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.917 0.389 . . . . 0.0 111.162 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 4.4 tp60 -86.71 129.76 34.74 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.913 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.541 HD11 ' HB2' ' A' ' 60' ' ' PHE . 8.5 mt -113.29 -39.42 4.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.882 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.56 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 48.2 t -129.6 110.73 12.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.963 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 2.5 p -74.47 -41.32 60.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.934 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 18.1 m-85 -66.51 -19.04 65.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.18 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.56 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -64.42 173.9 1.9 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.163 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -175.12 136.32 0.37 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.925 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.57 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.6 p -70.02 67.33 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.007 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -151.51 -46.0 0.11 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.989 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.83 -39.49 1.41 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.296 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.781 HG23 HD11 ' A' ' 30' ' ' ILE . 84.0 m -58.73 143.96 45.27 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.892 0.377 . . . . 0.0 111.244 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 47.8 mt -146.7 121.93 2.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.975 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.519 HD13 ' CZ3' ' A' ' 56' ' ' TRP . 14.6 tp -87.36 121.58 30.0 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.673 HD12 HD13 ' A' ' 18' ' ' LEU . 68.9 mt -149.04 172.25 15.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.965 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 -73.27 136.07 44.53 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.021 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.404 HG23 ' N ' ' A' ' 80' ' ' ASN . 3.7 tt -49.55 -39.75 14.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.181 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.032 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.404 ' N ' HG23 ' A' ' 79' ' ' ILE . 3.3 t-20 -57.22 -26.3 60.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.563 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.3 m-20 -80.86 -23.82 38.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.873 179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.753 HD11 ' HB ' ' A' ' 45' ' ' VAL . 34.3 mt -74.1 147.97 8.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.069 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.672 HD13 HG23 ' A' ' 24' ' ' ILE . 2.8 mp -131.59 89.93 38.58 Favored Pre-proline 0 C--N 1.331 -0.232 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.081 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.595 ' HB3' HG12 ' A' ' 16' ' ' VAL . 62.6 Cg_endo -73.43 -168.42 0.44 Allowed 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.52 2.146 . . . . 0.0 112.409 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -98.62 156.59 16.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.917 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 37.2 m -124.98 168.89 12.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.954 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 51.0 m 60.99 156.27 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.848 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 136.43 -61.07 0.62 Allowed Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.504 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -69.17 151.91 72.38 Favored 'Trans proline' 0 C--N 1.343 0.285 0 C-N-CA 122.61 2.207 . . . . 0.0 112.338 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 5.6 p -118.56 -39.47 3.0 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.967 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 62.85 90.51 0.08 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.894 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.365 -1.242 . . . . 0.0 112.516 -179.958 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.21 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.6 p -72.25 128.86 36.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.813 0.339 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.71 95.24 6.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.868 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 145.24 -154.77 26.13 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.536 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.16 131.74 51.14 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.833 0.349 . . . . 0.0 110.86 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.5 p -104.96 152.76 22.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -59.44 -92.66 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.506 179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 56.6 Cg_endo -70.86 139.13 35.78 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.464 2.109 . . . . 0.0 112.259 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.6 Cg_exo -57.73 -61.58 0.28 Allowed 'Trans proline' 0 C--N 1.347 0.461 0 C-N-CA 122.393 2.062 . . . . 0.0 112.188 179.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.71 HD11 HG11 ' A' ' 16' ' ' VAL . 9.0 tp -60.5 150.1 32.37 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.868 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.717 ' O ' HG11 ' A' ' 29' ' ' VAL . 16.4 mm-40 -86.7 169.29 12.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.891 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.552 HG22 ' OD1' ' A' ' 13' ' ' ASN . 23.1 mm -101.57 139.93 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.093 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.552 ' OD1' HG22 ' A' ' 12' ' ' ILE . 4.0 m120 60.0 31.42 20.64 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 40.9 m -104.91 173.25 6.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.904 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 3.3 mmt-85 -102.17 117.73 35.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.863 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.71 HG11 HD11 ' A' ' 10' ' ' LEU . 27.6 m -141.32 144.5 26.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.195 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -94.54 172.26 8.3 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.023 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.466 HD13 HD12 ' A' ' 77' ' ' LEU . 5.9 mt -137.77 143.84 41.3 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.888 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.449 ' HB2' HD11 ' A' ' 83' ' ' ILE . 1.8 tttp -90.45 102.2 14.94 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.9 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 4.8 m -117.02 110.13 30.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.114 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.89 -111.42 3.36 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.646 -0.787 . . . . 0.0 112.51 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -122.11 30.97 6.36 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.835 0.35 . . . . 0.0 110.886 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 4.3 t -158.33 172.62 18.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.892 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.611 HG23 HD13 ' A' ' 83' ' ' ILE . 8.8 mm -113.33 162.36 11.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.007 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 24' ' ' ILE . 4.4 mm-40 -145.42 116.0 7.65 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.977 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 9.2 m -63.63 144.77 56.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.401 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -157.83 -177.34 30.83 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.536 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -114.93 151.3 34.29 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.838 0.351 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.717 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.2 t -87.93 154.84 3.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.042 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.682 HD11 HG23 ' A' ' 74' ' ' THR . 12.6 pt -158.24 -42.86 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.26 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.624 ' O ' HG13 ' A' ' 45' ' ' VAL . 20.5 t80 -128.84 126.45 39.85 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.963 179.962 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 11.6 p -140.44 100.63 3.93 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.947 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -172.43 -169.37 0.6 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.924 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.2 m -98.38 179.12 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.155 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.6 mt -125.47 162.22 45.77 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -52.22 126.36 20.2 Favored 'Trans proline' 0 C--N 1.343 0.279 0 C-N-CA 122.591 2.194 . . . . 0.0 112.252 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.53 27.05 67.37 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.545 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.439 ' HG2' HD12 ' A' ' 41' ' ' LEU . 24.9 mttt -147.58 30.45 0.91 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.735 0.302 . . . . 0.0 110.889 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -76.52 -31.27 57.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 69.9 m -79.57 -27.13 41.18 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.978 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.443 ' HA ' HD23 ' A' ' 41' ' ' LEU . 16.1 mt -56.71 -39.62 74.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.045 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.627 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 157.46 -133.87 3.72 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.536 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 2.6 m-85 -140.62 97.48 3.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.801 0.334 . . . . 0.0 110.94 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.473 ' HB3' HD11 ' A' ' 76' ' ' LEU . 53.1 m-85 -67.61 153.54 43.46 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.879 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.647 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.0 t -150.87 138.55 13.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.151 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.09 117.94 5.83 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.514 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.401 HG12 ' HA3' ' A' ' 27' ' ' GLY . 23.4 t -104.78 124.86 59.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.822 0.344 . . . . 0.0 111.115 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -87.63 99.46 12.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.878 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.414 ' HG2' HD12 ' A' ' 75' ' ' ILE . 8.2 mmt -68.83 159.47 32.39 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.96 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.5 p-10 -77.4 -32.42 54.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.5 m-80 -102.32 152.07 38.24 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.926 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.8 87.04 0.57 Allowed 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.557 2.171 . . . . 0.0 112.277 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 18.8 pt -145.58 26.84 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.47 -165.27 40.31 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.461 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -175.07 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.814 0.34 . . . . 0.0 110.908 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.771 ' CZ2' HD22 ' A' ' 76' ' ' LEU . 3.2 t90 -154.11 114.65 3.96 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.925 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -79.11 -31.14 44.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.903 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.418 ' HA2' ' CZ3' ' A' ' 56' ' ' TRP . . . 123.1 55.41 0.2 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.439 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 73.9 mtt180 -146.3 165.5 29.08 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.578 ' O ' HG12 ' A' ' 63' ' ' VAL . 47.0 t80 -130.71 90.07 2.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.49 30.1 17.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.894 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 123.19 -56.59 0.66 Allowed Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.54 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.578 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.9 p -58.91 144.75 11.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.811 0.338 . . . . 0.0 111.101 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -99.42 132.62 44.63 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.848 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 56.6 mt -125.37 -44.45 1.86 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.907 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.497 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 5.9 t -110.07 95.93 5.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.844 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -71.53 -32.62 68.37 Favored 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.874 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 24.9 m-85 -69.8 -31.8 69.9 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.956 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.679 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -60.58 154.84 20.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -149.3 137.75 20.88 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.917 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 71' ' ' VAL . 8.2 p -68.64 74.3 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 121.029 0.442 . . . . 0.0 110.967 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -168.96 -41.8 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.977 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.1 m -126.08 -44.5 1.75 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.033 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.682 HG23 HD11 ' A' ' 30' ' ' ILE . 30.8 m -63.87 125.06 23.17 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.442 HG22 ' HG ' ' A' ' 77' ' ' LEU . 2.2 mt -130.07 114.31 29.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.072 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.771 HD22 ' CZ2' ' A' ' 56' ' ' TRP . 26.9 tp -81.29 114.17 19.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.886 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.466 HD12 HD13 ' A' ' 18' ' ' LEU . 75.7 mt -148.6 165.07 32.4 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.939 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -63.88 137.06 57.86 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.987 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 16.7 tt -48.81 -36.77 8.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.019 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -58.4 -28.68 65.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.469 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -78.06 -22.49 49.0 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.84 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.647 HD11 ' HB ' ' A' ' 45' ' ' VAL . 17.5 mt -77.17 152.79 5.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.03 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.611 HD13 HG23 ' A' ' 24' ' ' ILE . 4.2 mp -137.52 89.74 15.47 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.974 179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.426 ' HB3' HG12 ' A' ' 16' ' ' VAL . 17.1 Cg_exo -66.49 171.74 10.18 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.811 2.34 . . . . 0.0 112.174 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -106.04 87.49 2.58 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.947 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 m -138.02 174.24 10.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.838 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -167.58 35.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.853 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.51 92.29 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.476 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -68.54 142.69 54.56 Favored 'Trans proline' 0 C--N 1.345 0.372 0 C-N-CA 122.461 2.107 . . . . 0.0 112.337 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 t -127.83 -49.59 1.36 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.856 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.3 m -84.6 106.74 16.4 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.354 -1.248 . . . . 0.0 112.457 179.985 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.135 0 N-CA-C 112.5 -0.24 . . . . 0.0 112.5 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.5 t -131.39 37.05 3.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.872 0.368 . . . . 0.0 110.893 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 13.6 t -123.57 114.4 19.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.893 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -98.24 115.23 5.23 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.497 179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.6 p -123.84 102.23 7.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.833 0.349 . . . . 0.0 110.934 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 11.4 p -129.33 170.82 13.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.848 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -77.22 -106.02 0.16 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.665 -0.779 . . . . 0.0 112.435 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -73.69 155.57 49.33 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.467 2.111 . . . . 0.0 112.333 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.06 -47.13 2.56 Favored 'Trans proline' 0 C--N 1.345 0.381 0 C-N-CA 122.559 2.173 . . . . 0.0 112.203 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.625 HD22 HG11 ' A' ' 45' ' ' VAL . 3.4 tp -77.35 131.43 38.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.843 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -71.61 145.61 48.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.969 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.421 HG22 ' N ' ' A' ' 13' ' ' ASN . 27.3 mm -85.15 155.24 3.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.099 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.421 ' N ' HG22 ' A' ' 12' ' ' ILE . 23.7 m120 60.03 31.49 20.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 6.7 m -111.46 171.82 7.25 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.831 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.19 114.88 29.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.868 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.695 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.0 m -141.15 149.36 20.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.056 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.49 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -95.29 170.92 9.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.925 -179.993 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.608 HD13 HD12 ' A' ' 77' ' ' LEU . 2.8 mt -139.91 138.06 35.32 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.842 179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 26.6 tttt -85.43 105.52 16.12 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.939 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 3.8 m -119.48 115.47 47.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.158 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 74.1 -107.46 2.26 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.472 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -125.37 31.35 5.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.801 0.334 . . . . 0.0 110.841 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 6.2 t -162.5 175.12 11.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.849 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.429 HG21 HD12 ' A' ' 83' ' ' ILE . 14.5 mm -112.47 156.54 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.104 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.402 ' N ' HG22 ' A' ' 24' ' ' ILE . 63.4 mm-40 -136.36 121.06 18.44 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.864 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 63.3 m -67.34 134.63 51.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.825 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -150.23 -172.18 19.3 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.498 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -118.82 159.28 24.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.777 0.322 . . . . 0.0 110.934 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.489 ' CG1' HD23 ' A' ' 10' ' ' LEU . 21.4 t -96.46 135.99 28.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.139 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.75 HD11 HG23 ' A' ' 74' ' ' THR . 11.9 pt -136.56 -42.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.271 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.568 ' O ' HG13 ' A' ' 45' ' ' VAL . 49.5 t80 -127.92 162.49 26.63 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.908 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.727 ' SG ' HG22 ' A' ' 45' ' ' VAL . 29.0 t -173.49 110.73 0.18 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.898 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -175.15 176.56 2.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.937 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.706 HG12 ' O ' ' A' ' 42' ' ' GLY . 26.8 m -80.69 174.22 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.203 179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.577 HD12 ' CE2' ' A' ' 44' ' ' PHE . 7.6 mt -116.57 152.13 47.9 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_exo -52.02 125.43 17.23 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.615 2.21 . . . . 0.0 112.227 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.92 26.44 60.7 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.515 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 50.3 mttp -144.99 30.01 1.18 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.832 0.348 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -70.93 -31.51 68.14 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.822 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 49.8 m -64.91 -29.81 70.77 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.888 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 42.9 mt -58.66 -52.97 63.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.03 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.706 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 161.66 -134.38 3.5 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.536 179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -132.47 96.69 3.9 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.911 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.577 ' CE2' HD12 ' A' ' 35' ' ' LEU . 50.8 m-85 -62.62 152.43 35.18 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.793 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.749 ' HB ' HD11 ' A' ' 82' ' ' ILE . 13.8 t -142.04 134.65 27.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.259 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.59 110.16 3.97 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.422 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.413 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.3 t -99.39 129.77 49.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.25 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.402 ' HB2' HD13 ' A' ' 30' ' ' ILE . 11.3 t70 -95.54 96.45 9.07 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.816 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 4.1 mmt -68.22 161.25 27.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.945 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -79.16 -35.51 41.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.921 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -91.19 154.78 44.87 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.949 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.58 62.79 2.25 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.54 2.16 . . . . 0.0 112.337 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 20.3 pt -118.17 25.61 4.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.24 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -83.58 -177.06 51.59 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.512 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -175.32 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.878 0.37 . . . . 0.0 110.941 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.431 ' CE3' ' HB2' ' A' ' 76' ' ' LEU . 5.1 t90 -154.47 123.72 6.43 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.517 ' O ' ' HB3' ' A' ' 69' ' ' ALA . 1.4 t70 -84.33 -30.82 25.21 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.898 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 119.08 45.14 0.46 Allowed Glycine 0 N--CA 1.453 -0.174 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.357 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 31.1 mtt180 -144.06 176.76 9.06 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.787 0.327 . . . . 0.0 110.836 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.748 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.1 t80 -146.11 93.63 2.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.908 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 61.04 30.63 19.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.898 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.5 -50.53 0.79 Allowed Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.604 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.748 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.1 p -63.73 145.53 13.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.847 0.356 . . . . 0.0 111.104 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 3.5 tp60 -96.74 144.91 26.29 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.836 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 67.8 mt -138.01 -47.37 0.54 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.943 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.781 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 42.4 t -108.51 95.32 5.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.879 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 18.2 m -68.94 -23.59 64.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.012 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.575 ' O ' HD12 ' A' ' 30' ' ' ILE . 6.1 m-85 -96.41 33.64 1.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.433 -0.348 . . . . 0.0 111.058 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.781 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -117.29 156.58 27.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.003 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -155.77 130.64 9.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.82 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.615 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.1 p -65.62 79.22 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -172.95 -40.45 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.031 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -131.29 -43.42 1.04 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.211 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.75 HG23 HD11 ' A' ' 30' ' ' ILE . 17.2 m -61.19 144.36 53.85 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 mt -148.64 118.85 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.015 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.459 HD21 HD11 ' A' ' 35' ' ' LEU . 5.9 tp -91.54 116.15 28.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.904 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.608 HD12 HD13 ' A' ' 18' ' ' LEU . 31.6 mt -146.05 -179.94 7.06 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.934 -179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -74.47 137.69 42.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.866 -179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.427 HG23 ' N ' ' A' ' 80' ' ' ASN . 2.7 tt -48.67 -41.34 12.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.427 ' N ' HG23 ' A' ' 79' ' ' ILE . 4.3 m-80 -56.23 -28.92 60.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.471 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -73.83 -26.25 60.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.623 179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.749 HD11 ' HB ' ' A' ' 45' ' ' VAL . 26.4 mt -78.69 147.51 6.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.965 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.429 HD12 HG21 ' A' ' 24' ' ' ILE . 29.8 mt -130.58 89.8 42.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.02 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.695 ' HB3' HG12 ' A' ' 16' ' ' VAL . 11.4 Cg_exo -70.68 -179.73 3.55 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.787 2.325 . . . . 0.0 112.17 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -119.25 63.57 0.79 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.931 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -109.79 44.64 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.873 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 64.1 m -121.37 90.12 3.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.902 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -159.74 -164.13 14.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.454 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -69.44 -46.8 1.21 Allowed 'Trans proline' 0 C--N 1.344 0.342 0 C-N-CA 122.539 2.159 . . . . 0.0 112.336 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -120.55 -41.92 2.57 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.892 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 62.87 149.03 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.913 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.089 0 CA-C-O 118.395 -1.225 . . . . 0.0 112.508 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.186 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.92 172.43 11.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.772 0.32 . . . . 0.0 110.917 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 34.1 p -93.24 122.08 35.27 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.938 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -100.7 63.59 0.58 Allowed Glycine 0 N--CA 1.453 -0.216 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.443 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.2 p -146.72 -52.04 0.22 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 110.85 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.5 m -138.16 142.44 40.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.899 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 127.81 150.14 7.27 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.459 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.414 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 51.2 Cg_exo -53.36 140.04 63.56 Favored 'Trans proline' 0 C--N 1.344 0.317 0 C-N-CA 122.559 2.173 . . . . 0.0 112.223 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.3 Cg_exo -60.21 -63.4 0.12 Allowed 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.311 2.007 . . . . 0.0 112.147 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.754 HD23 HG11 ' A' ' 45' ' ' VAL . 12.8 tp -67.39 133.67 50.03 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.923 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -70.62 131.3 43.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.857 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.6 mm -75.89 149.36 6.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.108 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 21.1 m-20 60.64 31.37 20.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.956 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.461 ' O ' HG23 ' A' ' 29' ' ' VAL . 22.6 m -114.58 159.13 20.78 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.896 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.14 116.43 27.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.962 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.611 HG12 ' HB3' ' A' ' 84' ' ' PRO . 35.2 m -138.54 145.73 27.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.079 -179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.488 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.6 OUTLIER -89.33 173.58 8.3 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.059 -179.86 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.514 HD13 HD12 ' A' ' 77' ' ' LEU . 4.1 mt -145.44 139.51 26.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.844 179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 42.4 tttt -84.77 93.35 8.44 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.869 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.477 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.8 m -104.86 129.49 57.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.17 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.12 -98.37 0.11 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.549 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.85 30.43 2.8 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.833 0.349 . . . . 0.0 110.914 179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 9.8 m -160.11 158.83 30.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.974 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 17' ' ' SER . 9.4 mm -90.96 152.47 3.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.97 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.504 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.9 mm-40 -139.09 114.06 9.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.839 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.405 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 23.6 m -58.67 144.4 43.47 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.916 179.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.95 -172.95 25.74 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -123.71 152.1 42.46 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.875 0.369 . . . . 0.0 110.882 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.461 HG23 ' O ' ' A' ' 14' ' ' SER . 11.3 t -92.14 146.8 5.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.052 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 74' ' ' THR . 14.2 pt -151.54 -43.54 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.243 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.62 ' O ' HG13 ' A' ' 45' ' ' VAL . 5.4 t80 -117.59 135.22 54.12 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.943 179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 23.7 t -147.4 101.22 3.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.897 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -176.55 -171.11 0.38 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.87 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.402 HG12 ' O ' ' A' ' 42' ' ' GLY . 5.8 m -102.7 179.24 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.829 HD11 HD21 ' A' ' 76' ' ' LEU . 9.4 mt -125.62 163.36 39.32 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.907 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -52.34 125.49 17.75 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.482 2.121 . . . . 0.0 112.303 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.41 28.95 65.48 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.485 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.409 ' HE2' ' CE2' ' A' ' 44' ' ' PHE . 59.3 mtpt -148.61 34.06 0.78 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.855 0.36 . . . . 0.0 110.929 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 12.2 mt-10 -81.71 -31.6 32.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.841 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 22.3 t -73.42 -27.11 61.26 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.05 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.2 mt -56.85 -32.71 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.975 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.402 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 147.67 -130.45 3.53 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.577 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 17.4 m-85 -140.95 91.64 2.43 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.817 0.341 . . . . 0.0 110.908 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.469 ' HB3' HD11 ' A' ' 76' ' ' LEU . 43.6 m-85 -60.5 147.66 40.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.864 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.754 HG11 HD23 ' A' ' 10' ' ' LEU . 21.8 t -142.86 123.24 10.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.136 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.99 114.44 3.83 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.739 -0.744 . . . . 0.0 112.455 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 25.7 t -104.53 126.36 59.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.85 0.357 . . . . 0.0 111.166 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -93.88 99.55 11.88 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.844 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . . . . . . . . . 5.6 mmt -68.7 164.56 21.38 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.853 -179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -80.98 -40.71 23.93 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.845 -179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -90.6 153.3 45.78 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.872 -179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.98 79.98 0.98 Allowed 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.656 2.237 . . . . 0.0 112.307 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.504 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.8 pt -138.65 27.28 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.264 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -86.69 -169.98 46.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.529 ' HA ' HG23 ' A' ' 71' ' ' VAL . 0.7 OUTLIER -175.25 37.05 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.824 0.345 . . . . 0.0 110.982 179.965 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -148.49 120.05 7.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.931 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 40.5 t0 -103.28 30.04 5.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.857 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 59.58 52.54 52.49 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.46 179.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 13.0 mtt180 -144.56 137.99 27.17 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.875 0.369 . . . . 0.0 110.912 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.69 ' O ' HG12 ' A' ' 63' ' ' VAL . 34.0 t80 -116.08 89.9 3.21 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 62.71 26.88 15.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.975 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 120.73 -44.33 1.39 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.726 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.69 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -72.03 128.16 34.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.844 0.354 . . . . 0.0 111.16 -179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -76.76 133.19 39.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.931 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 65' ' ' LEU . 18.5 mt -123.87 -45.89 2.0 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.878 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 69' ' ' ALA . 4.8 t -107.36 93.06 4.34 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.905 -179.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 1.3 m -63.84 -27.05 68.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.049 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -97.29 33.72 1.92 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.015 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.443 ' HB2' ' HB3' ' A' ' 66' ' ' CYS . . . -109.43 -179.9 3.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.156 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 49.9 t -177.01 136.97 0.22 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.913 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.593 ' O ' HG13 ' A' ' 71' ' ' VAL . 11.2 p -76.81 65.8 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.012 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -157.98 -44.81 0.06 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.976 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.2 m -125.09 -41.18 2.1 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.128 -179.771 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.431 HG23 HD11 ' A' ' 30' ' ' ILE . 42.0 m -62.97 142.53 58.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.096 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 mt -151.44 118.51 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.082 179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.829 HD21 HD11 ' A' ' 35' ' ' LEU . 4.0 tp -91.24 111.9 23.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.832 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.514 HD12 HD13 ' A' ' 18' ' ' LEU . 6.4 mt -141.74 -179.99 6.51 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.008 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -74.13 132.22 42.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.003 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.619 ' HA ' HD12 ' A' ' 82' ' ' ILE . 19.0 tt -48.35 -38.66 8.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.969 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 23.7 m120 -57.24 -28.35 62.86 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.559 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -78.17 -23.51 47.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.619 HD12 ' HA ' ' A' ' 79' ' ' ILE . 25.5 mt -78.39 147.42 6.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.357 -0.383 . . . . 0.0 111.149 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.406 ' CD1' HD12 ' A' ' 24' ' ' ILE . 35.3 mt -129.23 91.28 42.39 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.128 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.611 ' HB3' HG12 ' A' ' 16' ' ' VAL . 54.6 Cg_endo -69.86 -170.47 0.4 Allowed 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.534 2.156 . . . . 0.0 112.286 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -123.26 -177.9 3.83 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.905 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -146.63 147.96 31.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.969 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.6 t -66.09 118.74 10.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.813 179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -160.08 102.95 0.22 Allowed Glycine 0 CA--C 1.518 0.267 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.524 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.67 -26.83 13.73 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.499 2.133 . . . . 0.0 112.371 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 6.3 m -90.51 88.55 7.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.84 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.5 p -146.93 97.92 2.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.347 -1.252 . . . . 0.0 112.463 -179.964 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.171 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.7 m 60.38 31.92 20.5 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.777 0.322 . . . . 0.0 110.863 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -131.43 93.78 3.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.884 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.25 78.0 0.1 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.436 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.4 m -69.19 144.09 53.85 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.828 0.347 . . . . 0.0 110.944 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -135.66 111.46 9.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.83 163.07 9.5 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.555 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.25 133.8 48.84 Favored 'Trans proline' 0 C--N 1.343 0.275 0 C-N-CA 122.568 2.179 . . . . 0.0 112.224 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.53 -44.99 0.62 Allowed 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.408 2.072 . . . . 0.0 112.288 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.508 HD22 HG11 ' A' ' 45' ' ' VAL . 8.0 tp -82.25 128.21 33.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.933 -179.929 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -74.47 131.18 40.81 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.86 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.481 HG22 ' N ' ' A' ' 13' ' ' ASN . 30.0 mm -73.52 158.41 6.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.079 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.481 ' N ' HG22 ' A' ' 12' ' ' ILE . 9.7 m120 60.33 31.26 20.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.894 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 44.7 m -120.01 164.98 15.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.871 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 9.9 mmt-85 -97.31 121.74 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.42 HG12 ' HB3' ' A' ' 84' ' ' PRO . 27.5 m -143.24 142.84 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.103 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -94.83 172.96 7.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.124 -179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.59 HD21 HG12 ' A' ' 82' ' ' ILE . 9.7 mt -139.21 137.19 35.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.718 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.1 tttm -82.24 97.59 8.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.854 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.2 m -107.44 125.03 63.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.121 -179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.85 -109.68 2.18 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.557 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -120.18 31.55 6.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.874 0.368 . . . . 0.0 110.988 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.4 t -161.07 174.53 13.6 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.809 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.659 ' CG2' HD13 ' A' ' 83' ' ' ILE . 8.8 mm -111.67 161.71 10.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.038 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.439 ' N ' HG22 ' A' ' 24' ' ' ILE . 13.3 mm-40 -144.28 119.52 10.17 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.976 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -64.84 143.05 58.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.834 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -157.61 176.55 34.7 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.1 m -108.53 156.66 19.25 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.803 0.335 . . . . 0.0 110.912 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.4 t -94.2 147.36 5.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.282 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.529 HD11 HG23 ' A' ' 74' ' ' THR . 12.1 pt -151.52 -43.95 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.178 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.732 ' O ' HG13 ' A' ' 45' ' ' VAL . 11.3 t80 -117.34 157.89 25.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.868 179.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 3.0 t -174.12 100.87 0.1 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.896 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.63 172.7 1.73 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.932 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.538 HG13 ' CE2' ' A' ' 43' ' ' TYR . 24.5 m -77.27 159.56 5.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.578 HD11 HD21 ' A' ' 76' ' ' LEU . 13.7 mt -102.95 159.86 27.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.84 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.409 ' HD2' ' CE2' ' A' ' 60' ' ' PHE . 63.5 Cg_exo -51.32 120.0 6.25 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.444 2.096 . . . . 0.0 112.311 -179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.67 27.85 59.33 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.483 -179.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 18.9 mttp -135.51 31.53 3.12 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.824 0.345 . . . . 0.0 110.972 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -74.83 -31.07 61.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.902 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.7 t -69.29 -31.81 70.55 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.007 179.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 87.4 mt -64.0 -42.49 97.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.967 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.528 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 152.95 -144.72 11.75 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.456 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.538 ' CE2' HG13 ' A' ' 34' ' ' VAL . 20.9 m-85 -127.95 95.54 4.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.873 0.368 . . . . 0.0 110.923 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 34.0 m-85 -60.24 156.17 16.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 31' ' ' PHE . 21.2 t -147.59 138.62 17.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.24 -179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.4 113.89 4.74 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.399 179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.4 t -101.83 119.65 50.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.802 0.334 . . . . 0.0 111.219 -179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -81.04 101.95 9.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.855 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.501 ' HE1' ' HB2' ' A' ' 18' ' ' LEU . 2.0 mmt -67.48 165.6 16.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.919 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -84.74 -31.43 24.0 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.866 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -105.17 159.91 27.79 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.879 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.48 84.03 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.571 2.18 . . . . 0.0 112.37 179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 44.9 pt -144.12 27.84 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.164 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.34 -178.73 41.33 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.512 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -164.97 32.09 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.72 0.295 . . . . 0.0 110.898 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.425 ' CD2' ' HB2' ' A' ' 76' ' ' LEU . 6.7 t90 -140.52 118.28 11.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.896 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -97.59 26.83 4.7 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.05 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.696 ' HA3' ' HB3' ' A' ' 69' ' ' ALA . . . 56.08 52.12 51.28 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.582 179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 97.9 mtt180 -147.6 159.1 44.14 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.823 0.344 . . . . 0.0 110.921 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.544 ' O ' HG12 ' A' ' 63' ' ' VAL . 7.7 t80 -126.97 90.93 3.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.903 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 60.83 30.2 19.51 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.918 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 125.85 -56.35 0.71 Allowed Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.574 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.544 HG12 ' O ' ' A' ' 60' ' ' PHE . 11.7 p -61.19 154.53 4.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.85 0.357 . . . . 0.0 111.129 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.415 ' N ' HG22 ' A' ' 63' ' ' VAL . 5.4 tp60 -106.35 127.08 52.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.815 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 79.7 mt -110.23 -43.93 3.84 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.982 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 51.4 t -112.1 117.14 31.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.933 -179.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 65.8 m -78.22 -24.0 47.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.968 179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . 0.491 ' O ' HD12 ' A' ' 30' ' ' ILE . 72.0 m-85 -94.17 21.56 6.77 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.409 -0.359 . . . . 0.0 111.192 -179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.696 ' HB3' ' HA3' ' A' ' 58' ' ' GLY . . . -110.66 148.86 31.36 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.041 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -152.58 137.32 17.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.918 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.577 ' O ' HG13 ' A' ' 71' ' ' VAL . 9.8 p -70.39 65.74 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.016 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -150.5 -45.02 0.12 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.997 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.6 -41.99 1.17 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.175 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.529 HG23 HD11 ' A' ' 30' ' ' ILE . 60.7 m -60.96 135.37 57.77 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.857 0.361 . . . . 0.0 111.204 -179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.498 HG22 ' HG ' ' A' ' 77' ' ' LEU . 28.7 mt -137.81 120.22 19.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.934 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.578 HD21 HD11 ' A' ' 35' ' ' LEU . 16.0 tp -84.08 110.38 18.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.859 179.895 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.498 ' HG ' HG22 ' A' ' 75' ' ' ILE . 85.5 mt -138.88 177.04 8.18 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.825 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -74.81 136.52 41.63 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.011 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.41 HG23 ' N ' ' A' ' 80' ' ' ASN . 1.4 tt -48.51 -40.18 10.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.128 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.41 ' N ' HG23 ' A' ' 79' ' ' ILE . 2.2 m-20 -58.14 -28.53 64.78 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 179.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.7 m-20 -78.37 -15.95 58.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.06 179.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.688 HD11 ' HB ' ' A' ' 45' ' ' VAL . 25.6 mt -83.85 145.93 7.56 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-O 120.804 0.335 . . . . 0.0 111.132 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.659 HD13 ' CG2' ' A' ' 24' ' ' ILE . 2.9 mp -130.84 96.4 23.12 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.201 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.42 ' HB3' HG12 ' A' ' 16' ' ' VAL . 53.0 Cg_endo -69.46 -176.5 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.385 0 C-N-CA 122.535 2.156 . . . . 0.0 112.276 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 14.9 mt-10 -84.85 -176.68 6.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.935 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 24.3 m -125.66 105.4 8.97 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.847 179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 54.6 p -114.65 121.05 42.21 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.931 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -135.98 61.53 0.62 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.513 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -70.37 93.64 0.58 Allowed 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.547 2.165 . . . . 0.0 112.256 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -76.71 -60.73 2.23 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 60.27 93.04 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.923 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.326 -1.263 . . . . 0.0 112.545 -179.974 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.154 0 N-CA-C 112.527 -0.229 . . . . 0.0 112.527 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -94.56 -31.74 13.76 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 0.0 110.92 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -134.29 -53.53 0.84 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.88 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 171.2 82.57 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.481 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 27.7 m -111.15 110.5 21.04 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.818 0.342 . . . . 0.0 110.934 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.4 m -92.03 98.83 11.8 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.907 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.98 168.15 32.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.47 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_exo -52.11 145.47 33.93 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.582 2.188 . . . . 0.0 112.194 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -71.1 -45.99 0.79 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.452 2.102 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.446 ' CD2' HG11 ' A' ' 45' ' ' VAL . 7.4 tp -80.45 130.47 35.18 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.019 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -73.97 132.99 42.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.879 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.3 mm -73.5 152.82 7.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.037 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 29.7 m120 60.72 36.06 19.51 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 70.9 m -122.41 157.98 30.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.93 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -84.06 126.72 33.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 29.1 m -153.7 143.69 14.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.153 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.44 ' O ' HG23 ' A' ' 82' ' ' ILE . 0.8 OUTLIER -97.83 179.98 4.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.903 179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.494 HD21 HG12 ' A' ' 82' ' ' ILE . 7.8 mt -141.81 136.31 30.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.817 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 14.3 ttpt -86.15 97.73 10.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.926 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 5.9 m -112.06 124.15 68.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.102 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.41 -99.49 0.15 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.53 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -134.8 28.67 3.54 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.74 0.305 . . . . 0.0 110.918 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 1.7 t -151.26 166.44 30.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.922 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.504 ' CG2' HD12 ' A' ' 83' ' ' ILE . 5.2 mm -114.29 154.08 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.942 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.0 mm-40 -138.15 114.97 10.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -67.27 136.77 55.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.985 -179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -149.61 -158.72 8.27 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.552 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 2.8 m -131.9 152.84 50.79 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.848 0.356 . . . . 0.0 110.865 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.461 ' O ' HG23 ' A' ' 30' ' ' ILE . 18.7 t -88.32 148.18 4.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.13 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.813 HD11 HG23 ' A' ' 74' ' ' THR . 8.3 pt -156.45 -43.21 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.265 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.676 ' O ' HG13 ' A' ' 45' ' ' VAL . 31.8 t80 -120.69 141.63 50.24 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.852 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.569 ' SG ' HG22 ' A' ' 45' ' ' VAL . 8.1 t -157.64 92.79 1.23 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.941 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -166.83 167.98 14.5 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.939 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.613 HG12 ' O ' ' A' ' 42' ' ' GLY . 30.7 m -67.88 178.29 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.236 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.704 HD11 ' CD2' ' A' ' 76' ' ' LEU . 18.8 mt -123.85 159.32 56.62 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.855 -179.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 65.8 Cg_exo -50.98 124.09 13.13 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.525 2.15 . . . . 0.0 112.381 179.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.27 27.62 60.62 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.495 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.69 ' HB3' HD12 ' A' ' 41' ' ' LEU . 15.3 mtpp -144.71 33.15 1.15 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.847 0.356 . . . . 0.0 110.94 -179.888 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -73.24 -27.57 61.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.967 -179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.5 m -74.21 -26.57 60.34 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.137 -179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.69 HD12 ' HB3' ' A' ' 38' ' ' LYS . 11.5 mt -55.86 -59.1 5.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.029 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.613 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 168.52 -123.05 1.07 Allowed Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.529 179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 34.9 m-85 -140.63 96.05 2.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.34 . . . . 0.0 110.995 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.557 ' CE1' HD12 ' A' ' 35' ' ' LEU . 36.8 m-85 -63.73 152.97 37.78 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.78 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.775 ' HB ' HD11 ' A' ' 82' ' ' ILE . 23.0 t -145.24 132.47 15.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.207 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.01 110.02 3.96 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.249 179.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.6 t -95.32 119.01 42.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.823 0.344 . . . . 0.0 111.228 -179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -84.75 99.92 11.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.751 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.406 ' HE3' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -72.54 158.85 34.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.026 -179.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -83.01 -31.47 27.43 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.714 179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -100.36 158.3 32.21 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.768 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -68.58 87.72 0.42 Allowed 'Trans proline' 0 C--N 1.345 0.355 0 C-N-CA 122.535 2.157 . . . . 0.0 112.319 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 5.8 pt -148.79 27.08 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.239 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.67 -174.9 39.97 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.452 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -174.14 38.26 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.887 0.375 . . . . 0.0 110.947 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.497 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.5 t90 -151.9 117.71 5.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.953 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -98.64 29.72 3.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.942 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.429 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 59.2 54.92 33.91 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.467 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 3.1 mtt180 -143.59 169.33 17.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.847 0.356 . . . . 0.0 110.841 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.852 ' O ' HG12 ' A' ' 63' ' ' VAL . 16.3 t80 -156.81 100.75 1.93 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.936 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 63.37 23.8 13.91 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.161 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 113.57 -31.98 6.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.607 -0.806 . . . . 0.0 112.84 179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.852 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.9 p -79.94 142.7 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.862 0.363 . . . . 0.0 111.185 -179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 5.3 tp60 -91.93 135.8 33.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.836 -179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 43.5 mt -115.47 -39.29 3.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.895 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 41.6 t -133.66 110.11 9.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.887 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 38.5 m -71.82 -35.59 69.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.84 179.967 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -63.33 -29.05 70.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.943 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.44 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.32 177.77 0.34 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.071 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.46 135.03 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.984 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.634 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -68.61 78.58 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.93 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -174.07 -39.37 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.027 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 4.9 m -128.43 -50.79 1.28 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.029 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.813 HG23 HD11 ' A' ' 30' ' ' ILE . 6.7 m -59.34 126.1 26.28 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.081 -179.916 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.403 HD12 ' HG2' ' A' ' 49' ' ' MET . 4.7 mt -129.28 115.19 34.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.1 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.704 ' CD2' HD11 ' A' ' 35' ' ' LEU . 11.5 tp -84.61 116.49 23.2 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.801 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 73.2 mt -150.59 178.05 9.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.964 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -72.07 134.75 46.0 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.997 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 80' ' ' ASN . 7.6 tt -47.91 -40.34 8.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.407 ' N ' HG23 ' A' ' 79' ' ' ILE . 1.6 m-20 -56.52 -28.25 59.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.605 179.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -76.85 -23.28 52.7 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.844 179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.775 HD11 ' HB ' ' A' ' 45' ' ' VAL . 19.1 mt -75.63 149.03 7.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.153 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' A' ' 24' ' ' ILE . 33.2 mt -132.35 95.38 21.05 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.069 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -68.62 -178.05 1.76 Allowed 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.444 2.096 . . . . 0.0 112.272 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -128.22 124.16 36.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.918 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -158.58 28.82 0.23 Allowed 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 1.8 t 57.68 96.18 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.947 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 113.75 -166.44 12.15 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.474 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -70.18 87.49 0.61 Allowed 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.558 2.172 . . . . 0.0 112.268 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 97.3 p -85.96 116.96 24.51 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.954 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 96.1 p -174.79 147.26 1.0 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.854 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.42 -1.211 . . . . 0.0 112.557 179.95 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.271 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -121.64 141.12 51.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.819 0.343 . . . . 0.0 110.899 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -137.77 103.25 4.95 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.854 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.58 141.38 3.22 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.498 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 10.9 t -159.43 83.02 0.76 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.865 0.364 . . . . 0.0 110.85 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 60.86 75.33 0.41 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.45 105.4 3.28 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.352 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.13 144.18 62.25 Favored 'Trans proline' 0 C--N 1.346 0.444 0 C-N-CA 122.409 2.072 . . . . 0.0 112.266 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -73.63 -29.72 10.48 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.481 2.12 . . . . 0.0 112.37 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 1.008 HD11 HG11 ' A' ' 16' ' ' VAL . 15.8 tp -90.29 121.08 31.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.911 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -64.88 132.36 49.21 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.864 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 13' ' ' ASN . 26.3 mm -75.14 155.87 6.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.104 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.426 ' N ' HG22 ' A' ' 12' ' ' ILE . 3.1 m120 59.95 30.76 20.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.853 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 2.3 m -114.96 175.03 5.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.875 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 18.0 mmt-85 -106.21 110.29 22.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 1.008 HG11 HD11 ' A' ' 10' ' ' LEU . 35.4 m -127.63 145.5 34.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.408 ' HB2' ' CG2' ' A' ' 24' ' ' ILE . 0.6 OUTLIER -93.19 169.99 9.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.0 179.997 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' HE2' ' A' ' 49' ' ' MET . 10.1 mt -132.48 139.36 47.92 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.0 tttm -82.07 106.58 14.09 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.618 HG23 HG23 ' A' ' 23' ' ' THR . 4.5 m -114.88 111.78 37.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.083 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.51 -109.1 1.96 Allowed Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.542 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -116.17 30.85 7.09 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.896 0.379 . . . . 0.0 110.907 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 20' ' ' VAL . 5.5 t -155.95 177.79 11.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.866 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.456 HG22 ' N ' ' A' ' 25' ' ' GLU . 11.0 mm -123.5 160.87 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.029 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.456 ' N ' HG22 ' A' ' 24' ' ' ILE . 8.5 mm-40 -142.18 117.7 10.31 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m -62.5 148.39 45.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.876 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.97 -171.24 24.51 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.471 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -121.48 150.55 41.42 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.766 0.317 . . . . 0.0 110.964 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.44 ' O ' HG23 ' A' ' 30' ' ' ILE . 17.3 t -90.26 150.05 3.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.204 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.472 HD11 HG23 ' A' ' 74' ' ' THR . 9.2 pt -155.56 -43.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.336 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.625 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -130.14 120.82 25.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.007 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 46.7 t -138.66 99.49 3.82 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.86 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -166.13 -170.89 1.83 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.967 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.54 HG13 ' CE2' ' A' ' 43' ' ' TYR . 10.6 m -92.54 159.68 2.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.169 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.889 HD12 ' CD2' ' A' ' 44' ' ' PHE . 10.6 mt -95.27 152.91 39.7 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.793 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -50.28 117.3 3.06 Favored 'Trans proline' 0 C--N 1.345 0.358 0 C-N-CA 122.596 2.198 . . . . 0.0 112.375 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.11 27.94 57.93 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.899 -0.667 . . . . 0.0 112.601 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 33.4 mttp -132.06 31.33 4.16 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.844 0.354 . . . . 0.0 111.01 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.426 ' CD ' HG11 ' A' ' 34' ' ' VAL . 0.0 OUTLIER -67.49 -31.44 71.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.876 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 34.0 m -63.6 -32.77 74.34 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.923 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 41' ' ' LEU . 25.3 mt -63.99 -42.39 97.21 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.845 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.534 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 146.78 -137.5 6.77 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.56 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.54 ' CE2' HG13 ' A' ' 34' ' ' VAL . 12.9 m-85 -128.91 96.67 4.42 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.823 0.344 . . . . 0.0 110.959 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.889 ' CD2' HD12 ' A' ' 35' ' ' LEU . 31.9 m-85 -67.43 144.77 55.57 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.811 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.736 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.0 t -141.94 138.6 30.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.164 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -100.62 109.95 3.8 Favored Glycine 0 N--CA 1.451 -0.367 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.409 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 18.1 t -98.58 123.52 51.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 111.165 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -88.37 102.03 14.46 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.902 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.473 ' HE2' HD12 ' A' ' 18' ' ' LEU . 6.6 mmt -67.37 169.81 8.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.951 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -79.54 -48.67 13.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.895 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -92.04 162.77 29.69 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.84 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -69.01 84.24 0.54 Allowed 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.5 2.133 . . . . 0.0 112.286 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 31.9 pt -139.13 30.92 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.13 -171.77 27.36 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.53 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -176.43 40.27 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.852 0.358 . . . . 0.0 110.926 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.712 ' CH2' HD13 ' A' ' 76' ' ' LEU . 11.1 t90 -149.12 116.03 5.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.955 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -97.43 32.2 2.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.976 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.421 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.92 53.12 49.07 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.474 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 60.5 mtt180 -146.13 131.86 18.97 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.862 0.363 . . . . 0.0 110.946 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.76 ' O ' HG12 ' A' ' 63' ' ' VAL . 40.1 t80 -112.01 89.93 3.2 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.91 179.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 66.43 27.96 9.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.016 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 117.73 -38.82 2.81 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.728 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.76 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.6 p -73.66 120.07 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.807 0.337 . . . . 0.0 111.113 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.4 tp60 -71.53 126.29 29.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.836 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.436 HD12 ' HB2' ' A' ' 60' ' ' PHE . 12.1 mt -112.77 -35.81 5.37 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.909 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.517 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 12.1 t -132.6 91.25 2.89 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.945 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 66.8 m -64.66 -31.41 72.62 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -70.7 -30.53 67.12 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.899 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.517 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -65.3 173.57 2.5 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.209 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.4 m -153.61 155.33 35.89 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.531 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.4 p -85.75 54.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.193 -179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -172.19 32.84 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.987 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 177.76 -55.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.797 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.472 HG23 HD11 ' A' ' 30' ' ' ILE . 54.6 m -67.2 145.2 55.46 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.021 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 37.5 mt -143.47 114.76 2.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.058 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.712 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.8 tp -81.19 113.92 19.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.828 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 45.1 mt -144.81 179.89 7.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.971 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . 0.419 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 2.2 t-80 -77.93 135.55 37.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.903 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.66 HD12 HD12 ' A' ' 82' ' ' ILE . 3.5 tp -48.77 -37.63 9.06 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.033 179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 12.7 t-20 -57.82 -28.07 63.73 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.533 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -78.66 -25.62 44.95 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.803 179.665 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.736 HD11 ' HB ' ' A' ' 45' ' ' VAL . 30.9 mt -75.89 150.15 6.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.092 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.433 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.2 mm -125.99 89.83 51.53 Favored Pre-proline 0 C--N 1.33 -0.246 0 CA-C-N 116.339 -0.391 . . . . 0.0 111.105 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -78.11 -168.02 0.56 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.599 2.199 . . . . 0.0 112.259 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.96 102.91 11.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.884 179.903 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.4 p -147.49 117.16 7.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.924 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 41.3 t -117.99 30.45 7.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.867 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 115.14 144.29 8.31 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.522 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_exo -56.54 -163.67 0.02 OUTLIER 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.569 2.179 . . . . 0.0 112.355 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 17.9 t -175.44 106.25 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.853 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -60.07 -50.34 74.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.889 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.988 0 CA-C-O 118.409 -1.217 . . . . 0.0 112.488 -179.948 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.217 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -73.92 111.61 9.25 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.869 0.366 . . . . 0.0 110.861 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.2 m -70.6 87.87 0.68 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.879 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.85 -45.13 2.95 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.793 -0.717 . . . . 0.0 112.462 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -90.8 -57.44 2.82 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.79 0.329 . . . . 0.0 110.922 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 20.0 m -88.89 108.65 19.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.872 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.61 143.13 4.27 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.478 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.431 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 53.2 Cg_exo -55.01 143.51 72.91 Favored 'Trans proline' 0 C--N 1.345 0.344 0 C-N-CA 122.407 2.071 . . . . 0.0 112.269 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 8' ' ' PRO . 31.9 Cg_exo -57.82 -59.66 0.52 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.374 2.049 . . . . 0.0 112.063 179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.516 HD22 HG11 ' A' ' 45' ' ' VAL . 3.8 tp -59.24 141.86 53.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.932 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -88.37 130.07 35.24 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.886 179.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.7 mm -71.17 153.09 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.067 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 60.12 31.69 20.66 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 72.4 m -118.38 176.05 5.42 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt180 -101.72 126.62 48.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.864 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.4 HG12 ' HB3' ' A' ' 84' ' ' PRO . 30.6 m -151.55 140.35 14.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.106 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -94.08 174.93 6.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.939 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.519 HD12 ' HB ' ' A' ' 47' ' ' VAL . 2.8 mt -140.52 139.36 35.06 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.79 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 35.4 tttm -81.23 100.69 9.27 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.811 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.489 HG21 ' HG3' ' A' ' 25' ' ' GLU . 5.1 m -108.75 110.07 30.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.06 -179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 71.19 -102.49 1.09 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.456 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -116.96 -14.93 10.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.563 0.221 . . . . 0.0 111.402 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 2.6 t -118.34 171.71 7.95 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.816 0.341 . . . . 0.0 111.059 -179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.448 HG22 ' N ' ' A' ' 25' ' ' GLU . 10.7 mm -105.16 161.82 4.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.979 179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.489 ' HG3' HG21 ' A' ' 20' ' ' VAL . 25.4 mm-40 -141.01 122.22 14.78 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.926 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 6.9 m -64.28 145.07 56.61 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.848 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -155.41 -166.26 15.34 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.506 179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 47' ' ' VAL . 4.1 m -125.24 163.14 23.13 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.847 0.356 . . . . 0.0 110.951 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.4 t -101.78 127.56 55.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.726 HD11 HG23 ' A' ' 74' ' ' THR . 10.1 pt -131.46 -41.81 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.283 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.714 ' O ' HG13 ' A' ' 45' ' ' VAL . 15.7 t80 -132.19 163.91 27.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.917 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' HG22 ' A' ' 45' ' ' VAL . 45.3 t -176.8 95.48 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -163.17 171.89 15.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.803 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.667 HG12 ' O ' ' A' ' 42' ' ' GLY . 9.3 m -71.79 168.73 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.199 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.444 HD22 ' CD2' ' A' ' 60' ' ' PHE . 10.2 mt -110.3 151.45 42.63 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.817 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -50.63 123.1 10.79 Favored 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.588 2.192 . . . . 0.0 112.342 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.11 30.48 67.12 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.441 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.402 ' HB3' HD12 ' A' ' 41' ' ' LEU . 19.7 mttt -144.74 38.66 1.22 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.92 0.391 . . . . 0.0 110.919 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 9.0 mt-10 -73.39 -27.57 61.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.039 -179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.8 m -71.09 -30.43 66.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.049 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.402 HD12 ' HB3' ' A' ' 38' ' ' LYS . 21.6 mt -58.33 -49.86 75.68 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.013 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.667 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 153.87 -127.2 2.09 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.494 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.542 ' CE1' HG13 ' A' ' 34' ' ' VAL . 15.6 m-85 -139.55 92.63 2.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.791 0.329 . . . . 0.0 110.995 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 28.0 m-85 -60.22 157.32 13.59 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.882 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.761 ' HB ' HD11 ' A' ' 82' ' ' ILE . 21.9 t -148.19 133.97 11.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.161 -179.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.71 109.96 3.91 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.397 179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.519 ' HB ' HD12 ' A' ' 18' ' ' LEU . 21.4 t -98.12 133.56 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 0.0 111.239 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -99.41 93.24 5.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.786 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.524 ' CG ' HD11 ' A' ' 53' ' ' ILE . 4.1 mmt -62.76 160.22 14.81 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.972 -179.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.1 t0 -76.1 -38.69 56.63 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.794 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -90.16 156.88 46.04 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -69.25 84.05 0.59 Allowed 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.499 2.133 . . . . 0.0 112.358 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.524 HD11 ' CG ' ' A' ' 49' ' ' MET . 4.2 pt -139.6 26.58 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.213 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -92.09 174.62 37.36 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.501 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -170.23 34.51 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.979 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.595 ' CH2' HD13 ' A' ' 76' ' ' LEU . 4.4 t90 -142.26 119.54 11.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t0 -99.34 28.59 4.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.008 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.424 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.73 61.87 6.89 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.562 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 70.0 mtt180 -150.65 155.37 39.22 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.794 0.331 . . . . 0.0 110.919 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.819 ' O ' HG12 ' A' ' 63' ' ' VAL . 41.6 t80 -144.36 103.22 3.95 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.889 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 32.2 t70 65.81 25.9 11.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.21 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 110.52 -37.48 3.73 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.735 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.819 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -74.66 145.65 10.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 111.144 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 6.4 tp60 -92.03 138.0 31.9 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.952 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 85.0 mt -118.79 -41.41 2.79 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.964 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 10.2 t -124.55 106.36 10.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.909 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -68.03 -32.51 72.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.927 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -72.55 -30.9 64.84 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.408 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.57 154.85 23.74 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 179.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -155.33 132.68 11.02 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.881 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.6 p -64.89 83.33 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.041 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -176.87 -38.95 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.037 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -130.59 -44.11 1.11 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.172 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.726 HG23 HD11 ' A' ' 30' ' ' ILE . 45.0 m -60.83 141.43 57.08 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.063 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 46.9 mt -141.87 113.22 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.595 HD13 ' CH2' ' A' ' 56' ' ' TRP . 9.8 tp -84.46 121.25 27.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.857 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.49 HD12 HD22 ' A' ' 18' ' ' LEU . 96.0 mt -150.69 179.99 7.73 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.2 t-80 -77.23 134.23 38.66 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.967 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.0 -36.83 8.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.928 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 -57.82 -27.56 63.27 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.518 179.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -79.33 -25.54 42.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.754 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.761 HD11 ' HB ' ' A' ' 45' ' ' VAL . 24.8 mt -72.53 150.35 8.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.102 179.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.5 mm -133.17 92.12 26.03 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.1 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.4 ' HB3' HG12 ' A' ' 16' ' ' VAL . 49.8 Cg_endo -69.08 -175.74 1.09 Allowed 'Trans proline' 0 C--N 1.345 0.37 0 C-N-CA 122.529 2.152 . . . . 0.0 112.292 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -78.78 152.75 31.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.889 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 4.1 p -161.31 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.15 107.45 10.39 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.839 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -90.22 143.0 16.7 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.459 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -74.42 -34.75 4.3 Favored 'Trans proline' 0 C--N 1.345 0.345 0 C-N-CA 122.572 2.181 . . . . 0.0 112.351 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -81.88 104.55 12.33 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 16.2 m -138.81 167.71 21.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.862 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.025 0 CA-C-O 118.416 -1.213 . . . . 0.0 112.525 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 112.491 -0.244 . . . . 0.0 112.491 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.4 m 60.44 94.8 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.79 0.329 . . . . 0.0 110.87 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.46 -46.61 5.17 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -86.24 -156.35 27.9 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.568 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 m -94.42 -179.42 4.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.842 0.353 . . . . 0.0 110.876 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.4 m -158.84 151.88 22.36 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.928 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -143.26 62.27 0.51 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.516 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -54.8 164.87 2.93 Favored 'Trans proline' 0 C--N 1.343 0.282 0 C-N-CA 122.648 2.232 . . . . 0.0 112.342 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_exo -59.45 -62.85 0.15 Allowed 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 122.579 2.186 . . . . 0.0 112.164 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 45' ' ' VAL . 9.6 tp -60.35 149.36 33.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -88.98 130.41 35.47 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.95 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.458 HD11 ' SG ' ' A' ' 32' ' ' CYS . 32.2 mm -70.58 149.49 10.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.105 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 50.8 t30 59.37 37.79 23.19 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.858 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 56.7 m -114.24 179.82 3.84 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.917 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -115.54 117.55 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.674 HG12 ' HB3' ' A' ' 84' ' ' PRO . 33.9 m -143.68 149.6 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.118 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -96.17 170.44 9.26 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.069 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.472 HD21 HG12 ' A' ' 82' ' ' ILE . 12.9 mt -135.79 150.55 49.5 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.757 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 18.4 tttp -87.41 100.93 13.1 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.919 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.577 HG21 ' HG3' ' A' ' 25' ' ' GLU . 6.0 m -111.93 121.44 64.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.135 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.05 -108.74 1.72 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.587 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 -122.37 31.49 6.12 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.878 0.37 . . . . 0.0 110.904 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -160.47 169.05 23.81 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.848 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.532 HD12 ' CD1' ' A' ' 83' ' ' ILE . 6.3 mm -105.67 159.09 5.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.037 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.577 ' HG3' HG21 ' A' ' 20' ' ' VAL . 3.9 mm-40 -142.99 120.13 11.45 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.996 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -65.25 143.56 57.73 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.814 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.439 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -155.93 -179.61 31.13 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.557 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 8.3 m -110.71 145.91 37.19 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 0.0 110.94 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.544 HG13 HD23 ' A' ' 10' ' ' LEU . 20.8 t -83.17 142.48 13.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.176 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.634 HD11 HG23 ' A' ' 74' ' ' THR . 9.4 pt -147.13 -43.23 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.277 179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.623 ' O ' HG13 ' A' ' 45' ' ' VAL . 59.8 t80 -125.74 137.11 53.8 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.896 0.379 . . . . 0.0 110.901 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.458 ' SG ' HD11 ' A' ' 12' ' ' ILE . 4.9 p -156.5 102.19 2.06 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.942 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . 0.433 ' HA ' ' CE2' ' A' ' 43' ' ' TYR . 0.5 OUTLIER -178.84 -175.92 0.43 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.965 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.662 HG13 ' CE1' ' A' ' 43' ' ' TYR . 17.3 m -83.3 146.48 6.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.229 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.589 HD21 HD21 ' A' ' 76' ' ' LEU . 26.0 mt -81.8 159.37 66.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.819 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.447 ' HG2' ' CD1' ' A' ' 60' ' ' PHE . 31.3 Cg_endo -64.16 110.83 1.44 Allowed 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.586 2.19 . . . . 0.0 112.205 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.86 28.4 60.91 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.377 -179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 16.7 mttp -144.25 30.97 1.24 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.818 0.342 . . . . 0.0 110.911 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.456 ' HG2' HG21 ' A' ' 34' ' ' VAL . 12.9 mt-10 -66.52 -31.52 72.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 1.3 m -65.08 -31.12 72.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.943 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 49.6 mt -60.76 -56.72 17.81 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.873 -179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.649 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 160.43 -134.55 3.66 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.589 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.662 ' CE1' HG13 ' A' ' 34' ' ' VAL . 0.2 OUTLIER -128.19 101.03 6.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.789 0.328 . . . . 0.0 110.867 179.988 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -74.26 160.53 30.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.799 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.777 ' HB ' HD11 ' A' ' 82' ' ' ILE . 26.1 t -152.51 138.82 12.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.268 -0.423 . . . . 0.0 111.238 -179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -110.61 118.04 4.84 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.306 179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.439 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.2 t -107.06 124.52 62.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.854 0.359 . . . . 0.0 111.133 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.1 t70 -82.35 100.8 10.18 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.87 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.406 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 22.1 mmt -60.18 166.07 3.1 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.957 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -78.27 -39.06 41.17 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.869 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -107.39 163.61 16.57 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.909 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.58 88.0 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 122.532 2.155 . . . . 0.0 112.258 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.419 HD13 ' OE2' ' A' ' 25' ' ' GLU . 3.7 pt -146.21 29.73 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.193 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.04 -164.81 31.26 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.5 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -176.9 44.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.827 0.346 . . . . 0.0 111.01 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.645 ' CH2' HD13 ' A' ' 76' ' ' LEU . 21.6 t90 -155.4 101.97 2.23 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.937 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.49 -29.94 69.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.406 ' HA2' ' CZ2' ' A' ' 56' ' ' TRP . . . 109.7 38.98 1.66 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.421 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 5.8 mtt-85 -134.03 -179.91 5.85 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.862 0.363 . . . . 0.0 110.85 179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.618 ' O ' HG12 ' A' ' 63' ' ' VAL . 29.6 t80 -145.75 89.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 62.8 30.11 16.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.11 -53.57 0.72 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.572 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.618 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.0 p -62.18 135.41 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.09 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 7.2 tp60 -85.81 127.18 34.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.926 179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 72.6 mt -103.18 -45.22 4.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.899 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 6.9 t -132.67 106.93 8.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.912 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 3.3 m -68.16 -39.3 82.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.884 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 91.5 m-85 -61.86 -32.37 72.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.863 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -62.73 173.46 1.3 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 1.6 m -163.42 160.52 23.54 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.814 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.56 HG22 ' O ' ' A' ' 71' ' ' VAL . 11.6 p -88.38 51.0 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -176.44 36.44 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.855 -179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 179.01 -58.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.812 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.634 HG23 HD11 ' A' ' 30' ' ' ILE . 56.9 m -71.17 138.74 49.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.948 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 19.7 mt -134.67 113.16 16.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.006 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.645 HD13 ' CH2' ' A' ' 56' ' ' TRP . 11.4 tp -78.31 119.44 21.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.879 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 92.0 mt -151.05 169.56 21.51 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.929 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.0 t-80 -70.17 138.32 51.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.94 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 13.9 tt -48.6 -39.25 10.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.025 179.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -57.27 -27.35 62.03 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.557 179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -79.39 -22.1 44.79 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.947 179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.777 HD11 ' HB ' ' A' ' 45' ' ' VAL . 14.4 mt -74.11 143.67 13.31 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.119 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.532 ' CD1' HD12 ' A' ' 24' ' ' ILE . 29.3 mt -128.78 89.94 47.56 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.129 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.674 ' HB3' HG12 ' A' ' 16' ' ' VAL . 61.1 Cg_endo -72.96 -168.17 0.4 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.577 2.185 . . . . 0.0 112.363 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -105.15 87.89 2.74 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.818 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.57 -59.17 2.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -174.11 159.81 3.31 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.899 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 135.08 119.77 1.96 Allowed Glycine 0 CA--C 1.519 0.341 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.409 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -69.91 124.13 10.72 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.436 2.091 . . . . 0.0 112.329 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -100.89 31.95 3.37 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.876 179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 22.2 m -123.5 177.08 5.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.888 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.385 -1.231 . . . . 0.0 112.48 -179.97 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.157 0 N-CA-C 112.516 -0.234 . . . . 0.0 112.516 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 83.9 p -152.16 170.15 20.68 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.865 0.364 . . . . 0.0 110.858 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.5 96.41 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.893 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.22 -92.55 1.89 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.503 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.5 m -100.73 93.86 5.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.896 0.379 . . . . 0.0 110.849 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.4 m -157.33 -179.3 8.05 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.872 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 137.72 79.94 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -70.59 125.59 11.87 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.564 2.176 . . . . 0.0 112.275 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -57.49 -59.84 0.52 Allowed 'Trans proline' 0 C--N 1.347 0.47 0 C-N-CA 122.428 2.086 . . . . 0.0 112.277 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 10' ' ' LEU . 10.8 tp -58.87 150.34 24.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.002 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.516 ' O ' HG11 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -90.78 148.88 22.25 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.895 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 24.4 mm -86.9 152.67 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 60.81 31.69 20.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.415 ' O ' HG23 ' A' ' 29' ' ' VAL . 66.2 m -119.24 161.9 19.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -92.29 119.3 31.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.9 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.416 ' HB ' ' CG2' ' A' ' 82' ' ' ILE . 27.6 m -136.21 142.34 38.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.158 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.574 ' OG ' HG22 ' A' ' 24' ' ' ILE . 0.1 OUTLIER -91.28 171.93 8.89 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.124 -179.866 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.562 HD11 ' HB ' ' A' ' 47' ' ' VAL . 12.6 mt -138.35 118.44 13.48 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.945 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.0 tttp -70.65 91.49 0.81 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.874 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 20' ' ' VAL . 32.1 m -99.98 115.14 40.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.134 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.13 -107.91 1.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.527 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 mt-10 -119.21 31.67 6.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.774 0.321 . . . . 0.0 110.914 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.528 HG23 HG23 ' A' ' 20' ' ' VAL . 3.7 t -153.57 171.29 18.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.574 HG22 ' OG ' ' A' ' 17' ' ' SER . 10.3 mm -113.88 148.19 16.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.886 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 mm-40 -129.72 110.28 11.64 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.946 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 17' ' ' SER . 8.5 m -67.79 135.96 53.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.867 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -152.4 -171.3 19.83 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.558 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -116.74 166.09 12.54 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.793 0.33 . . . . 0.0 110.913 179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.516 HG11 ' O ' ' A' ' 11' ' ' GLU . 20.7 t -105.87 141.66 20.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.138 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.86 HD11 HG23 ' A' ' 74' ' ' THR . 9.5 pt -149.57 -43.37 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.361 179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.515 ' O ' HG13 ' A' ' 45' ' ' VAL . 30.7 t80 -119.18 144.02 46.92 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.822 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 45' ' ' VAL . 12.0 t -160.23 108.29 1.66 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.95 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -176.88 174.65 1.73 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.694 HG12 ' O ' ' A' ' 42' ' ' GLY . 17.6 m -81.79 165.16 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.576 HD11 ' CD2' ' A' ' 76' ' ' LEU . 9.6 mt -111.93 154.44 44.16 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.835 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -51.79 123.75 13.03 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.509 2.139 . . . . 0.0 112.318 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.36 33.85 86.08 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.507 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -148.0 31.59 0.85 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.786 0.327 . . . . 0.0 110.9 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -74.47 -31.48 62.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.48 -31.94 71.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.9 mt -62.02 -46.82 87.49 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.862 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.694 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 155.28 -135.31 4.57 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.498 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . . . . . . . . . 14.5 m-85 -132.8 101.07 5.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.337 . . . . 0.0 110.908 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -60.51 156.48 16.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.818 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.67 ' HB ' HD11 ' A' ' 82' ' ' ILE . 10.7 t -147.92 132.5 10.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.223 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.24 110.01 3.89 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.371 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.562 ' HB ' HD11 ' A' ' 18' ' ' LEU . 21.2 t -97.13 131.42 43.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 111.215 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -97.22 103.73 15.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.84 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.518 ' HE2' HD12 ' A' ' 75' ' ' ILE . 7.2 mmt -70.88 168.35 17.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.971 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -84.38 -34.93 23.49 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.847 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.7 m-20 -100.54 160.33 27.21 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.892 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.65 63.6 2.31 Favored 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.588 2.192 . . . . 0.0 112.299 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.405 HD11 ' HG3' ' A' ' 49' ' ' MET . 1.2 pp -120.1 29.32 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.223 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.457 ' HA2' HD11 ' A' ' 75' ' ' ILE . . . -90.39 179.64 43.54 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.521 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -165.68 32.87 0.05 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.804 0.335 . . . . 0.0 110.917 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.482 ' CH2' HD13 ' A' ' 76' ' ' LEU . 7.4 t90 -144.44 111.93 6.08 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.936 179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.99 -24.14 52.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.017 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 115.16 28.96 2.68 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.453 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 67.5 mtt180 -129.45 164.37 23.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.785 0.326 . . . . 0.0 110.873 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.562 ' CE1' HD13 ' A' ' 35' ' ' LEU . 11.9 t80 -133.47 96.41 3.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.864 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 63.95 28.06 14.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.022 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 122.06 -57.0 0.63 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.773 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 60' ' ' PHE . 10.6 p -62.55 140.98 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.834 0.35 . . . . 0.0 111.121 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.5 tp60 -93.48 121.64 35.09 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.892 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 65.5 mt -101.81 -44.26 5.58 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 8.0 t -115.55 128.19 55.79 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.959 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 37.9 m -90.21 -32.59 16.52 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -72.91 -29.89 63.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.989 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.631 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -65.54 148.74 51.23 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.67 142.48 25.66 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.842 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.7 p -70.15 73.45 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.087 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -170.02 -41.79 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.05 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -125.97 -48.71 1.61 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.04 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.86 HG23 HD11 ' A' ' 30' ' ' ILE . 2.9 m -62.44 144.35 56.0 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.967 -179.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.518 HD12 ' HE2' ' A' ' 49' ' ' MET . 25.7 mt -149.61 118.0 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.155 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.576 ' CD2' HD11 ' A' ' 35' ' ' LEU . 8.3 tp -89.51 118.96 29.54 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.815 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . . . . . . . . . 44.3 mt -147.1 -179.98 7.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.985 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -74.48 131.9 41.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.921 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.539 ' HA ' HD12 ' A' ' 82' ' ' ILE . 16.4 tt -48.34 -36.35 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.965 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 32.8 m-20 -57.95 -28.71 64.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.466 179.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 74.0 m-20 -78.64 -25.92 45.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.722 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.67 HD11 ' HB ' ' A' ' 45' ' ' VAL . 40.5 mt -72.97 151.94 7.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.067 179.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.568 HD12 HD12 ' A' ' 24' ' ' ILE . 30.0 mt -140.15 89.82 10.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.137 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -65.56 -161.23 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.626 2.217 . . . . 0.0 112.196 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -99.96 31.31 3.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.913 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 8.3 t -98.54 -169.92 1.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.828 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 31.4 t -174.34 -41.02 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -100.91 -88.34 2.01 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.463 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -69.32 -173.17 0.61 Allowed 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.546 2.164 . . . . 0.0 112.226 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 m 61.4 154.39 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.847 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -75.85 -179.97 5.14 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.412 -1.215 . . . . 0.0 112.466 179.977 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER 66.43 -74.93 0.06 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.704 0.288 . . . . 0.0 110.915 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 29.7 t 63.2 -79.4 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.006 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.24 -97.87 1.15 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.453 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -167.1 97.44 0.52 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.784 0.326 . . . . 0.0 110.874 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 2.9 m -118.58 131.26 56.2 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.918 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 99.36 -179.71 30.86 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.519 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -70.32 111.66 2.98 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.555 2.17 . . . . 0.0 112.279 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.71 -55.53 2.33 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.433 2.089 . . . . 0.0 112.205 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.427 HD21 HG21 ' A' ' 16' ' ' VAL . 6.8 tp -59.37 148.86 30.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.939 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -84.69 127.62 34.19 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.877 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 27.0 mm -74.45 152.37 6.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.187 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 9.3 m120 60.21 31.39 20.48 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.834 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.442 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.8 m -119.41 160.85 21.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 4.0 mmt85 -93.0 113.76 26.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.921 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.427 HG21 HD21 ' A' ' 10' ' ' LEU . 29.1 m -131.72 145.94 34.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.105 179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.78 175.3 6.86 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.942 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.461 HD13 HD12 ' A' ' 77' ' ' LEU . 4.8 mt -142.29 134.41 27.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.919 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 25.7 tttp -82.76 99.7 9.82 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.894 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 7.0 m -107.31 118.96 56.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.16 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 59.31 -102.76 0.33 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.468 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -125.96 31.45 5.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.887 0.375 . . . . 0.0 110.868 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.401 HG22 ' H ' ' A' ' 24' ' ' ILE . 1.9 m -156.86 168.47 27.37 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.852 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.619 HD12 ' CD1' ' A' ' 83' ' ' ILE . 5.5 mm -113.19 157.59 13.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.047 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.42 ' HB2' ' HE1' ' A' ' 49' ' ' MET . 34.6 mm-40 -142.06 117.97 10.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.913 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 38.9 m -64.46 146.19 54.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.883 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.426 ' HA3' HG12 ' A' ' 47' ' ' VAL . . . -159.41 -172.46 26.58 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.44 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.3 m -119.53 157.2 28.81 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.83 0.347 . . . . 0.0 110.872 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 14' ' ' SER . 24.2 t -95.38 145.92 7.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.06 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.685 HD11 ' CG2' ' A' ' 74' ' ' THR . 12.7 pt -149.68 -43.72 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.322 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.66 ' O ' HG13 ' A' ' 45' ' ' VAL . 10.9 t80 -128.16 137.69 52.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.939 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 13.1 t -151.06 103.39 3.04 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.924 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -176.66 175.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.574 HG12 ' O ' ' A' ' 42' ' ' GLY . 8.9 m -74.06 179.32 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.116 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.588 HD11 ' CG ' ' A' ' 44' ' ' PHE . 13.1 mt -126.41 150.67 71.02 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.898 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.55 125.67 18.53 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.611 2.208 . . . . 0.0 112.244 -179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.77 28.11 73.62 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.492 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.597 ' CB ' HD12 ' A' ' 41' ' ' LEU . 20.8 mttp -149.64 36.19 0.71 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 110.889 179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 4.4 mp0 -76.72 -21.88 54.68 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.079 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 18.7 m -93.97 20.08 8.25 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 111.314 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.597 HD12 ' CB ' ' A' ' 38' ' ' LYS . 10.8 mt -109.71 -31.23 7.53 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.891 0.377 . . . . 0.0 110.927 179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.574 ' O ' HG12 ' A' ' 34' ' ' VAL . . . 143.02 -124.64 2.39 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.449 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.544 ' CE2' HG13 ' A' ' 34' ' ' VAL . 28.4 m-85 -151.68 100.22 2.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.825 0.345 . . . . 0.0 110.896 -179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.588 ' CG ' HD11 ' A' ' 35' ' ' LEU . 57.9 m-85 -69.79 161.93 28.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.873 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.763 ' HB ' HD11 ' A' ' 82' ' ' ILE . 16.7 t -151.42 141.48 15.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.187 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -101.61 109.98 3.74 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.404 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.426 HG12 ' HA3' ' A' ' 27' ' ' GLY . 25.7 t -97.83 114.78 36.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.856 0.36 . . . . 0.0 111.107 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -79.73 94.35 5.73 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.898 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.466 ' HE2' HD12 ' A' ' 75' ' ' ILE . 5.1 mmt -62.94 155.91 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.892 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 8.8 p-10 -76.24 -31.3 58.27 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.895 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 51.6 m-80 -101.13 155.35 36.43 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.819 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 78.75 1.01 Allowed 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.558 2.172 . . . . 0.0 112.252 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 pt -139.49 30.09 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.119 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.33 -170.6 27.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.584 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -174.79 39.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.771 0.319 . . . . 0.0 110.9 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.415 ' CH2' ' HA2' ' A' ' 58' ' ' GLY . 8.0 t90 -142.95 116.25 9.01 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.882 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.0 t0 -97.84 29.75 3.28 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.021 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.415 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 58.31 50.72 63.81 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.524 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 20.4 mtt180 -136.1 155.74 49.74 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 110.957 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.808 ' O ' HG12 ' A' ' 63' ' ' VAL . 30.0 t80 -137.95 91.02 2.54 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.846 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 63.88 28.16 14.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.077 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 116.9 -38.82 2.87 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.821 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.808 HG12 ' O ' ' A' ' 60' ' ' PHE . 12.2 p -74.79 134.42 29.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.798 0.333 . . . . 0.0 111.233 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . . . . . . . . . 2.6 tp60 -91.3 126.92 36.54 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.821 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 75.0 mt -110.12 -47.99 3.24 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . 0.616 ' SG ' ' HB2' ' A' ' 69' ' ' ALA . 45.4 t -104.68 115.63 30.66 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.965 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 87.5 p -78.61 -28.53 45.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.956 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -96.76 37.48 1.29 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.971 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.616 ' HB2' ' SG ' ' A' ' 66' ' ' CYS . . . -127.05 137.77 53.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.091 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 3.4 m -130.35 155.18 46.78 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.817 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.585 ' O ' HG13 ' A' ' 71' ' ' VAL . 13.4 p -82.0 58.29 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 121.01 0.433 . . . . 0.0 111.043 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -176.56 35.1 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.973 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 178.11 -54.0 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.792 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.685 ' CG2' HD11 ' A' ' 30' ' ' ILE . 16.7 m -76.87 138.11 39.57 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.966 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.466 HD12 ' HE2' ' A' ' 49' ' ' MET . 24.0 mt -135.83 119.91 25.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.055 -179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.587 HD21 HD11 ' A' ' 35' ' ' LEU . 13.0 tp -81.8 114.52 20.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.91 -179.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.461 HD12 HD13 ' A' ' 18' ' ' LEU . 98.1 mt -145.32 -179.91 6.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.926 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -77.62 137.99 38.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.968 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 80' ' ' ASN . 9.5 tt -49.31 -43.68 16.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.071 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.477 ' N ' HG23 ' A' ' 79' ' ' ILE . 64.0 t30 -55.75 -27.13 49.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.694 179.61 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 16.1 m-20 -77.63 -23.96 49.64 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.871 179.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.763 HD11 ' HB ' ' A' ' 45' ' ' VAL . 36.6 mt -74.35 150.03 7.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.154 -179.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.619 ' CD1' HD12 ' A' ' 24' ' ' ILE . 34.3 mt -135.81 96.78 12.99 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.028 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -64.41 175.36 3.46 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.427 2.085 . . . . 0.0 112.313 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.28 39.32 1.3 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.923 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 3.3 m -160.75 30.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.932 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER 59.14 -170.08 0.13 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.867 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 173.93 93.36 0.09 OUTLIER Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.564 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_exo -50.97 110.67 0.43 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.653 2.235 . . . . 0.0 112.329 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.5 t -111.41 113.72 26.36 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.885 -179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -159.91 106.13 1.61 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.848 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.099 0 CA-C-O 118.317 -1.268 . . . . 0.0 112.541 179.936 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.126 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.59 165.76 11.06 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.765 0.317 . . . . 0.0 110.862 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.3 p -156.03 123.61 5.53 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.987 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 102.9 92.64 2.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.512 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.8 m -157.28 -67.86 0.1 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.87 0.367 . . . . 0.0 110.922 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 10.0 m -80.31 178.79 8.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.885 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 120.79 109.51 2.18 Favored Glycine 0 CA--C 1.52 0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.44 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -67.37 153.62 76.35 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.389 2.059 . . . . 0.0 112.289 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -46.32 1.27 Allowed 'Trans proline' 0 C--N 1.345 0.393 0 C-N-CA 122.544 2.163 . . . . 0.0 112.309 -179.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.854 HD11 HG11 ' A' ' 16' ' ' VAL . 20.9 tp -79.61 131.17 35.92 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.941 -179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.5 mm-40 -71.31 153.52 42.31 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.453 HG22 ' OD1' ' A' ' 13' ' ' ASN . 24.7 mm -86.86 150.31 3.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.139 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.453 ' OD1' HG22 ' A' ' 12' ' ' ILE . 8.5 m-20 60.57 38.21 18.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.92 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.417 ' O ' HG23 ' A' ' 29' ' ' VAL . 1.5 m -115.19 161.92 17.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.6 mmt85 -95.07 112.45 24.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.916 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.854 HG11 HD11 ' A' ' 10' ' ' LEU . 27.2 m -137.43 146.02 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.175 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -96.88 -179.96 4.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.934 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.411 ' HB2' ' CE ' ' A' ' 49' ' ' MET . 8.9 mt -142.38 139.19 31.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.852 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 tttt -80.23 93.87 5.96 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.932 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG23 HG23 ' A' ' 23' ' ' THR . 3.3 m -103.32 112.62 37.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.145 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 58.18 -114.83 6.2 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -111.37 30.73 6.67 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.868 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.455 HG23 HG23 ' A' ' 20' ' ' VAL . 4.0 t -157.77 172.29 18.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.903 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 6.0 mm -118.02 161.24 17.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.989 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.441 ' OE2' HD13 ' A' ' 53' ' ' ILE . 4.3 mm-40 -143.43 118.06 9.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.851 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 41.4 m -67.63 142.71 56.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.007 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -153.43 -169.22 18.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.3 m -122.71 153.83 38.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.784 0.326 . . . . 0.0 110.974 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 30' ' ' ILE . 15.0 t -91.04 151.25 3.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.085 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.62 HD11 HG23 ' A' ' 74' ' ' THR . 9.1 pt -155.53 -43.13 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.231 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . 0.412 ' O ' HG13 ' A' ' 45' ' ' VAL . 34.5 t80 -126.52 122.41 35.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.884 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.493 ' SG ' HG22 ' A' ' 45' ' ' VAL . 16.7 t -142.69 107.6 4.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.916 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -176.81 -171.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.713 HG13 ' CE1' ' A' ' 43' ' ' TYR . 29.6 m -85.85 165.51 2.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.255 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . 0.795 HD11 HD21 ' A' ' 76' ' ' LEU . 17.5 mt -114.0 152.18 45.51 Favored Pre-proline 0 C--N 1.326 -0.427 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.842 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.41 ' HB2' ' CE2' ' A' ' 60' ' ' PHE . 64.5 Cg_exo -51.25 124.47 14.14 Favored 'Trans proline' 0 C--N 1.344 0.335 0 C-N-CA 122.569 2.179 . . . . 0.0 112.371 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 64.23 32.4 84.06 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LYS . . . . . 0.53 ' CG ' HD12 ' A' ' 41' ' ' LEU . 17.5 mttt -152.78 32.15 0.5 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.886 0.374 . . . . 0.0 111.062 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -69.29 -30.73 68.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.834 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -79.1 -26.3 42.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.024 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.53 HD12 ' CG ' ' A' ' 38' ' ' LYS . 5.0 mt -55.67 -57.38 12.21 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.949 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' HA3' ' CE1' ' A' ' 78' ' ' HIS . . . 167.99 -119.11 0.82 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.638 -0.791 . . . . 0.0 112.515 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TYR . . . . . 0.713 ' CE1' HG13 ' A' ' 34' ' ' VAL . 37.6 m-85 -152.94 97.49 2.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.351 . . . . 0.0 111.042 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.504 ' CD1' HD12 ' A' ' 35' ' ' LEU . 44.9 m-85 -67.82 155.72 38.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.753 179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.74 ' HB ' HD11 ' A' ' 82' ' ' ILE . 18.3 t -148.39 134.78 12.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.272 -179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -97.95 112.44 4.47 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.313 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 21.8 t -97.51 126.97 50.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.895 0.379 . . . . 0.0 111.341 -179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 17.5 t70 -91.45 96.24 10.4 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.715 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' MET . . . . . 0.411 ' CE ' ' HB2' ' A' ' 18' ' ' LEU . 24.3 mmt -64.31 163.99 12.0 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.144 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.16 -31.15 34.22 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.792 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 11.4 m-20 -106.42 158.37 32.8 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.842 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -70.48 80.25 1.1 Allowed 'Trans proline' 0 C--N 1.345 0.354 0 C-N-CA 122.489 2.126 . . . . 0.0 112.347 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.441 HD13 ' OE2' ' A' ' 25' ' ' GLU . 18.4 pt -137.64 28.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.208 179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.65 -165.91 41.28 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.487 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -177.38 37.64 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.83 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' TRP . . . . . 0.634 ' CH2' HD13 ' A' ' 76' ' ' LEU . 5.2 t90 -146.95 122.14 10.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.49 ' OD1' HG12 ' A' ' 71' ' ' VAL . 3.2 t70 -97.71 27.14 4.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.053 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.428 ' HA2' ' CH2' ' A' ' 56' ' ' TRP . . . 56.66 68.37 1.73 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.583 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ARG . . . . . . . . . . . . . 92.0 mtt180 -156.94 163.51 39.06 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.845 0.355 . . . . 0.0 110.937 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PHE . . . . . 0.633 ' CD1' HD22 ' A' ' 35' ' ' LEU . 14.2 t80 -133.99 89.9 2.63 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.3 t70 61.54 27.31 16.85 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.938 179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 130.42 -61.39 0.66 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.689 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.441 HG22 ' N ' ' A' ' 64' ' ' GLN . 12.0 p -61.22 155.64 4.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.907 0.384 . . . . 0.0 111.165 -179.719 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLN . . . . . 0.441 ' N ' HG22 ' A' ' 63' ' ' VAL . 1.8 tp60 -102.12 133.71 46.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.83 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.451 HD11 ' HB2' ' A' ' 60' ' ' PHE . 76.3 mt -114.27 -38.5 4.09 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.96 179.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' CYS . . . . . . . . . . . . . 35.6 t -124.92 101.64 7.16 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.006 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -67.46 -36.26 80.82 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.798 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PHE . . . . . . . . . . . . . 47.6 m-85 -65.94 -26.47 67.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.96 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.412 ' CB ' HG21 ' A' ' 74' ' ' THR . . . -61.98 175.75 0.65 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.053 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -176.0 131.91 0.25 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.845 179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 71' ' ' VAL . 7.5 p -65.51 79.08 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.017 179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -173.26 -39.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -129.13 -48.74 1.21 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.056 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.62 HG23 HD11 ' A' ' 30' ' ' ILE . 36.1 m -59.59 130.6 47.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.02 -179.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.48 HG22 ' CD1' ' A' ' 77' ' ' LEU . 2.2 mp -132.45 110.78 16.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.992 179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.795 HD21 HD11 ' A' ' 35' ' ' LEU . 7.8 tp -82.25 109.98 17.02 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.814 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LEU . . . . . 0.48 ' CD1' HG22 ' A' ' 75' ' ' ILE . 9.2 mt -142.91 165.01 28.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.914 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' HIS . . . . . 0.437 ' CE1' ' HA3' ' A' ' 42' ' ' GLY . 1.4 t-80 -64.19 137.67 58.06 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ILE . . . . . . . . . . . . . 17.4 tt -48.98 -34.28 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.932 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -59.04 -27.66 65.69 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.412 179.439 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 73.0 m-20 -80.42 -23.44 40.33 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.815 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.74 HD11 ' HB ' ' A' ' 45' ' ' VAL . 29.3 mt -75.15 151.79 6.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.122 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 82' ' ' ILE . 24.9 mm -137.31 89.76 15.89 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.73 169.56 14.32 Favored 'Trans proline' 0 C--N 1.344 0.323 0 C-N-CA 122.647 2.231 . . . . 0.0 112.189 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.61 97.93 3.2 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 1.3 m -146.59 153.17 40.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' SER . . . . . . . . . . . . . 22.8 t -150.71 122.11 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.865 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . -127.32 -88.74 0.65 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.526 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.29 -30.37 42.24 Favored 'Trans proline' 0 C--N 1.344 0.31 0 C-N-CA 122.604 2.202 . . . . 0.0 112.246 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -89.4 137.93 31.9 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.896 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -105.8 -175.99 2.95 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.07 0 CA-C-O 118.411 -1.216 . . . . 0.0 112.511 179.985 . . . . . . . . 0 0 . 1 stop_ save_